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 Abstract 
 Photodynamic therapy (PDT) uses the combination of non-
toxic dyes and harmless visible light to produce reactive 
oxygen species that can kill cancer cells and infectious 
microorganisms. Due to the tendency of most photosensi-
tizers (PS) to be poorly soluble and to form nonphotoactive 
aggregates, drug-delivery vehicles have become of high 
importance. The nanotechnology revolution has provided 
many examples of nanoscale drug-delivery platforms that 
have been applied to PDT. These include liposomes, lipo-
plexes, nanoemulsions, micelles, polymer nanoparticles 
(degradable and nondegradable), and silica nanoparticles. 
In some cases (fullerenes and quantum dots), the actual 
nanoparticle itself is the PS. Targeting ligands such as 
antibodies and peptides can be used to increase specifi c-
ity. Gold and silver nanoparticles can provide plasmonic 
enhancement of PDT. Two-photon excitation or optical 
upconversion can be used instead of one-photon excita-
tion to increase tissue penetration at longer wavelengths. 
Finally, after sections on  in vivo studies and nanotoxicol-
ogy, we attempt to answer the title question,  “ can nano-
technology potentiate PDT ? ” 
 Keywords:  dendrimer;  fullerene;  graphene;  lipoplex;  
lipoprotein;  liposome;  magnetic nanoparticle;  micelle; 
 nanocell;  nanoparticle;  ORMOSIL;  polymeric nanoparticle; 
 porphysome;  quantum dot;  single-walled carbon nanotube; 
 two-photon excitation;  upconversion. 
 1. Introduction 
 Photodynamic therapy (PDT) is an emerging modality for the 
treatment of a variety of diseases that require the killing of 
pathological cells (e.g., cancer cells, infectious microorgan-
isms) or the removal of unwanted tissue (e.g., neovasculariz-
tion in the choroid, atherosclerotic plaques in the arteries). It 
is based on the excitation of nontoxic photosensitizers (PS) 
by harmless visible light leading to the production of highly 
toxic reactive oxygen species (ROS) that kill cells. Suitable 
PS have a high extinction coeffi cient in the far-red or near-
infrared (NIR) spectral region and a high yield of the long-
lived triplet electronic state (formed from the excited singlet 
state by intersystem crossing). The triplet PS is able to react 
with surrounding molecular oxygen by one of two distinct 
pathways. The type 1 pathway involves electron transfer to 
or from the triplet PS that can lead to a variety of oxygen free 
radicals such as superoxide, hydroxyl radicals, and hydroper-
oxides. The type 2 pathway relies on the fact that molecular 
oxygen is a triplet in its ground state and therefore has a spin-
allowed interaction with PS triplet producing both species in 
the singlet state and singlet oxygen ( 1 O 2 ) is a potent oxidizing 
agent. Figure  1 shows a Jablonski diagram and the resulting 
type 1 and type 2 pathways. 
 For PDT to be both effective and safe, it is crucial that 
the PS should be delivered in therapeutic concentrations to 
the target cells (such as tumor cells) while simultaneously 
being absorbed in only small quantities by nontarget cells, 
thus minimizing undesirable side effects in healthy tissues. 
There are two main obstacles to achieving this aim: most PS 
have extended  π -conjugation systems, making the molecules 
highly planar and, in addition, the molecules tend to be highly 
hydrophobic, and therefore, most PS form aggregates in an 
aqueous environment  [1] . This aggregation lowers the effi -
ciency of the PS, which must be in monomeric form to be 
photoactive  [2] . Second, PS have generally not been found to 
bind or migrate preferentially to tumor cells, making it diffi -
cult to target only the diseased tissue when applying PDT  [3] . 
Considerable efforts have therefore been directed at design-
ing delivery systems that can incorporate PS in monomeric 
form without diminishing its activity and without causing any 
harmful effects  in vivo . 
 Many of these delivery systems take the form of nano-
particles or other nanostructures. Indeed, lipid and detergent 
nanostructures (liposomes and micelles) were routinely used 
in PDT before nanotechnology became a separate and rap-
idly growing area of specialization. Several questions need 
to be answered in the design of nanoparticle delivery agents 
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 Figure 1  Jablonski diagram. 
 Initial absorption of a photon by the ground state of the singlet PS 
gives rise to the short-lived excited singlet state. This can lose energy 
by fl uorescence, internal conversion to heat, or by intersystem cross-
ing to the long-lived triplet state. PS triplet states are effi ciently 
quenched by energy transfer to molecular oxygen (a triplet state) to 
give type 2 (singlet oxygen) or by electron transfer to oxygen or to 
biomolecules to give type 1 ROS (superoxide and hydroxyl radical). 
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 Figure 2  Representative chemical structures of PS that have been used in combination with nanoparticles. 
 (A) BPD, (B) ZnPC, (C) ce6, (D)  m -THPC, (E), PPIX, (F) hypericin, (G) pyropheophorbide a (Ppa), (H) HPPH, and (I) MB. 
for PS. First, should the PS be noncovalently encapsulated 
in the nanoparticle or covalently attached to it ? If the PS 
is only noncovalently associated, it is likely to be released 
more easily and therefore better taken up into cells. However, 
the PS may be prematurely released in the serum before the 
nanoparticles has had a chance to accumulate in the tumor as 
is hypothesized to occur  via the enhanced permeability and 
retention (EPR) effect. Second, should the nanoparticles be 
biodegradable or not ? If they are biodegradable, the mate-
rial composition will be limited to lipids or certain polymers, 
whereas nonbiodegradable nanoparticles may remain in the 
body for long periods and this may lead to concerns of toxic-
ity caused by the delivery vehicle and not the drug. 
 Although the majority of nanoparticles have been used as 
delivery vehicles for recognized PS such as tetrapyrroles, phe-
nothiazinium dyes, or perylenequinones (see Figure  2 for rep-
resentative chemical structures of PS covered in this review). 
However, there are some instances when the nanoparticles 
themselves act as the PS in the absence of preformed PS. For 
this to occur, the nanoparticles themselves have to be able to 
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absorb light by virtue of possessing an extinction coeffi cient 
of appreciable size in an appropriate region of the electromag-
netic spectrum and to then form an excited state that can lead 
to some photochemical generation of ROS. Examples of these 
classes of nanoparticle include fullerenes, zinc oxide (ZnO), 
titanium dioxide (TiO 2 ), and even quantum dots (QDs). 
 The aim of this review is therefore to give an overview 
of nanostructures that have been used in the PDT fi eld and 
relevant examples of each class. The fi eld has grown so rap-
idly in recent years that it is no longer possible to compile a 
comprehensive review, so we will concentrate on important 
and recent contributions. The readers will have to excuse the 
diffi culties we have faced when classifying multifunctional 
nanoparticles. Many nanoparticles could have been covered 
in multiple sections (sometimes up to three or four differ-
ent classifi cations) and there is no obvious rule for deciding 
between them. We will then try to critically answer our title 
question,  “ can nanotechnology potentiate PDT ? ” 
 2. Lipid-based nanoparticles 
 Lipids are amphiphilic molecules with both a hydrophobic and 
a hydrophilic part that spontaneously assemble into ordered 
structures in an aqueous environment, where the amphiphiles 
are arranged such that the hydrophobic parts cluster together 
and the hydrophilic parts face the water (usually on the out-
side). Many lipids will spontaneously form a membrane com-
posed of a lipid bilayer, and this fact underlies one of the basic 
processes in the creation of life as we know it, the forma-
tion of cells. Lipid-based nanoparticles, such as liposomes, 
lipoplexes, and nanoemulsions have been used extensively in 
recent decades as drug carrier vehicles for hydrophobic PS. 
 2.1. Liposomes 
 Liposomes are nanosized artifi cially prepared vesicles of 
spherical shape made from natural phospholipids and cho-
lesterol. Liposomes were discovered in 1961 by Alec D. 
Bangham who was studying phospholipids and blood clot-
ting, and since then they have become very versatile tools 
in biology, biochemistry, and medicine  [4] . Liposomes can 
be fi lled with drugs and used to deliver drugs for cancer and 
other diseases. 
 Liposomes have thus far been the most intensively stud-
ied carrier system for PS  [5] . Their structure is composed of 
phospholipids with a hydrophilic head group and two hydro-
phobic chains, which enables them to contain both hydro-
philic and hydrophobic drugs  [6] . The liposome is made up of 
one or more concentric phospholipid bilayers, with an aque-
ous phase inside and between the bilayers  [7] . The bilayers 
also often contain cholesterol, which is used to control mem-
brane fl uidity and increase stability, as well as for modulating 
membrane-protein interactions  [3] . PS can be packaged into 
liposomes in two distinct manners depending on the lipophi-
licity and water solubility of the PS itself. First, water-soluble 
hydrophilic PS or even solid particles of PS are dissolved 
or suspended in the aqueous interior of the liposomes (see 
Figure  3 A). Second, hydrophobic non-water-soluble PS can 
be dissolved in the hydrophobic environment produced the 
fatty acid side-chains in the interior of the lipid bilayer (see 
Figure 3B). Once the PS has been packaged in the liposome, 
Water soluble or solid PS
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Lipid soluble PS
PS
Lipid bilayers
Detergent
NanocellNanoemulsion
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Oil dropletPS
Lipoplex
 Figure 3  Lipid nanoparticles. 
 (A) Liposomes containing water-soluble PS in aqueous interior. (B) Liposomes containing lipid soluble PS in hydrophobic region of lipid 
bilayer. (C) Lipoplex formed from cationic lipids encapsulating anionic PS. (D) Nanoemulsion formed from nanometer-sized oil droplets with 
dissolved hydrophobic PS coated by neutral detergent. (E) Nanocell formed from a liposome with hydrophobic PS encapsulating additional 
targeting molecules such as antibodies in interior. 
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it can be delivered to cells in two main ways: the liposome 
can fuse with cell membranes and release its contents into 
the cytosol or it can be taken up by phagocytic cells and then 
disintegrate in the endosomes or lysosomes, again releasing 
the active drug into the cell  [8] . 
 Many experiments have demonstrated unequivocally that 
using liposomes to administer PS can substantially improve 
the effi cacy and safety of PDT. For example, when rats whose 
brains were implanted with a human glioma were treated with 
PDT using the PS Photofrin and the uptake into the tumor 
tissue was signifi cantly enhanced when the PS was delivered 
using liposomes  [9] . Similar results have been observed with 
different tumor models and different PS  [10] . This increased 
effi ciency can be partly attributed to the role of liposomes 
in preventing aggregation of the PS. For example, when the 
hydrophobic PS, hypocrellin A (HA), was packaged in lipo-
somes, it remained in monomeric form, unlike the aggregates 
formed when suspended in dimethyl sulfoxide-solubilized 
saline  [11] . Liposomal HA also achieved a higher tumor-
to-normal tissue ratio and higher maximal levels within the 
tumor cells compared with the saline suspension. 
 One of the most successful examples of the use of lipo-
somal delivery vehicles has been that of Visudyne (see Figure 
2A). Visudyne is a lipid-formulated composition of benzo-
porphyrin derivative mono acid ring A (BPD), or verteporfi n, 
which is provided by (QLT Phototherapeutics, Vancouver, 
Canada); as a freeze-dried preparation composed of egg 
phosphatidyl glycerol and dimyristoyl phosphtidylcholine 
(BPD/EPG/DMPC; 1.05:3:5 w/w/w)  [12] . Visudyne has been 
widely used in ophthalmology as a PS in combination with 
transpupillary red laser for destroying neovasculature in the 
eye secondary to disease such as wet age-related macular 
degeneration  [13] . A second successful application of lipo-
somes in PDT drug delivery was that of zinc(II) phthalocya-
nine (ZnPC; see Figure 2B). ZnPC is highly insoluble and 
was formulated by Ciba-Geigy Pharmaceuticals in liposomes 
composed of palmitoyl-oleoyl-phosphatidylcholine and di-
oleoyl phosphatidylserine (ZnPC/OPOC/OOPS; 1:90:10 
w/w/w) to form CGP55847  [14] . Although CGP55847 was 
tested in clinical trials of PDT for squamous cell carcinomas 
of the upper aerodigestive tract  [15] , it never received regula-
tory approval. 
 However, such  “ conventional ” liposomes, with no additional 
features, have the drawback of a short plasma half-life, of the 
order of minutes  [16] . This is fi rst due to rapid lipid exchange 
between the liposomes and the lipoproteins, which leads to 
irreversible disintegration of the liposome. Second, conven-
tional liposomes are easily opsonized by plasma proteins and 
are then quickly taken up by cells of the mononuclear phago-
cyte system, thus, they accumulate in mononuclear phagocytes 
in the liver, spleen, bone marrow, and blood circulation  [3] . The 
resulting short circulation time of unmodifi ed liposomes makes 
it diffi cult to achieve elevated tumor-to-normal tissue ratios of 
PS. Therefore, to make liposomes tumoritropic, they must be 
altered in some way. There are two main ways in which lipo-
somes can be modifi ed: passive and active targeting. 
 Passive targeting relies on the fact that if liposomes are 
allowed to circulate for a suffi ciently long time, they will 
naturally preferentially accumulate in tumor tissue. This is 
due to the fast angiogenesis in malignant tissues, which results 
in enhanced vascular permeability and the lack of a functional 
lymphatic system in tumor tissue that impedes the return of 
extravasated macromolecules to the central circulation  [17] . 
To achieve this effect, liposomes have been designed with 
longer circulation half-lives by making them  “ invisible ” to 
lipoproteins and the mononuclear phagocyte system. Long-
circulating liposomes can be created by using lipids with 
polyethylene glycol (PEG) headgroups; such liposomes are 
referred to as  “ sterically stabilized ” or Stealth  ®  liposomes 
 [16, 18] . PEG is most commonly used as the polymeric steric 
stabilizer for liposomes, as it can be manufactured in large 
quantities with high purity, has low toxicity, and is nonim-
munogenic and antigenic  [6, 19] . One drawback of passive 
targeting is that Stealth  ®  liposomes have been demonstrated 
to have decreased interaction with cells, suggesting that they 
may be less effective than conventional liposomes in transfer-
ring PS to tumor cells  [3, 20] . Further studies are needed to 
see if this is indeed the case. 
 Liposomes have also been developed with a triggered 
release mechanism, so that the release of the PS can be tightly 
controlled. Various stimuli, such as heat, light, pH, and target 
binding have been used as the trigger  [21] . Thermosensitive 
liposomes are constructed using temperature-sensitive lipids 
or coated with thermosensitive polymers that disintegrate 
when their temperature increases above 42 ° C  [3, 22] . pH-
sensitive liposomes are constructed by adding acid-sensitive 
molecules to the liposomal membrane and are designed to 
release their contents between pH 5 and 6.3  [23] . The basic 
principle underlying these mechanisms is the same: the lipo-
somes are designed so that applying a  “ switch ” will destabi-
lize the phospholipid bilayer, thus increasing its permeability 
and releasing the PS contained within. 
 In active targeting, one or more molecules that have a high 
affi nity for specifi c membrane markers on malignant cells are 
bound to the surface of the liposome, resulting in increased 
interaction of the liposomes with target cells  [24] . The mole-
cule can be covalently bound to the liposome, either by using 
a spacer molecule or by binding directly to a hydrophobic 
anchor in the phospholipid bilayer. In many cases, a spacer 
arm is used to enhance binding to the tumor cells by reducing 
interference from other surface molecules on the liposome 
that may have been added to increase the circulation half-life 
or to increase hydrophilicity  [25] . A wide range of molecules 
has been used for active targeting, including glycoproteins, 
glycolipids, peptides, growth factors, and monoclonal anti-
bodies (MoAbs)  [3, 6, 26] . Although MoAbs are expensive, 
are time consuming to produce, and may result in undesirable 
immune reactions  in vivo , they have the advantage of excellent 
specifi city and signifi cantly increase the ability of liposomes 
to deliver PS selectively to malignant cells  [27] . Some stud-
ies have used antibody fragments (at the cost of potentially 
decreasing specifi city) to minimize adverse immune reactions 
 [28] . Other nonantibody ligands are often less expensive and 
carry a lower risk of inducing immune reactions: however, 
they do not have such high specifi cities for tumor cells, as 
many normal cells express the same receptors. 
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 One application of liposomally encapsulated BPD was 
to destroy lymphatic vessels that might be responsible for 
allowing tumors to metastasize even after surgery  [29] . 
Many tumors produce vascular endothelial growth factor C 
(VEGF-C) or VEGF-D, factors that promote the formation 
of new lymphatic vessels (lymphangiogenesis). The newly 
formed lymphatic vessels enable tumor cells to travel from 
the primary tumor to the regional lymph nodes from whence 
they can spread throughout the body. Tammela et al.  [29] fi rst 
used the mouse ear containing tumors formed by mouse mela-
noma cells or human lung tumor cells after 2 weeks when 
the primary tumors had become established and lymphangio-
genesis had been induced. Liposomal BPD accumulated spe-
cifi cally in the lymphatic vessels, and after illumination, they 
started to shrink and fragment and became leaky. When the 
experiment was repeated with tumors in the fl anks of mice 
and PDT was followed by surgery, the mice had a much lower 
relapse rate than those that underwent surgery alone. Finally, 
they demonstrated PDT shutdown of lymphatic vessels in a 
large animal model (leg and hoof of a pig). 
 There have been several studies examining the use of lipo-
somally encapsulated PS to mediate antimicrobial photody-
namic inactivation (PDI)  [30 – 33] . There is a well-known 
requirement for optimal antimicrobial PS to either possess 
one or more cationic charges on the PS itself or alternatively 
on the delivery vehicle in which the PS is contained  [34] . 
Therefore, the liposomes for delivery of antimicrobial PDI 
are constructed to contain cationic lipids such as  N -[1-(2,3-
dioleoyloxy)propyl]- N , N , N -trimethylammonium chloride 
 [33] or cationic detergents such as (1 S ,2 S )- N -hexadecyl- N -
methylprolinolinium bromide  [32] . Longo et al.  [35] used 
aluminum-chloride-phthalocyanine encapsulated in cationic 
liposomes to mediate PDI of oral bacteria and went on to 
test the antimicrobial PDT protocol in a clinical trial of 10 
patients with carious lesions of the teeth. 
 2.2. Lipoplexes 
 Lipoplexes are complexes of cationic liposomes with other 
molecules (most commonly, negatively charged polynucleic 
acids), and have been most commonly used in gene therapy, 
for the delivery of nucleic acids such as DNAs and small inter-
fering RNAs  [36] . The cationic liposomes are created using 
positively charged cationic lipids (cytofectins). Recent stud-
ies have begun testing lipoplexes as a possible delivery sys-
tem for negatively charged PS, and there is reason to believe 
that lipoplexes may improve the activity and specifi city of the 
PS. For example, chlorin e6 (ce6) (Porphyrin Products, Inc., 
Logan, UT, USA) (see Figure 2C), a derivative of natural chlo-
rophyll a, is a hydrophilic PS with seemingly limited poten-
tial, as it has low retention in tumor tissues and low potency 
 [37] . However, when complexed with cationic liposomes, ce6 
showed increased cellular uptake  in vitro and selective target-
ing of tumor tissues  in vivo , as well as increased retention 
within the tumor cells  [38] . The use of cationic liposomes was 
crucial, as complexation effi ciency of ce6 was higher than 
90 % with these liposomes, as compared with  < 12 % for neu-
tral and negatively charged liposomes. These fi ndings suggest 
that lipoplexes would be a profi table area of research for PS 
delivery systems. 
 2.3. Nanoemulsions 
 Nanoemulsions are yet another proposed method for the effi -
cient delivery of PS and are promising as a therapeutic option 
as they are easy to prepare and thermodynamically stable  [39] . 
They consist of dispersions of oil and water that have dispersed 
phase droplets of size 20 – 200 nm and are often stabilized with 
a surfactant and co-surfactant  [40] . Due to the nanosize range 
of the droplets, they are optically transparent and may be stored 
without the occurrence of sedimentation or droplet coalescence. 
Studies have demonstrated that nanoemulsions can enhance 
preferential delivery of PS to tumor sites and thus diminish the 
toxic side effects of PDT  [41] . The application of nanoemul-
sions in PDT is likely to be in topical application of PS to the 
skin or to other mucosal surfaces. Primo et al.  [42] formulated 
Foscan ( meta -tetrahydroxyphenyl chlorin, mTHPC) (Scotia 
Pharmaceuticals Ltd, Guilford, Surrey, UK) (see Figure 2D) in a 
nanoemulsion composed of soy-phosphatidylcholine Epikuron 
170/Tween 80 and nonionic surfactants Poloxamer 188/Span  ®  80. 
This formulation showed improved transdermal transport after 
6 h. The same group  [43] also investigated a magnetic nanoemul-
sion composed of biodegradable surfactants and biocompatible 
citrate-coated cobalt ferrite-based magnetic fl uid to encapsulate 
ZnPC (Figure 2B) with the intention of combining PDT and 
magnetohyperthermia to produce synergistic cell killing. 
 5-Aminolevulinic acid (ALA) is not a PS itself but is 
a well-known precursor of the naturally formed PS, proto-
porphyrin IX [PPIX; (Porphyrin Products, Inc., Logan, UT, 
USA) see Figure 2E]  via enzymes of the heme biosynthetic 
cycle  [44] (see Figure  4 ). When exogenous ALA is applied 
to tumors or other unwanted tissue, the feedback inhibition 
of the heme cycle is bypassed and excess PPIX is accumu-
lated after a period of a few hours. As ALA is often topically 
applied, methods of increasing uptake and penetration through 
the skin have been intensively investigated  [45] . For instance, 
Maisch et al.  [46] used a nanoemulsion consisting of 30-nm 
particles of egg lecithin to increase ALA delivery through a 
full-thickness  ex vivo skin model. Biofrontera has developed 
this BF-200 ALA nanoemulsion formulation in clinical trials 
of actinic keratoses  [47] . 
 2.4. Nanocells 
 Nanocells are a newly proposed technology that has been 
specifi cally designed to enhance drug delivery to solid 
tumors  [48] . The traditional treatment method for tumors, 
which involves the simultaneous administration of chemo-
therapy and anti-angiogenesis agents, can actually inhibit 
the action of the chemotherapy agent. First, the action of 
the anti-angiogensis agent eventually decreases the blood 
supply to the tumor cells, making it more diffi cult for thera-
peutic concentrations of the chemotherapy drug to reach the 
tumor  [49] . Second, the inhibited blood supply results in the 
accumulation of hypoxia-inducible factor 1 α in the tumor, 
which leads to increased tumor invasiveness and resistance 
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 Figure 4  Heme biosynthesis cycle. 
 Exogenous ALA is added that bypasses feedback control inhibition of ALA synthase. Because the rate-limiting step is the introduction of iron 
into PPIX by ferrochelatase to form heme, the levels of PPIX build up and allow effective PDT to be carried out. 
to chemotherapy  [50] . The nanocell is designed to avoid 
this scenario by sophisticated packaging of the two drugs: 
it consists of a nuclear nanoparticle (containing the che-
motherapy agent) within an extra pegylated lipid envelope 
(containing the anti-angiogenesis agent). When the nanocell 
is absorbed by the tumor, the outer envelope releases the 
anti-angiogenesis agent, thus shutting down the blood sup-
ply to the cancer cells. The inner nanoparticle then releases 
the chemotherapy agent, which can easily access the tumor 
cells, as the nanocell is already trapped inside the tumor. In 
addition to ensuring effi cient delivery, this strategy results 
in decreased toxicity as the drugs are isolated from healthy 
cells. So far, this technique has only been demonstrated with 
chemotherapy agents, but it may be possible to design nano-
cells that can carry photosynthesizers. Early studies have 
shown preferential uptake of nanocells by tumors, which 
could be enhanced by active targeting in a similar manner to 
that of liposomes  [40] . 
 2.5. Porphysomes 
 Porphysomes are an interesting hybrid of a lipid nanoparticle 
and a potential PS developed by Gang Zheng ’ s laboratory in 
Toronto  [51, 52] . They consist of nanovesicles formed from 
self-assembled porphyrin bilayers that generate large, tun-
able extinction coeffi cients, structure-dependent fl uorescence 
self-quenching and unique photothermal and photoacoustic 
properties. The basic building block is a conjugate between 
pyropheophorbide and a cationic phospholipid (Figure  5 A) 
that spontaneously assembles into 100-nm particles com-
posed of two high-density layers, ca. 5 nm thick in total and 
separated by a  ∼ 2-nm gap. Each layer is thought to correspond 
to a monolayer of porphyrin lipid (see Figure 5B). Because 
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N
N
N
N
H
H
O
O
P
N+
 Figure 5  Porphysomes. 
 As described by Lovell  [51] , lysophosphatidylcholine pyropheo-
phorbide a (A) spontaneously assembles into nanovesicles desig-
nated  “ porphysomes ” (B). 
the porphyrins are packed in high density, they undergo self-
quenching and at short time points can mediate photoacoustic 
and photothermal effects. However, at later time points, they 
dissociate  in vivo and the released porphyrins can then medi-
ate PDT. 
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 3. Polymer-based nanoparticles 
 Polymeric nanoparticles have recently emerged as a new and 
promising tool for the delivery of drugs in PDT. Polymer-
based PDT drugs offer several key advantages over molecular 
PDT drugs such as the ability to deliver a large amount of 
PS to the target area, fl exibility toward surface modifi cation 
for better effi ciency, the ability to prevent degradation in the 
living biological environment, and the possibility of being 
loaded with multiple components such as targeting ligands 
and contrast agents. These advantages have a potential to 
improve several aspects of PDT such as tumor selectivity and 
hydrophobicity of the PS. The size of polymeric nanoparticles 
makes them an excellent tool for drug delivery. Tumor tissue 
has abnormally leaky blood vessels (with fenestrae up to 780 
nm  [53] ) and nanoparticles preferentially escape from nor-
mal vasculature into the tumor, where they are subsequently 
retained due to poor lymphatic drainage. This effect is known 
as EPR  [54] . A variety of polymer nanoparticles have been 
used to create PDT agents, and the structures are illustrated in 
Figure  6 . These include synthetic polymers like polylactide-
polyglycolide copolymers (PLGA),  N -(2-hydroxypropyl)-
methacrylamide (HPMA) copolymers, and polyacrylamide 
(PAA). Natural polymers composed of polysaccharides such 
as chitosan and alginate and proteins such as albumin and col-
lagen have also been used. Following is a summary of recent 
polymeric nanoparticle applications in PDT. 
 3.1. Poly( D , L -lactide-co-glycolide) 
 PGLA (see Figure 6A) is a polymer made from a mixture of 
lactic acid and glycolic acid monomers that has been widely 
investigated for drug delivery due to its ease of formulation 
and biodegradability  [61] . PS such porphyrins, chlorins, 
hypericin, and phthalocyanines (see Figure 2) have been 
loaded into PLGA nanoparticles and investigated for their 
potential in PDT. It has been reported that hypercin-loaded 
PLGA nanoparticles demonstrated a higher photoactivity 
than the free drug in NuTu-19 ovarian cancer cells  [62] . The 
same effect was demonstrated in another study, where the 
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 (A) PLGA  [55] , (B) PAA  [56] , (C) HPMA  [57] , (D) 18m-ALA-dendrimer  [58] , (E) PEG-PLL  [59] , and (F) chitosan  [60] . 
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effi cacy of PDT with  meso -tetra(4-hydroxyphenyl)porphy-
rin ( m -THPP) (see Figure 2D with one extra double bond)-
loaded nanoparticles was compared with that seen with the 
free drug in EMT-6 mammary tumor cells  [63] . Treatment 
with the 50:50 PLGA nanoparticles allowed for lower drug 
doses and shorter time intervals between drug administration 
and irradiation when compared with free  m -THPP. ZnPc has 
also been loaded into PLGA nanoparticles and successfully 
used in PDT  [55] . 
 Several studies have been done to determine the depen-
dence of PDT effi ciency on properties of PLGA such as 
size and copolymer molar ratios. It has been reported in 
several studies that effi cacy of PDT increases as the size of 
the nanoparticle decreases  [64, 65] . When verteporfi n was 
loaded into two PLGA nanoparticles, one 167 nm and the 
other 370 nm in diameter and tested on EMT-6 mammary 
tumor cells. It was found that the smaller nanoparticles 
exhibited a higher phototoxic effect than the larger ones or 
the free drug  [64] . Another study examined three different 
PLGA nanoparticles with mean diameters of 117, 285, and 
593 nm were loaded with  m -THPP. The 117-nm particles 
demonstrated the fastest  m -THPP release and highest rate of 
ROS production  in vitro  [65] . The improved performance of 
the smaller PLGA nanoparticles may be due to better intra-
cellular uptake of the drug as well as a larger fraction of the 
particle that is exposed to its surroundings, which allows 
for a higher drug release rate  [66] . It has also been found 
that the molar ratio of polylactide (PLA) to polyglycolide 
(PGA) affects the biodegradation rate  [67] and the photo-
toxicity of the loaded PS. When  m -THPP was loaded into 
same size nanoparticles with three different molar ratios, 
its  in vitro phototoxicity increased in the order of 50:50 
PLGA > 75:25PLGA > PLA  [63] . PGA is more hydrophilic 
than PLA; thus, this demonstrates that the phototoxicity 
of the incorporated PS depends on the lipophilicity of the 
polymer nanoparticle  [68] . 
 3.2. Polyacrylamide 
 PAA (see Figure 6B) is a favorable substance for systemic 
administration because it is highly water-soluble, which pre-
vents aggregation. It has been demonstrated to be nontoxic 
and biologically inert  [69] . Another advantage of PAA nano-
particles is that biodegradable cross-linkers can be introduced 
to make them slowly biodegradable, which improves their 
bioelimination  in vivo  [70] . PAA with nonbiodegradable 
cross-linkers has also been used successfully in PDT  [71] . The 
polymer was shown to be an effective PDT agent when loaded 
with PS such as methylene blue (MB)  [71, 72] and Photofrin 
 [73] . In one study, 2- to 3-nm  meta -tetra(hydroxyphenyl)-
chlorin ( m -THPC)-loaded PAA particles were prepared and 
successfully used in PDT to kill rat C6 glioma cells, proving 
to be as effective as the free drug  [74] . The main advantage 
of these particles is their small size, which means  1 O 2 should 
diffuse more rapidly out of them and they can be removed 
from the body by renal clearance. PAA-coated MB particles 
were also successfully used in PDT to eliminate bacterial 
infections  [75] . The nanoparticles inhibited biofi lm growth 
of both Gram-positive and Gram-negative strains, but killing 
effi ciency was much higher for the Gram-positive bacteria. 
 3.3.  N -(2-Hydroxypropyl)methacrylamide 
 HPMA (see Figure 6C) is a biocompatible copolymer that has 
been shown to passively accumulate in tumors and can be 
easily formulated to include targeting ligands  [57] . HPMA 
copolymer-bound drugs have been developed for the com-
bination of PDT and chemotherapy  [76] . It has been dem-
onstrated using two different cancer models (Neuro 2A 
neuroblastoma  [76] and human ovarian carcinoma  [77] ) that 
this novel approach is more effective than PDT or chemo-
therapy alone. 
 3.4. Dendrimers and hyperbranched polymers 
 Dendrimers are highly branched polymeric materials that 
have been used to deliver 5-ALA. ALA delivery is diffi cult 
due to its hydrophilic nature. Battah et al.  [58] prepared an 
ALA-dendrimer, [1,3,5-Tris[ N -( N -bis{ N -[tris(5-aminolaevu-
linyloxymethyl)methyl] propionamido}propionamido)car-
bamido]benzene 18 trifl uoroacetic acid salt (18m-ALA; see 
Figure 6D). An  in vitro study demonstrated that dendrimers 
such as 18m-ALA could be used to carry ALA into PAM 212 
murine keratinocyte and A431 human epidermoid carcinoma 
cell lines. It also showed that the dendrimer ALA nanopar-
ticles are more effi cient at porphyrin production than free 
ALA. 
 Li and Aida  [78] have reviewed the fi eld of dendri-
meric porphyrins, phthalocyanines, and other tetrapyrroles. 
Kataoka ’ s laboratory has prepared dendrimer PS based on 
both a Zn-porphyrin and on a Zn-phthalocyanine  [79] . The 
porphyrin dendrimers were complexed with poly- l -lysine-
PEG (PEG-PLL; see Figure 6E) block copolymers to form 
nanocarriers  [80] . Interestingly, the larger the dendrimer (i.e., 
the higher the generation number), the smaller was the overall 
size of the nanocarrier. Dendrimeric phthalocyanines (DPc) 
with carboxyl groups at the periphery were complexed with 
PEG-PLL in a similar manner to form nanocarriers (DPc/m) 
with 50 nm diameter  [81] . The nanoparticles were taken up 
into A549 human lung cancer cells, accumulated in lyso-
somes, and were released upon illumination. Nude mice with 
A549 tumors received DPc or DPc/m intravenously at a dose 
of 1.85 mg/kg, and after 24 h, tumor sites were irradiated 
with a 670-nm diode laser with a light dose of 100 J/cm 2 . 
Mice treated with DPc/m-PDT showed a much better tumor 
response than those with DPc-PDT. 
 Li et al.  [82] prepared conjugates between the PS ce6 and 
hyperbranched poly(ether-ester), HPEE. HPEE-ce6 nanopar-
ticles were synthesized by carbodiimide-mediated reaction 
between HPEE and ce6 and characterized by ultraviolet-visi-
ble absorption spectroscopy (UV-Vis) and transmission elec-
tron microscopy. The uptake and phototoxicity of HPEE-ce6 
nanoparticles toward human oral tongue cancer CAL-27 cells 
was detected by confocal laser scanning and MTT assay. The 
HPEE-ce6 nanoparticles showed signifi cantly greater PDT 
effect than free ce6. 
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 3.5. Natural polymers 
 Natural polymers such as proteins and polysaccharides 
have also been studied for potential use in PDT. Human 
serum albumin has been loaded with the PS pheophorbide. 
The nanoparticles were incubated with Jurkat cells for 24 h, 
and the treatment resulted in higher phototoxicity and lower 
dark toxicity than free pheophorbide  [83] . In a study with 
polysaccharide nanoparticles, 5,10,15-triphenyl-20-(3- N -
methylpyridinium-yl)porphyrin was encapsulated in marine 
atelocollagen/xanthan gum  [84] . The incorporated PS dis-
played almost four times greater phototoxicity toward HeLa 
cells when prepared with the nanoparticles than with phos-
phatidylcholinelipidic emulsion. 
 3.6. Chitosan 
 Chitosan is a  β -1,4-linked polymer of glucosamine 
(2-amino-2-deoxy- β - d -glucose) and lesser amounts of 
 N -acetylglucosamine. It is a derivative of chitin (poly- N -
acetylglucosamine) (Figure 6F) and is the second most abun-
dant biopolymer after cellulose. Chitosan was fi rst discovered 
in 1811 by Henri Braconnot  [85] , a French chemist and phar-
macist. Bracannot observed that a certain substance (chitin) 
found in mushrooms did not dissolve in sulfuric acid. Later 
in the century, chitin was found in crustaceans (such as crabs, 
lobsters, shellfi sh, and shrimp), the indigestible outer skel-
eton of insects, and the material from which the cell walls 
of the mycelial fungi are made. Over the last 200 years, the 
study and application of chitosan has taken on many different 
forms, but in recent years, it has been used to manufacture 
nanoparticles that have been investigated for improved drug 
delivery  [86] . 
 Reza-Saboktakin et al.  [87] prepared biodegradable poly-
meric nanoparticles loaded with PS  m -THPP.  N -Sulfonato-
 N , O -carboxymethylchitosan was grafted with polymethacrylic 
acid. The nanoparticles were loaded with  m -THPP (10% – 30 % 
loading) and tested for PDT killing of 14C carcinoma cells. 
After 6 h of incubation, the phototoxicity of the nanoparticles 
was comparable with that of free  m -THPP. 
 Lee et al.  [88] prepared hydrophobically modifi ed glycol 
chitosan (HGC) nanoparticles by self-assembling amphiphilic 
glycol chitosan-5 β -cholanic acid conjugates. Ce6 was chemi-
cally conjugated to the glycol chitosan polymers, resulting 
in amphiphilic glycol chitosan-ce6 conjugates that formed 
self-assembled nanoparticles in aqueous condition. Both ce6-
loaded glycol chitosan nanoparticles (HGC-ce6) and ce6-con-
jugated chitosan nanoparticles (GC-ce6) had similar average 
diameters of 300 – 350 nm, a similar  in vitro  1 O 2 generation 
effi cacy under buffer conditions, and a rapid cellular uptake 
profi le in the cell culture system. However, compared with 
GC-ce6, HGC-ce6 showed a burst of drug release  in vitro 
(65 % released from the particles within 6.5 h). When injected 
through the tail vein into nude mice bearing HT29 human colon 
carcinoma tumors, HGC-ce6 did not accumulate effi ciently in 
tumor tissue, refl ecting the burst in the release of the physi-
cally loaded drug, whereas GC-ce6 showed a prolonged cir-
culation profi le and a more effi cient tumor accumulation. PDT 
(2.5 mg/kg) ce6 followed by two separate illuminations at 4 
and 12 h postinjection with a red laser (671 nm, 220 mW/cm 2 ) 
for 30 min gave best tumor growth delay with GC-ce6, 
whereas HGC-ce6 was less effective, and free ce6 gave hardly 
any response. 
 The same group  [89] prepared similar nanoparticles from 
glycol-chitosan with PPIX conjugated and found these 
amphiphilic PPIX-eGC conjugates formed a stable nano-
particle structure in aqueous condition, wherein conjugated 
PPIX molecules formed hydrophobic inner cores and they 
were covered by the hydrophilic GC polymer shell. PPIX-
eGCeNP showed a self-quenching effect, but after cellular 
uptake, the compact structure gradually decreased to gener-
ate a strong fl uorescence signal and  1 O 2 generation when irra-
diated. Nude mice with SCCVII squamous cell carcinomas 
were intravenously injected  via a tail vein with free PPIX or 
PPIX-GC-NP (20 mg/kg of PPIX). After 1 day postinjection, 
tumors were irradiated with a 633-nm HeNe laser, 3 mW/cm 2 
for 30 min. PPIX-GC-NP gave a pronounced tumor destruc-
tion and growth delay not seen with free PPIX. 
 3.7. Pegylated polymers 
 One problem with using polymer nanoparticles for drug 
delivery is that they tend to be taken up by macrophages after 
intravenous administration  [90] . To reduce this uptake, the 
nanoparticle can be coated with PEG, which allows for lon-
ger plasma circulation and better accumulation in tumors. In 
one study, it was reported that pegylation (the attachment of 
PEG) of PLL and ce6 conjugates increased the selectivity and 
improved the phototoxicity of PDT in OVCAR-5 ovarian can-
cer cell lines  [59] . In an  in vivo study, hexadecafl uoro ZnPc 
was loaded into PEG coated PLA nanoparticles and tested for 
photodynamic activity and tumor response in EMT-6 tumor-
bearing mice  [91] . The results showed an improved response 
and longer tumor sensitivity to PDT compared with treat-
ment with the same PS prepared in Cremophor El (CRM) 
emulsions. Another way to improve tumor selectivity of 
the polymer nanoparticle is by conjugating its surface with 
tumor-specifi c ligands for active targeting. As an example, 
in an  in vitro study done with MDA-MB-435 human breast 
carcinoma F3-targeted PAA nanoparticles were loaded with 
Photofrin and iron oxide and were successfully concentrated 
within the nuclei of the cells  [73] . Subsequent administration 
of light caused cell death. Active targeting is a major advan-
tage of polymeric nanoparticles because they can be packed 
with multiple targeting ligands and they frequently exhibit 
better selectivity than targeted molecular drugs  [92] . 
 4. Micelles 
 Micelles are so-called colloidal dispersions (with particle size 
normally within the 5- to 100-nm range) of aggregates of sur-
factant molecules dispersed in a liquid colloid. Such colloids 
are spontaneously formed under certain concentration and 
temperature by amphiphilic or surface-active agents. These 
surfactant molecules consist of two clearly distinct regions 
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with opposite affi nities toward a given solvent (see Figure  7 ). 
Micelles have been widely used to carry hydrophobic drugs, 
which are physically entrapped in and/or covalently bound 
to the hydrophobic core. Micellar nanocarriers demonstrate a 
series of attractive properties as drug-delivery systems, such 
as improved bioavailability, enhanced permeability across 
the physiological barriers (EPR effect), and substantial ben-
efi cial changes in drug biodistribution  [93, 94] . Micelles can 
be classifi ed in two general groups based on the nature of the 
amphiphilic core: polymeric micelles, which are formed by 
block copolymers consisting of hydrophilic and hydrophobic 
monomer units, and micelles prepared from water-soluble 
polymers conjugated with lipids. 
 4.1. Polymeric micelles 
 Polymeric micelles represent widely used nanocarriers, com-
prising several possible classifi cations and types of polymers 
and copolymers. Among others, PEG-b-poly(caprolactone) 
(PEG-PCL) diblock copolymers seem to be successful with 
the delivery of photosensitizing agents. Li et al.  [95] studied 
the formulation of hydrophobic PPIX PEG-PCL micelles and 
compared their PDT response with that of free PPIX. PEG-
PCL micelles have also been used for the encapsulation of 
phthalocyanines  [96] , chlorins  [97, 98] , and pheophorbides 
 [99] with successful results. These fi ndings suggest that PEG-
PCL micelles have great potential as a drug-delivery system 
for hydrophobic photodynamic sensitizers. 
 The encapsulation of dendrimer PS can be also improved 
by means of PEG-PLL micelles  [81, 100, 101] . 
 Using another biocompatible and biodegradable block 
copolymer, PEG-b-poly( d,l -lactide) (PEG-PLA), Gao et al. 
 [102] recently published the nanoscopic structure-property 
relationships of micelle-delivered PPIX and established a via-
ble formulation for  in vivo evaluation of antitumor effi cacy. 
This group also explored the advantages of using PEG-PLA 
micelles for the encapsulation of mTHPC in head and neck 
cancer treatment  [103, 104] . 
Hydrophilic region
Hydrophobic region
PS
Micelle
 Figure 7  Micelle structure. 
 Detergents with hydrophilic and hydrophobic blocks spontaneously 
assemble into micelles with hydrophobic interiors that dissolve lipo-
philic PS. 
 Pluronics (poloxamers) are commercially available water-
soluble triblock copolymers of poly(ethylene oxide) and 
poly(propylene oxide) (PEO-PPO-PEO) and have been fre-
quently used as a solubilization agent in drug formulations. 
Gallavardin et al.  [105] used the pluronic nanoparticles for 
encapsulating two-photon chromophores. Chowdhary et al. 
 [106] compared the pluronic P123 formulation with a lipid-
based system to improve the verteporfi n delivery to lipopro-
teins in tumor and arthritis mouse models. 
 Some authors reported the use of pH sensitivity of the 
micelle to release the PS selectively at the target site. It is 
known that tumors and infl amed tissues exhibit a decreased 
extracellular pH as well as some intracellular compartments 
such as lysosomes or endosomes. Low pH may change the 
polymer polarity and structure causing the PS deliver  [107] . 
Following this strategy, Le Garrec et al.  [108] synthesized 
different  N -isopropylacrylamide (NIPAM) copolymers to 
prepare pH-responsive micelles encapsulating AlPc. NIPAM 
copolymers exhibit substantially lower cell cytotoxicity and 
greater activity  in vivo than that seen with Cremophor micelle 
formulation. Koo et al.  [109] also demonstrated an enhanced 
therapeutic response of PPIX-encapsulated pH-responsive 
micelles for cancer treatment. 
 4.2. PEG-lipid micelles 
 The structure of PEG-lipid micelles correspond to that of 
amphiphilic copolymers. However, the hydrophobic part is 
represented by a lipid instead of hydrophobic polymer block. 
There are several water-soluble polymers-lipid conjugates 
commercially available or they can be easily synthesized; 
however, phosphatidyl ethanolamine (PE) constituted the 
most used diacyl phospholipid chain. The lipid part receives 
the hydrophobic PS, while PEG prevents rapid uptake of the 
particles by RES  [110] . Torchilin et al.  [111 – 113] has exten-
sively studied PEG-PE micelles as PS delivery systems. The 
use of PEG-PE micelles allowed for a 150-fold increase in 
the solubilization of tetraphenylporphyrin (TPP), compared 
with the nonformulated drug. TPP-loaded PEG-PE micelles 
were additionally modifi ed with tumor-specifi c monoclonal 
2C5 antibody (mAb 2C5), which resulted in signifi cantly 
improved anticancer effect of the drug under the PDT condi-
tions against murine Lewis lung carcinoma  in vivo in female 
C57BL/6 mice. Zhang et al.  [114] developed micellar PEG-
DSPE formulations for increasing the solubility of lipophilic 
benzoporphyrins. 
 Cremophor EL is another easily commercially available 
micelle constituent. It is polyethoxylated castor oil and has 
been widely used for the formulation of a variety of hydro-
phobic drugs, also in PDT, as a simple and biocompatible 
solubilization system  [115 – 119] . 
 5. Silica-based nanoparticles 
 Silica is a major component of sand and glass, and it has been 
used in the synthesis of nanoparticles. Functional groups can 
also be added to the surface of silica nanoparticles (SiNPs), 
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making them appealing for designs for different applications. 
Very recently, SiNPs have emerged as promising vectors for 
PDT applications  [120] . Among the variety of nanoparticles, 
SiNPs have several advantages: their particle size, shape, 
porosity, and monodispersibility can be easily controlled dur-
ing their preparation; furthermore, a variety of precursors and 
methods are available for their syntheses, allowing fl exibil-
ity and thus numerous PDT drugs to be encapsulated. SiNPs 
also have advantages as drug vectors. There is no swelling 
or porosity change occurring with change of pH. Moreover, 
SiNPs are known for their compatibility in biological systems 
and are not subject to microbial attack. Although these SiNPs 
do not release the entrapped PS, their porous matrix is per-
meable to molecular as well as  1 O 2 . Therefore, the desired 
photodestructive effect of the drug will be maintained even in 
the encapsulated form. 
 There are many methods to make SiNPs, such as organi-
cally modifi ed silicates (ORMOSIL), hollow silica, mesopo-
rous SiNPs (MSN), and sol-gel method. The St ö ber procedure, 
which is known to generate amorphous SiNPs of a controlled 
size  [121] , the reverse microemulsion (water-in-oil) method, 
and recently direct microemulsion (oil-in-water) procedure 
 [122, 123] , and the sol-gel method have all been applied to 
design nanoparticles for PDT applications. Both noncovalent 
encapsulation and covalent conjugation have been used as 
methods for the immobilization of the PS inside or on the 
surface of the SiNPs  [122] . Noncovalent encapsulation is the 
most frequently described method, whereas covalent linkage 
of the PS appears to be more effi cient, as no release of the PS 
from the nanoparticles occurs. 
 MB (see Figure 2I) is a heterocyclic aromatic chemical 
compound with photodynamic toxicity. Intravenous adminis-
tration of MB is Food and Drug Administration approved for 
methemoglobinemia. However, clinical use of MB is limited 
because of the poor penetration of this drug in the cellular 
compartment of the tumor. Encapsulation of MB inside SiNPs 
is a way to vectorize it and protect it from degradation. Tang 
et al.  [72] was the fi rst to encapsulate MB in ORMOSIL. They 
compared three types sub-200-nm nanoparticles composed of 
PAA, sol-gel silica, and ORMOSIL, respectively. As a result, 
they showed that although PAA nanoparticles exhibited the 
most effi cient delivery of 1O 2 and positive photodynamic 
effect on rat C6 glioma tumor cells, the sol-gel SiNPs had the 
best MB loading but the least effi cient 1O 2 delivery. 
 In 2005, Roy et al.  [124] established the feasibility of using 
ORMOSIL nanoparticles as a carrier for PS. This formula-
tion of nanoparticles overcomes many of the limitations of 
 “ unmodifi ed ” SiNPs. The presence of both hydrophobic and 
hydrophilic groups on the precursor alkoxy organosilane helps 
them to self-assemble as both normal micelles and reverse 
micelles under appropriate conditions. ORMOSIL nanoparti-
cles are prepared from oil-in-water microemulsions, avoiding 
corrosive solvents such as cyclohexane and through a com-
plex purifi cation process. Their organic groups can be further 
modifi ed for the attachment of targeting molecules and can be 
possibly biodegraded through the biochemical decomposition 
of the silicon-carbon bond. 2-Devinyl-2-(1-hexyloxyethyl) 
pyropheophorbide (HPPH) (see Figure 2H), an effective 
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 Figure 8  ORMOSIL nanoparticle bound to porphyrin. 
 As described by Hocine et al.  [126] , a trimethoxysilane functional-
ized tris-cationic porphyrin was prepared and copolymerized intro 
a SiNP. 
PS that is in phase I/II clinical trials, was encapsulated into 
ORMOSIL with diameter of 30 nm  [125] by copolymeriza-
tion mediated by controlled hydrolysis of triethoxyvinylsilane 
and the triethoxysilane-derivatized HPPH in micellar media 
(see Figure  8 ).  In vitro studies demonstrated the active uptake 
of drug-doped nanoparticles into the cytosol of tumor cells. 
Signifi cant damage to such photosensitized tumor cells was 
observed upon irradiation with light of wavelength 650 nm. 
 Following the pioneering work of Roy et al.  [124] and Yan 
et al.  [127] , many other researchers encapsulated PS inside 
SiNPs by noncovalent methods. Different PS, such as MB 
 [72] and PPIX  [128] have been encapsulated or covalently 
linked to ORMOSIL particles. Higher 1O 2 -generation quan-
tum yield was found for the encapsulated PS than for free PS 
with  m -THPC  [127] , HPPH  [124] , or HA  [129] . 
 There is a strong relationship between the sites of subcellular 
localization of the PS and photodamage to nearby organelles 
involved in cell death. Zhou et al.  [129] constructed porous 
hollow silica nanospheres and embedded HA. Compared with 
free HA, the silica embedded HA showed superior light sta-
bility, higher  1 O 2 generation, and  in vitro experiments showed 
the mitochondrial membrane potential was destroyed as evi-
denced by rhodamine-123 staining  [129] . 
 The silicon phthalocyanine, Pc4 was encapsulated in 
ORMOSIL (Pc4SNP) with a size ranging from 25 to 30 nm 
based on hydrophobic silicon by the method modifi ed from 
Roy et al.  [124] . Pc4SNP not only improved the aqueous solu-
bility, stability, and delivery of the photodynamic drug but 
also increased its photodynamic effi cacy compared with free 
Pc4 molecules. Pc4SNP generated photoinduced  1 O 2 more 
effi ciently. They found Pc4SNP was more phototoxic to A375 
or B16-F10 melanoma cells than free Pc4. The mechanism 
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 (A) Gold nanoshell encapsulating a PS. (B) Plasmonic AuNP. The 
local electric fi eld caused by conductance electrons potentiates the 
optical fi eld close to the surface and increases the fl uorescence or 
photoactivity of an attached PS. 
studies of Pc4SNP photodamaged melanoma cells showed an 
increase of intracellular protein-derived peroxides, suggest-
ing a type 2 ( 1 O 2 ) mechanism for phototoxicity. More Pc4SNP 
than free Pc4 were localized in the mitochondria and lyso-
somes and cause cell death primarily by apoptosis. 
 Covalent coupling of the PS inside the nanoparticles offered 
an advantage in that this covalently linked nanofabrication 
meant that the PS is not released during systemic circulation. 
Prasad and collaborators fi rst reported the covalent incor-
poration of PS molecules into ORMOSIL nanoparticles by 
synthesizing iodobenzyl-pyro-silane (IPS) with vinyltriethox-
ysilane in the nonpolar core of Tween-80/water microsmul-
sion. IPS is a precursor for ORMOSIL with the linked PS 
iodobenzylpyropheophorbide  [125] . The covalently incorpo-
rated PS molecules are of an ultralow size (approx. 20 nm), 
which retained their spectroscopic and functional properties 
and could robustly generate cytotoxic  1 O 2 molecules upon 
photoirradiation. The synthesized nanoparticles are highly 
monodispersed and stable in aqueous suspension. Moreover, 
these nanoparticles are also avidly taken up by tumor cells 
 in vitro and exhibit a phototoxic effect on the cultured cells 
proportional to the cellular uptake, thereby highlighting their 
potential in diagnosis and PDT of cancer. 
 PPIX can be considered as a natural PS because ALA is a 
metabolic precursor in the biosynthesis of heme, and PPIX 
is the immediate precursor to heme (see Figure 4). Qian et 
al.  [130] encapsulated PPIX in ormosil nanoparticles (25 nm 
diameter) following Prasad ’ s method. They showed PDT 
effect performed on HeLa cells, and the cell structures were 
destroyed by a 532-nm light source at low dose (2 mW/cm 2 , 
2 min). Simon et al.  [131] recently published the synthesis 
and properties of PPIX in ORMOSIL nanoparticles prepared 
by Prasad ’ s method. There is a strong relationship between the 
sites of subcellular localization of the PPIX and photodamage 
to nearby organelles involved in cell death. The intracellular 
accumulation of PPIX SiNPs takes place in the cytoplasm of 
cells. Higher ROS generation, which leads to cell destruction, 
was found correlated to the presence of PPIX SiNPs in both 
HCT 116 and HT-29 colon cancer cells  [131] . 
 MSN have been also used for various biomedical applications 
such as cell markers or drug and gene delivery platform. MSN 
are a suitable carrier for hydrophobic PS and protect the PS from 
degradation due to their large surface area and pore volume, as 
well as uniform pore size. Tu et al.  [132] conjugated PPIX with 
MSN through covalent bonding to yield PPIX modifi ed MSN 
for PDT. In  in vitro experiments, they found that the uptake of the 
PPIX-modifi ed particles by HeLa cells was quite effi cient. An 
almost linear relationship between cellular uptake and dosage 
was observed. Both necrosis and apoptosis could be observed 
depending on the concentration and dosage- and irradiation time-
dependent loss of cell viability was observed. The same group 
grafted a phosphorescent Pd- meso -tetra(4-carboxyphenyl)por-
phyrin (PdTPP) as the PS in prepared MSN  [133] . 
 A marked advantage of using nanoparticles is that they can 
be used as multifunctional platforms. A single particle plat-
form that combines two functions has been described by Rossi 
and collaborators in 2007  [134] . MB as a PS was added to 
the silica precursor tetraorthosilicate during the growth of the 
silica layer and was therefore entrapped in the silica matrix. 
Then the magnetic cores were prepared by coprecipitation of 
Fe 2 +  /Fe 3 +  ions under alkaline conditions followed by stabi-
lization with tetraethylammonium oxide. Liu et al. reported 
another magnetic nanocarrier using purpurin-18 as a PS for 
PDT  [135] . They continued prepared 2,7,12,18-tetramethyl-
3,8-di(1-propoxyethyl)-13,17-bis-(3-hydroxypropyl)porphy-
rin (PHPP) as a PS encapsulated into silica covered Fe 3 O 4 
magnetic nanoparticles (MNPs)  [136] . 
 6. Gold nanoparticles 
 Gold nanoparticles (AuNPs) have been used in two ways in 
PDT: fi rst, as drug-delivery platforms in a similar manner to 
other inorganic nanoparticles (see Figure  9 A); second, as sur-
face plasmon-enhanced agents taking account of the nonlin-
ear optical fi elds associated with very close distances to metal 
nanoparticles (see Figure 9B). 
 6.1. Standard AuNPs 
 The conjugation of PS molecules to AuNPs  [123] and other 
inorganic nanoparticles  [124, 137 – 139] represents an effec-
tive way to improve the targeting effect and effi cacy for can-
cer treatments  [66, 123, 140 – 145] . 
 It is possible to modify the AuNPs either covalently or non-
covalently with PS  [146] . Moreover, the small size of AuNPs 
can be presented as a benefi t, allowing them to permeate tissue 
and the leaky vasculature of tumors  [147] . In that way, tun-
able AuNPs can serve as both diagnostic and therapeutic tools 
for cancer  [148] once they are recognized for their chemical 
inertness and have minimum toxicity as well  [149] . 
 The AuNPs have good biocompatibility, versatile surfaces, 
tunable sizes, and unique optical properties  [150] . When 
coated with PEG, which has been approved for human intra-
venous application, they can result in promising drug-deliv-
ery systems for cancer PDT  [123] due to the stabilization by 
steric repulsion and inhibition of colloid aggregation in physi-
ological conditions  [151, 152] . 
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 Although PEG provides solubility in water and minimizes 
any protein adsorption [144] , the AuNP surface provides an 
amphiphilic environment for lipophilic PDT drugs  [123] . The 
PEG-AuNP drug-delivery systems for PDT in HeLa cells 
were previously evaluated and showed effi cient drug release 
by membrane-mediated diffusion when the noncovalent 
adsorption of the PS to AuNPs was used  [153] . 
 Using the noncovalent delivery of Pc4 with PEG-gold NPs, 
Cheng et al.  [123] observed surprisingly effi cient release and 
penetration of the drug into the tumor  in vivo . In addition, 
both the drug and the AuNPs were excreted by renal clearance 
and the hepatobiliary system. Another study also revealed 
that pegylated AuNP-Pc4 conjugates dramatically improved 
the delivery of the drug. In addition, the Pc4 could be well 
dispersed in aqueous solutions once it was formulated as an 
AuNP conjugate  [123] . 
 AuNP-modifi ed porphyrin-brucine conjugates have been 
claimed to represent a signifi cant improvement in PDT com-
pared with free PS  [146] . Both  para and  meta substitution 
patterns, when bound to modifi ed AuNPs, were able to effec-
tively reduce tumor size  in vivo , with complete tumor regres-
sion.  In vitro , PDT of synthesized hematoporphyrin-nanogold 
composites was much enhanced if compared with that of the 
original PS alone  [145] . It was also concluded that nanocom-
posites with gold particles of 45 nm presented better results 
than the ones with 15-nm particles, which could be connected 
to the fact that bigger particles can transport more porphyrin 
molecules into malignant cells. 
 6.2. Plasmon-enhanced AuNPs 
 The phenomenon of localized surface plasmon resonance 
is based on the interaction of the conduction electrons of 
metal nanostructures with incoming light  [154] . The electro-
magnetic waves induce an oscillation of these electrons and 
resonances can be observed. These resonances depend on 
parameters such as the kind of metal and its composition (in 
the case of a mixture), geometry (size, shape), and immedi-
ate environment. The last is the basis for its potential use as 
a sensor: for example, using an affi nity layer, certain mol-
ecules bind to the surface of such a structure, infl uencing, and 
shifting the resonance, which can be observed and used as the 
sensed signal for readout. Molecular plasmonics represent the 
fi eld that deals with localized surface (also called particle) 
plasmon resonance effects in interactions with molecular 
components (usually bound to the surface of metal nanostruc-
tures). The observed effects can be used for novel conjugates 
for nano-optics (here the molecules act as a tool) as well as for 
biomolecular analytics aimed at molecular analytes. 
 A report from Fales et al.  [155] in Vo-Dinh ’ s laboratory 
showed that gold nanostars could be tuned for maximal 
absorption in the NIR spectral region and tagged with an 
NIR dye for surface-enhanced resonance Raman scattering. 
Silica coating was used to encapsulate the PS MB in a shell 
around the nanoparticles. Upon 785-nm excitation, surface-
enhanced Raman spectroscopy (SERS) from the Raman dye 
was observed, whereas excitation at 633 nm showed fl uores-
cence from MB. MB-encapsulated nanoparticles showed a 
signifi cant increase in singlet-oxygen generation as compared 
with nanoparticles synthesized without MB. This increased 
singlet-oxygen generation showed a cytotoxic effect on 
BT549 breast cancer cells upon laser irradiation. 
 Khlebtsov et al.  [156] prepared novel composite nanopar-
ticles consisting of a gold-silver nanocage core and a mes-
oporous silica shell functionalized with the photodynamic 
sensitizer Yb-2,4-dimethoxyhematoporphyrin (Yb-HP). In 
addition to the long-wavelength plasmon resonance near 750 –
 800 nm, the composite particles exhibited a 400-nm absor-
bance peak and two fl uorescence peaks, near 580 and 630 nm, 
corresponding to bound Yb-HP. The fabricated nanocompos-
ites generated  1 O 2 under 630-nm excitation and produced heat 
under laser irradiation at the plasmon resonance wavelength 
(750 – 800 nm). In particular, they observed enhanced killing 
of HeLa cells incubated with nanocomposites and irradiated 
by 630-nm light. Furthermore, an additional advantage of 
fabricated conjugates was an IR-luminescence band (900 –
 1060 nm), originating from Yb(3 + ) ions of bound Yb-HP and 
located in the long-wavelength part of the tissue transparency 
window. This modality was used to control the accumulation 
and biodistribution of composite particles in mice bearing 
Ehrlich carcinoma tumors in a comparative study with intra-
venously injected free Yb-HP molecules. 
 7. Semiconductor and quantum dot 
nanoparticles 
 Semiconductors are materials with conduction properties 
intermediate between metals and insulators. The typical 
structure is a crystalline lattice where the electron conduc-
tion band is <4 eV above the valence band. Electrons excited 
to the conduction band (either by an applied voltage or by 
absorption of light) leave behind electron holes, i.e., unoc-
cupied states in the valence band. Both the conduction band 
electrons and the valence band holes contribute to electrical 
conductivity. Although hsemiconductors used in electronics 
are usually made from silicon doped with small amounts of 
other elements, other semiconductors will absorb or emit light 
and are composed of alloys of pairs of elements in the II – VI 
periodic groups (e.g., ZnO, ZnS, CdSe) or the III – V groups 
(GaAs, InN, InP, AlAs). These substances produce excitons 
on photon absorption (a bound state of an electron and hole 
that are attracted to each other by electrostatic force) (see 
Figure  10 A). 
 7.1. Zinc oxide and titanium dioxide 
 Both ZnO and TiO 2 can produce ROS upon light absorption 
by electron transfer reactions involving oxygen and water. 
The active species is thought to be mainly hydroxyl radical 
(HO · )  [157] , but superoxide anion and  1 O 2 are also produced 
 [158, 159] . Most studies have examined excitation of these 
materials with UV light, but recently, attempts have been 
made to use visible light (often blue light) as well  [160] . 
 Zhang et al.  [161] used ZnO nanorods loaded with the 
cytotoxic drug daunorubicin to mediate synergistic killing of 
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 Figure 10  Semiconductor nanoparticles. 
 (A) Semiconductors such as ZnO will form electron-hole pairs upon 
absorption of UVA or blue photons, and these electrons can be trans-
ferred to oxygen-forming superoxide that leads to further ROS. (B) 
Typical QD with CdSe core, followed by a zinc sulfi de capping pas-
sivation layer covered by a biologically compatible layer made of 
thiol containing compounds. PS are covalently attached to the QD 
that can take part in FRET with the emission of the QD being used 
to excite the PS. 
human hepatocarcinoma cells. UV illumination signifi cantly 
improved cytotoxicity over that seen with daunorubicin 
alone. 
 TiO 2 has been more widely studied as a PS than ZnO in a 
process termed  “ photocatalysis, ” which has been proposed as 
an antimicrobial strategy for disinfecting wastewater  [162] . 
However, there have also been reports of the use of photoacti-
vated TiO 2 as an anticancer treatment. Yamaguchi et al.  [163] 
constructed TiO 2 nanoparticles by the adsorption of chemi-
cal modifi ed PEG on the TiO 2 surface. When C6 rat glioma 
cells (both as monolayers and as multicellular spheroids) 
were incubated with TiO 2 -PEG nanoparticles followed by 
UV illumination, 90 % of the cells were killed. Zhang and Sun 
 [164] reported similar results by inactivating Ls-174-t human 
colon carcinoma cells using incubation with TiO 2 nanopar-
ticles and ultraviolet A irradiation (UVA, 320 – 400 nm) but 
had to use much higher concentrations (200 – 1000  μ g/ml) 
possibly because they did not use PEG solubilization. Wang 
et al.  [165] showed that TiO 2 -PDT could produce a therapeu-
tic effect  in vivo as well. They grew U87 gliomas in nude 
mice, injected TiO 2 nanoparticles around the subcutaneous 
tumor, and after 12 h exposed the tumor and irradiated it with 
UVA. Signifi cant areas of tumor necrosis and extended mouse 
survival were obtained by PDT. 
 7.2. Quantum dots 
 QD are semiconductor crystals whose size regulates the band-
gap (difference in energy between the highest valence band 
and the lowest conduction band). The absorption spectrum 
has a relatively broad peak, but the fl uorescence emission is 
relatively narrow and tunable by size. The typical composi-
tion of the alloys in QD is chosen from cadmium selenide 
(CdSe), cadmium sulfi de, indium arsenide, and indium phos-
phide (see Figure 10B). There have been scattered reports 
about the photoactivated generation of ROS after illumina-
tion with UV or visible light, but it is still uncertain whether 
they could be designed to carry out useful PDT  [166] . Some 
workers have used QD as part of a Forster resonance energy 
transfer (FRET) pair to improve excitation of a standard 
PS. For instance, Samia et al.  [167] used CdSe QD with an 
average diameter of 5 nm and linked to a silicon Pc PS(Pc4) 
through an alkyl amino group on the PS. Pc4 is a known PDT 
agent currently undergoing clinical trials  [168] . For excita-
tion wavelengths between 550 and 630 nm, Pc4 was directly 
activated. However, if wavelengths between 400 and 500 nm 
were used, the QD acted as a primary energy donor transfer-
ring excitation to Pc4 with a 77 % FRET effi ciency. In the pro-
cess of investigating the two-step energy transfer mechanism 
in the QD/Pc4/oxygen system, they found that semiconduc-
tor QD alone could actually generate  1 O 2 without a mediat-
ing Pc4 molecule. They measured radiative relaxation of  1 O 2 
causing emission at 1270 nm and found the  1 O 2 quantum 
yield of QD to be 5 % . In comparison, Pc4 alone was reported 
to have a  1 O 2 effi ciency of 43 %  [169] . Theory predicts that 
the lowest excited state of CdSe QD is a triplet state, and it 
appears that the triplet QD can interact with  3 O 2 to generate 
 
1
 O 2 . Moreover, the amount of defect sites on the QD surface 
could be controlled to some extent using additional surface 
passivation layers  [170] , which may systematically improve 
 
1
 O 2 generation. 
 Generalov et al.  [171] suggested that upon entry into a 
cell, QD are trapped and their fl uorescence is quenched in 
endocytic vesicles such as endosomes and lysosomes. They 
investigated the photophysical properties of QD in liposomes 
as an  in vitro vesicle model. Generation of free radicals by 
liposomal QD is inhibited compared with that of free QD. 
Nevertheless, QD fl uorescence lifetime and intensity increases 
due to photolysis of liposomes during irradiation. In addition, 
protein adsorption on the QD surface and the acidic environ-
ment of vesicles also lead to quenching of QD fl uorescence, 
which reappears during irradiation. Morosini et al.  [172] used 
hydrophilic CdTe(S) QD conjugated to folate with different 
spacers (PEG or Jeffamine D-400) and examined phototoxic-
ity against folate-receptor-positive or -negative cancer cells. 
They obtained evidence for foliate-receptor-mediated target-
ing and PDT effects using 515- or 658-nm light. 
 8. Fullerenes 
 Fullerenes are the third allotropic form of carbon material 
forming a family of closed-cage carbon molecules, C 
n
 , where 
n = 60, 70, 72, 76, 84, and even up to 100. The molecules 
characteristically contain 12 pentagons and a variable num-
ber of hexagons arranged in soccer ball structure (Figure  11 ). 
These nanomolecule with their unique structure have a great 
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 Figure 11  Chemical structures of fullerenes used for PDT. 
 (A) Mono-(dimethylpyrolidinium) fullerene (BF4)  [118, 173] . (B) Dicyano diphenylaminofl uorene functionalized fullerene (C60,  > CPAF-
OMe)  [174] . (C) Tris-(dimethylpyrolidinium) fullerene (BF6)  [175, 176] . (D) Hexakis-sulfonated anionic fullerene (FC 4 S)  [177] . 
potential for variety of application and are being recently 
studied for biological activities relevant to biomedical appli-
cations. The fullerenes are seen as potential PDT agents as 
they possess some the characteristics that render them well 
suited as a photosensitive drug. Although pristine C 60 is 
highly insoluble in water and biological media and thus forms 
nanoaggregates, which makes it photoinactive  [178] , fuller-
enes still have gained considerable attention as possible PDT 
mediators  [179] after chemists have exploited this molecule 
by attaching the some hydophilic or amphiphilic functional 
groups  [180] . This functionalization imparts a higher ability 
to produce  1 O 2 , hydroxyl radicals and superoxide anion thus 
making them potent PS (see Figure 11 for structures of some 
functionalized fullerenes used as PS). 
 Following are some of the advantages that these fullerenes 
possess over the traditional PS:
 They are comparatively more photostable and are less pho-• 
tobleached as compared with tetrapyrroles. 
 Fullerenes follow both type 1 and type 2 pathways. • 
 They can be chemically modifi ed easily for tuning the • 
drug ’ s partition coeffi cient for the variation of  in vivo li-
pophilicity and the prediction of their distribution in a 
biological system. 
 To enhance the overall ROS quantum yield, light harvest-• 
ing antenna can be chemically attached on C 60  [174] . 
 Molecular self-assembly of fullerene cages into vesicles • 
allows multivalent drug delivery and can produce self-
assembled nanoparticles that may have different tissue 
targeting properties. 
 In addition to these advantages, fullerenes demonstrate 
some particular disadvantages as PS for PDT. First, their 
extreme hydrophobicity and their innate tendency to aggre-
gate render them even more diffi cult to formulate than other 
tetrapyrrole PS. Nevertheless, there has been many different 
strategies applied for drug delivery of fullerenes, e.g., lipo-
somes  [181 – 183] , micelles  [184, 185] , dendrimers  [186, 187] , 
pegylation  [188 – 191] , cyclodextrin  [192, 193] , and self-nano-
emulsifying systems  [194 – 197] . Second, the main absorption 
of fullerenes is in the blue and green regions of the visible 
spectrum, rather than the red/NIR where light transmission 
through tissue is maximized. This unfavorable absorption 
could possibly be overcome by various strategies such as 
covalent attachment of light harvesting antennae to fullerenes 
 [198 – 202] , using optical clearing agents  [203 – 207] , or using 
two-photon PDT  [208 – 212] . 
 One potential paradox or contradiction in this fi eld is 
the observation that fullerenes act as antioxidants or ROS 
quenchers in the absence of light  [213 – 217] while as produc-
ers of ROS and pro-oxidants under illumination. The obvious 
question then arises: how then can fullerenes scavenge ROS 
and act as antioxidants in the dark on one hand and act as effi -
cient producers of ROS under illumination with the correct 
light parameters on the other ? Andrievsky et al.  [218] in 2009 
fi rst proposed a way to explain this seeming contradiction. 
They showed that the main mechanism by which hydrated 
C 60 can inactivate the highly reactive ROS, hydroxyl radi-
cal, was not by covalently scavenging the radicals but rather 
by action of the coat of  “ ordered water ” that was associated 
with the fullerene nanoparticle  [219] . They also claimed that 
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the ordered water coat could slow down or trap the hydroxyl 
radicals for suffi cient time for two of the radicals to react with 
each other, thus producing the less reactive ROS, hydrogen 
peroxide. 
 There have been many studies using fullerenes as PS to 
mediate PDT of both cancer cells and of pathogenic microor-
ganisms both  in vitro and  in vivo  [220, 221] . The fi rst study 
demonstrating the phototoxic effect of fullerenes was done by 
Tokuyama et al.  [222] using carboxylic acid-functionalized 
fullerenes in HeLa cells. It was shown that tris-malonic acid 
fullerene was more phototoxic than the dendritic derivative in 
killing Jurkat cells when irradiated with UVA or UVB light 
 [223] . Burlaka et al.  [224] used pristine C 60 at 10  μ m with 
visible light from a mercury lamp to produce some phototox-
icity in Ehrlich carcinoma cells or rat thymocytes. Yang et al. 
 [225] reported three C 60 derivatives with two to four malonic 
acid groups (DMA C 60 , TMA C 60 , and QMA C 60 ) that were 
tested for their relative effi cacy in HeLa cells, and the results 
showed the following order of effi cacy: DMA C 60 > TMA 
C 60 > QMA C 60 . 
 There have been several studies from our laboratory using a 
range of functionalized fullerenes  [221] . We tested a group of 
six functionalized fullerenes that were prepared in two groups 
of three compounds  [173, 175] . We established that the C 60 
molecule monosubstituted with a single pyrrolidinium group 
(BF4; Figure 11A) was an effi cient PS that effectively killed a 
panel of mouse cancer cells at the low concentration of 2  μ m 
on exposure to white light. Chiang et al.  [174] reported the 
synthesis of two new photoresponsive diphenylaminofl uo-
rene nanostructures and they investigated their intramolecular 
photoinduced energy and electron transfer phenomena. They 
demonstrated that the large light-harvesting enhancement of 
CPAF-OMe moiety was more effi cient triplet state genera-
tor than the C 60 > cage moiety. C 60 ( > CPAF-OMe; Figure 11B) 
was signifi cantly better than C 60 ( > DPAF-OMe) at light-
mediated killing of human cancer cells. 
 The ability of cationic fullerenes for the PDI of bacteria 
and other pathogens has also been demonstrated in our labo-
ratory. We were the fi rst to demonstrate that cationic water-
soluble functionalized fullerenes, especially the tris-cationic 
compound (BF6; Figure 11C) were effi cient antimicrobial 
PS and could mediate PDI of various classes of microbial 
cells  [175] . In a study by Spesia et al.  [226] , it was reported 
that a novel fulleropyrrolidinium iodide [DT-C 60 (2 + )] pro-
duced PDI  in vitro on  E. coli. Lee et al.  [227] showed that 
C 60 derivatives were effi cient in inactivating  Escherichia coli 
and MS-2 bacteriophage. Recently, we have demonstrated the 
use of innovative cationic fullerenes as broad-spectrum light-
activated antimicrobials, which was determined by quantita-
tive structure-function relationships  [228] . The most effective 
compound overall against the various classes of microbial 
cells had the hexacationic structure. 
 A variety of different delivery vehicles have been tested to 
see if the PDT effi cacy of fullerenes could be improved. Ikeda 
et al.  [229] used a series of liposomal preparations of C 60 con-
taining cationic or anionic lipids together. Illumination with 
136-J/cm 2 350- to 500-nm light gave 85 % cell killing in the 
case of cationic liposomes, and apoptosis was demonstrated. 
Akiyama et al.  [185] solubilized unmodifi ed C 60 with high 
stability using various types of PEG-based block copolymer 
micelles, which showed cytotoxicity under photoirradiation 
in HeLa cells. In another study, both direct and rapid uptake 
(within 10 min) of fullerene into the cell membrane using an 
exchange reaction from a fullerene- γ -cyclodextrin complex, 
and the resulting photodynamic activity for a cancer cell was 
demonstrated  [230] . Doi et al.  [183] showed the PDT activity 
of cerasome-encapsulated C 70 in HeLa cells was similar to that 
of surface cross-linked liposome C 70 , indicating that C 70 can 
act as a PS without release from cerasome membranes. Thus, 
from the above  in vitro studies, it was supposed that fullerenes 
might be suffi ciently active as PS to enable  in vivo applica-
tions both for anticancer and for anti-infective use [231]. 
 In 1997, Tabata et al.  [191] fi rst reported the use of fuller-
enes to carry out PDT of actual tumors. In this study, the 
fullerenes were chemically modifi ed to make it soluble in 
water as well as to enlarge its molecular size by pegylating 
C 60 . On intravenous injection in mice carrying a subcutane-
ous tumor on the back, the C 60 -PEG conjugate demonstrated 
a higher accumulation and more prolonged retention in the 
tumor tissue than in normal tissue. The volume increase of the 
tumor mass was suppressed and the C 60 conjugate exhibited 
a stronger suppressive effect than Photofrin. In another study, 
a novel PS was prepared from fullerene [C(60)] possessing 
magnetic resonance imaging (MRI) activity for effi cient PDT 
of tumor. This therapeutic and diagnostic hybrid system was 
found to be a promising tool to enhance the PDT effi cacy for 
tumor  [190] . 
 Chi et al.  [177] , in a preliminary  in vivo study, performed 
PDT using hydrophilic nanospheres formed from hexa(sulfo-
 n -butyl)-C 60 (FC 4 S; Figure 11D). Intraperitoneal admin-
istration of FC 4 S in mice had a slightly better inhibition 
effectiveness than the intravenous route. 
 We have recently shown  [118] that intraperitoneal 
PDT with BF4 fullerene and white light has signifi cant 
therapeutic effects in a challenging mouse model of dis-
seminated abdominal cancer produced by engineered bio-
luminescent tumor cells. Intraperitoneal injection of a 
preparation of  N -methylpyrrolidinium-fullerene formulated 
in Cremophor-EL micelles followed by white-light illumina-
tion delivered through the peritoneal wall (after creation of a 
skin fl ap) produced a statistically signifi cant reduction in bio-
luminescence signal from the mouse abdomen and a survival 
advantage in mice. This article suggested fullerenes should 
continue to be explored as PS for PDT of cancer and other 
dreaded diseases. 
 In addition to  in vivo anticancer applications, we have been 
able to translate the high degree of antimicrobial action of 
photoactivated fullerenes  in vitro to a therapeutic effect in an 
 in vivo infection model  [176] . We used stable bioluminescent 
bacteria and a low-light imaging system to follow the prog-
ress of the infection noninvasively in real time in two poten-
tially lethal mouse models of infected wounds. An excisional 
wound on the mouse back was contaminated with one of two 
bioluminescent Gram-negative species,  Proteus mirabilis 
(2.5 × 10 7 cells) and  Pseudomonas aeruginosa (5 × 10 6 cells). 
Fullerene-mediated PDT of mice infected with  P. mirabilis 
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led to 82 % survival compared with 8 % survival without treat-
ment (p < 0.001). PDT of mice infected with highly virulent 
 P. aeruginosa did not lead to survival, but when PDT was 
combined with a suboptimal dose of the antibiotic tobramycin 
(6 mg/kg for 1 day), there was a synergistic therapeutic effect 
with a survival of 60 % compared with a survival of 20 % with 
tobramycin alone (p < 0.01). The data suggested that cationic 
fullerenes have clinical potential as an antimicrobial PS for 
superfi cial infections where red light is not needed to pen-
etrate tissue. 
 9. Carbon nanotubes and graphene 
 Carbon nanotubes are allotropes of carbon with a cylindrical 
nanostructure. Nanotubes have been constructed with length-
to-diameter ratio of up to 132,000,000:1  [232] and can be 
several millimeters long, signifi cantly larger than any other 
material. Nanotubes are categorized as single-walled nano-
tubes and multi-walled nanotubes. Most single-walled nano-
tubes have a diameter of close to 1 nm, with a tube length 
that can be many millions of times longer. The structure of a 
single-walled nanotube can be conceptualized by wrapping a 
one-atom-thick layer of graphite called graphene into a seam-
less cylinder. 
 Zhu et al.  [233] engineered a novel molecular complex of 
a PS, an ssDNA aptamer, and single-walled carbon nanotubes 
(SWCNTs) for controllable  1 O 2 generation (Figure  12 A). It is 
well known that  1 O 2 is one of the most important cytotoxic 
agents generated during PDT. Because the lifetime and dif-
fusion distance of  1 O 2 is very limited, a controllable  1 O 2 gen-
eration (SOG) with high selectivity and localization would 
lead to more effi cient and reliable PDT and fewer side effects. 
First, the aptamer was developed by an  in vitro process known 
as systematic evolution of ligands by exponential enrich-
ment. Second, a PS was covalently attached to one end of the 
DNA aptamer that wrapped onto the SWCNT surface. In the 
absence of a target, the design becomes operational by close 
proximity of the PS to the SWCNT surface, which causes effi -
cient quenching of SOG. Importantly, the conformation of the 
probe can be altered upon target binding. Thus, in the pres-
ence of its target, the binding between the aptamer and target 
molecule will disturb the DNA interaction with SWCNTs and 
cause the DNA to fall off the SWCNT surface, resulting in 
a restoration of SOG for PDT applications.  1 O 2 can thus be 
regulated by target binding. 
Bound aptamer
Target
Active chlorin(e6)
Graphene oxide sheets
PS
+
Unbound nanotube
Single walled
carbon nanotube
A
B
Quenched chlorin(e6)
O
H2C
H3C
H3C
H2C
CH2
CH3
CH3
CH3
COOH
COOHHH
HH
N
N N
N
C
O
H3C
H
H H
H
N N
NN
H2C
H2C
CH3
CH3
CH3
CH2
H3C
COOH
COOH
C
Aptamer
 Figure 12  SWCNT and graphene. 
 (A) Zhu et al.  [233] engineered a novel molecular complex of a PS, an ssDNA aptamer, and SWCNTs that became activated upon aptamer 
binding to its target releasing the SWCNT that had been quenching the PS. (B) PS can be  “ sandwiched ” between two sheets of GO, providing 
enhanced activity. 
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 Qualitative Jablonski diagrams of two possible photon UC processes and a two-photon excitation for use in PDT. ESA, excited state absorption; 
ETU, energy transfer UC; Si, intermediate; Sv, virtual. 
 An important issue with regard to PDT agents is the deliv-
ery of these molecules into the organs/tumor tissues/tissues 
cells. There are many strategies for drug targeting, but a 
satisfactory multifunctional delivery agent is nevertheless 
needed. SWCNTs are one distinct possibility. Erbas et al. 
 [234] tested the use of noncovalent functionalized SWCNTs 
as delivery agents for Bodipy-based potential PS in PDT. 
The target molecule carried a solubilizing group (PEG2000), 
red-absorbing chromophore (distyryl-Bodipy), intersystem-
crossing promoter heavy atoms (iodines at 2 and 6 positions 
of the Bodipy core), and two pyrene substituents on the styryl 
branches of the chromophore for p-stacking interactions with 
the SWCNTs. 
 Shiraki et al.  [235] developed a thermo- and light-respon-
sive system consisting of SWCNT and helical polysaccharide 
modifi ed with poly(NIPAM) side-chains through supramo-
lecular polymer wrapping. Coagulation of the complex can 
be induced by the external stimuli, which leads to a catch-
and-release action of a porphyrin derivative. This method, 
therefore, is expected to develop a novel site selective PDT 
technique by dual-light irradiation using visible and NIR 
light sources; for example, a nondisease site close to a disease 
site can be protected by irradiating with NIR laser through 
SWCNT quenching and only the disease site was selectively 
decomposed by visible light irradiation. 
 Graphene oxide (GO) consists of sheets sp2- and sp3-
hybridized carbon atoms, including carboxyl, hydroxyl, and 
epoxide functional groups  [236] . It has gained increasing 
attention owing to its excellent biocompatibility, well-dis-
persed stability in aqueous solution, and ability of the GO 
sheets, which have a large specifi c surface area, to be loaded 
with large amounts of hydrophobic drugs  [237] such as doxo-
rubicin  [238] . Zhou et al.  [239] loaded GO with HA (GO-HA) 
as shown in Figure 12B, a perylenequinonoid hydrophobic 
nonporphyrin PS isolated from parasitic fungi  Hypocrella 
bambuase found in the People ’ s Republic of China  [240]. 
The optimal loading was found to be 1 mg/mg by fl uores-
cence and the GO-HA had a somewhat lower  1 O 2 quantum 
yield compared with free HA. The stability of the GO-HA in 
aqueous solution was much higher than HA, and there was 
less dark toxicity but comparable phototoxicity toward HeLa 
cells. Huang et al.  [241] conjugated GO with folic acid and 
then loaded ce6 (80 % loading). These nanocarriers delivered 
ce6 to MGC803 folate-receptor-positive cells, and this uptake 
could be blocked by free folate, suggesting a receptor-medi-
ated process.  In vitro PDT gave signifi cant killing. Tian et al. 
 [242] loaded ce6 onto PEG-functionalized GO  via  π - π supra-
molecular stacking. They not only studied PDT killing using a 
660-nm laser but also found signifi cant synergism when PDT 
was combined with the preadministered photothermal effect 
of exciting the GO with a 808-nm laser .
 10. Miscellaneous nanoparticles 
 In this section, we will cover some nanoparticles that have 
been used for PDT and that do not conveniently fi t into our 
other categories. 
 10.1. Upconverting nanoparticles 
 Upconversion (UC) refers to a family of nonlinear optical 
processes in which the sequential absorption of two or more 
photons leads to the emission of light at shorter wavelength 
than the excitation wavelength (anti-Stokes-type emission). 
In contrast to other emission processes based on multiphoton 
absorption, UC can be effi ciently excited even at low excita-
tion densities. There are three possible mechanisms for this to 
occur  [243] : APTE effect (for the French  “ addition de photon 
par transferts d ’ energie ” ), later also named ETU for energy 
transfer upconversion  [4, 5] excited-state absorption (ESA), 
and photon avalanche (PA). All three mechanisms are based 
on the sequential absorption of two or more photons by meta-
stable, long-lived energy states. This sequential absorption 
leads to the population of a highly excited state from which 
UC emission occurs. In the case of ESA, the emitting species 
sequentially absorb at least two photons of suitable energy to 
reach the emitting level (Figure  13 ). In ETU, one photon is 
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absorbed by the ground state but subsequent energy transfer 
from neighboring metastable states results in the population of 
a highly excited state of the emitting species (Figure 13). The 
most effi cient UC mechanisms (even at room temperature) are 
present in solid-state materials doped with lanthanide ions. 
The most effi cient UC phosphor to date, Yb 3 +  - and Er 3 +  -doped 
NaYF 4 , was introduced by Menyuk et al. in 1972  [244] . The 
development of nanocrystal research has evoked increasing 
interest in the development of synthesis routes, which allow 
the synthesis of highly effi cient, small UC particles with nar-
row size distribution able to form transparent solutions in a 
wide range of solvents. High-quality UC nanocrystals can 
be routinely synthesized, and their solubility, particle size, 
crystallographic phase, optical properties, and shape can be 
controlled  [243] . In recent years, these particles have been 
discussed as promising alternatives to organic fl uorophos-
phors and QD in the fi eld of medical imaging and PDT. 
 Chatterjee and Yong  [245] designed UC NPs composed of 
sodium yttrium fl uoride (NaYF 4 ) nanocrystals co-doped with 
Yb 3 +  and Er 3 +  with a polymeric coat of poly(ethylenimine) 
(PEI). PS ZnPC was superfi cially noncovalently adsorbed to 
the NPs. They could image cellular uptake by fl uorescence 
imaging microscopy of PEI/NaYF 4 :Yb 3 +  :Er 3 +  NPs, and they 
found signifi cant cell death following irradiation with NIR 
laser light. 
 Ungun et al.  [246] synthesized UCP nanocrystals by a 
high-temperature ligand exchange reaction that produced 
nanoparticles of approximately 160 nm in diameter with a 
hydrophobic trioctyl phosphene-oleic acid surface coating. 
The co-encapsulation of the UCP nanocrystals with the TPP 
PS and a PEG protective layer to form the complex func-
tional nanoparticle UCPs was done in one step using a  “ fl ash 
nano-precipitation process ”  [247] . When these UCP-NP were 
excited by two 980-nm photons, they produced UC 560-nm 
light that excited the TPP and produced  1 O 2 as measured by 
bleaching of the fl uorescent dye 9,10-anthracenedipropionic 
acid. 
 Wang et al.  [248] were able to show that UCP NP con-
taining ce6 were able to kill HeLa and 4T1 cancer cells after 
illumination with a 980-nm laser. Furthermore, they used 
intratumoral injection of UCP NP into 4T1 subcutaneous 
tumors growing on backs of Balb/c mice followed by 980-nm 
laser (0.5 W/cm 2 for 30 min to give 900 J/cm 2 ). Tumors on 
7 of 10 mice disappeared in 2 weeks after PDT and showed 
no tumor regrowth and survived over 60 days. Hematoxylin 
and eosin staining of tumor slices collected from UCNP-ce6 
PDT treated mice at day 7 showed that most tumor cells were 
severely destroyed, in marked contrast to the control tumor 
slices where no obvious damage was found. 
 10.2. Simultaneous two-photon excitation 
nanoparticles 
 In contrast to UC, simultaneous two-photon excitation (Figure 
13) requires extremely high power densities that can only 
be readily achieved with femtosecond lasers. Two-photon 
absorption (TPA) was originally proposed by Maria G ö ppert-
Mayer in 1931 in her doctoral dissertation  [208] , but the fi rst 
experimental verifi cation was provided by Werner Kaiser in 
1961, facilitated by the recent development of the laser, which 
was required for excitation because of the intrinsically low 
intensity of TPA. TPA is a third-order nonlinear optical pro-
cess and therefore is most effi cient at very high intensities. 
 Long-wavelength near-IR light  λ > 780 nm has relatively 
low photon energy ( > 1.5 eV) and is generally too low to 
activate most PS by one-photon excitation. Therefore, one-
photon absorption fails in the phototherapeutic window 
780 – 950 nm, where tissues have maximum transparency to 
light. Sensitization by simultaneous TPA  [209] combines 
the energy of two identical photons arriving at the PS at the 
same time and can provide the energy of a single photon of 
half the wavelength, which is suffi cient to excite the PS to 
the fi rst excited singlet state. It was not until the 1990s that 
rational design principles for the construction of two-photon-
absorbing molecules began to be developed, in response to a 
need from imaging and data storage technologies and aided 
by the rapid increases in computer power that allowed quan-
tum calculations to be made. The accurate quantum mechani-
cal analysis of two-photon absorbance is orders of magnitude 
more computationally intensive than that of one-photon 
absorbance. 
 Gary-Bobo et al.  [249] prepared MSN containing a por-
phyrin for effi cient TPA-PDT. The MSN surface was post-
functionalized with a mannose derivative to target lectins 
overexpressed by cancer cells  [14] . Incubated with cancer 
cells, these MSNs were nontoxic under daylight illumina-
tion. TPE-PDT with these MSNs was investigated  in vitro on 
human breast and colon cancer cell lines.  In vivo experiments 
were also performed on athymic mice bearing xenografted 
tumors from colon cancer cells. They showed that the por-
phyrin was covalently encapsulated inside MSNs (6850 units 
of PS per nanoparticle) and having a hydrodynamic diameter 
of 118 nm. Grafting of the mannose moiety on the surface 
yielded MSN-mannose. The TPA properties of PS are retained 
in the MSNs with 1200 Goppert-Mayer units [GM, where 1 
GM = 10(50) cm 4 s/photon/molecule] per PS. TPA-PDT was 
carried out at 760 nm using a confocal microscope equipped 
with a mode-locked Ti/sapphire laser generating 100-fs-wide 
pulses at a rate of 80 MHz. The laser beam was focused by 
a microscope objective lens (10 × , NA 0.4). The wells were 
irradiated at 760 nm by three successive scans of 1-s dura-
tion each at an average power of 80 mW. The surface of the 
scanned areas was 1.5 × 1.5 mm (mean fl uence of 10.6 J/cm 2 ). 
Three cancer cells lines (MCF-7, MDA-MB-231, and HCT-
116) showed TPA-PDT killing with evidence of mannose 
receptor targeting. TPA-PDT  in vivo , on nude mice bearing 
HCT-116 xenografts used intravenous injection with MSN1-
mannose (16 mg/kg). Three hours later, tumors were submit-
ted to two-photon irradiation at 760 nm for three periods of 
3 min and light was focused on three different tumor areas. 
Thirty days after treatment, PDT-treated tumors showed a 
growth delay compared with saline controls. 
 Grimland et al.  [250] conjugated polymer nanoparticles 
(CP dots) that allow effi cient intraparticle energy transfer 
from the conjugated polymer donor to a variety of acceptors. 
These nanoparticles formed from poly(2-fl uoro-1,4-phenylene 
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 This consists of a magnetite core (Fe 3 O 4 ) coated by a biologically 
compatible layer and the PS are covalently attached by linkers. 
vinylene) (PFPV) were conjugated to TPP and were 50 nm 
diameter and formed a stable colloidal suspension in water. 
The TPA cross section of TPP-doped PFPV nanoparticles at 
an excitation wavelength of 800 nm was determined using 
a passively mode-locked Ti/sapphire laser (800 nm, 100 fs). 
The particles contained 600 molecules of PFPV and 6000 
molecules of TPP. The two-photon fl uorescence cross section 
of the TPP-doped PFPV CP dots was determined to be 5 × 10 5 
GM. The  1 O 2 quantum yield in aqueous solutions was deter-
mined to be 0.5 for PFPV dots doped with TPP. 
 10.3. Self-illuminating nanoparticles 
 Chen and Zhang  [139] developed an innovative class of nano-
particle for PDT that was termed  “ self-lighting.  ” It relied on 
the combination of conventional ionizing radiation therapy 
with PDT. Scintillation or persistent luminescence nanoparti-
cles with attached PS such as porphyrins were used and upon 
exposure to ionizing radiation such as X-rays, the nanopar-
ticles emitted scintillation or persistent luminescence, which, 
in turn, activated the PS; as a consequence,  1 O 2 was produced. 
Importantly, this approach could be used for deep tumor treat-
ment as X-rays can penetrate much deeper into the tissue 
compared with visible light. First, absorption of the ionizing 
radiation (X-ray photons) creates primary electrons and holes 
in pairs. Next, thermalization of the low-energy secondary 
electrons (holes) results in a number of electron-hole pairs 
(excitons) with energy roughly equal to the band-gap energy 
Eg or electron-phonon relaxation. Energy transfer from the 
electron-hole pairs to the luminescence centers induces their 
excitation and emission from the luminescence centers occurs. 
High-density materials made with high-atomic-number ele-
ments will have high luminescence effi ciency. Nanoparticles 
constructed from BaFBr/Eu 2 +  have three emission bands, 
peaking at around 400, 500, and 640 nm, respectively. The 
emission spectrum of these nanoparticles perfectly matches 
the absorption spectra of most porphyrins such as 5,15-
diphenyl-2-3-dihydroxychlorin. 
 10.4. Magnetic nanoparticles 
 MNPs have been intensively investigated as MRI contrast 
agents and exhibit a unique MR contrast enhancement effect 
that enables noninvasive MRI of cell traffi cking, gene expres-
sion, and cancer  [251] . In addition, MNPs have been recognized 
as a promising tool for the site-specifi c delivery of drugs and 
diagnostic agents by an external magnetic fi eld applied outside 
the body  [252] . Figure  14 shows the general structure of a MNP 
with biocompatible coating and PS attached by a linker. 
 Huang et al.  [253] coprecipitated FeSO 4 and FeCl 2 to form 
10-nm MNP, functionalized them with amino groups using 
a silane, and conjugated ce6 using carbodiimide chemistry. 
Fluorescence microscopy showed uptake into human gastric 
cancer MGC803 cells, and phototoxicity was observed after 
24-h incubation. MGC803 tumors grown in nude mice were 
imaged by both  in vivo fl uorescence and MRI after intrave-
nous injection of 0.125  μ mol ce6 eq/kg up to 8 h postinjection. 
 In vivo PDT was carried out at 8-h time point with 632.8 nm 
HeNe laser, with a total light dose 5.88 J/cm 2 at an irradi-
ance of 9.8 mW/cm 2 , and signifi cant tumor destruction was 
observed. 
 Tada et al.  [254] prepared nanoparticles consisting of a 
silica layer over a magnetic core composed of magnetite and 
entrapping MB as PS. The  1 O 2 quantum yield of MB was 
reduced somewhat to a level of 6 % . Ding et al.  [255] prepared 
magnetic Fe 3 O 4 coated with  meso -tetra(4-sulfonatophenyl) 
porphyrin dihydrochloride. They were able to perform MRI 
in mice with tumors and demonstrate a therapeutic effect after 
light delivery. 
 Sun et al.  [256] prepared magnetic chitosan nanoparticles 
(MTCNPs) of 20.6-nm diameter containing a porphyrin PS 
called PHPP. Drug loading was 5.08 % (w / w). First, the Fe 3 O 4 
was incubated with PHPP and then added to chitosan. Fe 3 O 4 
nanoparticles have extensive hydroxyl groups on the surface 
and thus possess negative charges. The protonation of the 
amine groups of chitosan allowed electrostatic interaction 
of cationic chitosan and negatively charged Fe 3 O 4 . Results 
showed that PHPP-MTCNPs could be used in MRI monitored 
PDT with excellent targeting and imaging ability. Nontoxicity 
and high PDT effi cacy on SW480 carcinoma cells was shown 
 in vitro . Two bilateral tumors were grown in nude mice and 
PHPP-MTCNP (1.25  μ mol PHPP eq/kg) were injected intra-
venously. A magnetic fi eld (1 Tesla) was placed over the 
left tumor that led to increased accumulation measured by 
MRI after 8 h. Laser illumination (650-nm, power density, 
9.8 mW/cm 2 ; fl uence, 5.88 J/cm 2 ) led to signifi cant regression 
of the magnetically targeted tumor not seen in the contralat-
eral tumor treated with PDT. 
 10.5. Lipoprotein nanoparticles 
 Lipoproteins are naturally occurring nanoparticles composed 
of specifi c apoproteins, phospholipids, and cholesterol on the 
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 The reconstituted lipoprotein nanoparticle consists of the hydropho-
bic PS dissolved in the hydrophobic core of cholesterol esters and 
triglycerides surrounded by an outer layer of unesterifi ed cholesterol 
and phospholipids and held together by an apoprotein chain. 
surface that encapsulate a mixture of cholesterol esters and 
triglycerides in the hydrophobic core  [257] . The family con-
sists of chylomicron (75 – 1200 nm), very-low-density lipo-
protein (30 – 80 nm), low-density lipoprotein (LDL, 18 – 25 
nm), and high-density lipoprotein (HDL, 5 – 12 nm). Such bio-
compatible, lipid-protein complexes are ideal for loading and 
delivering cancer therapeutic and diagnostic agents. By mim-
icking the endogenous shape and structure of lipoproteins, the 
nanocarrier can remain in circulation for an extended period 
while largely evading the reticuloendothelial cells in the 
body ’ s defenses. The small size ( < 30 nm) of LDL and HDL 
allows them to maneuver deeply into tumors. Furthermore, 
LDL has innate cancer-targeting potential, as LDL receptors 
are overexpressed on malignant cells and has been used to 
incorporate diverse hydrophobic molecules and deliver them 
to tumors. 
 Li et al.  [258] prepared a tetra- t -butyl silicon phthalo-
cyanine bisoleate, SiPcBOA, and effi ciently incorporated it 
into reconstituted LDL to form r-SiPcBOA-LDL (see Figure 
 15 ). It was tested with HepG2 human hepatocarcinoma cells 
(which overexpress LDL receptors). The nanoparticles had 
a very high payload (SiPcBOA to LDL molar ratio, 3000 –
 35,001:1). Using electron microscopy, they found reconsti-
tuted LDL essentially retained the mean particle size of native 
LDL. As acetylated LDL binds to scavenger receptors of 
endothelial and microglial cells instead of LDLR, SiPcBOA-
reconstituted acetylated LDL, r-SiPcBOA-AcLDL, was also 
prepared to serve as a negative control to validate the LDL 
receptor LDLR-targeting specifi city. Confocal microscopy 
studies demonstrated that the internalization of r-SiPcBOA-
LDL by HepG2 tumor cells was mediated by LDLR pathway. 
The  in vitro PDT response of HepG2 cells to r-SiPcBOALDL 
was compared with SiPcBOA-free drug control using a clo-
nogenic assay and indicated greatly enhanced effi cacy of 
LDLR-targeted PDT. 
 Marotta et al.  [259] from the same group prepared an anal-
ogous molecule, bacteriochlorin e6 bisoleate and incorpo-
rated it into reconstituted LDL to form (r-Bchl-BOA-LDL). 
HepG2 cells were injected into nude mice to form subcutane-
ous tumors. Three hours after intravenous doses of 2  μ mol/kg 
r-Bchl-BOA-LDL, 750-nm laser illumination was delivered 
at fl uences of 125, 150, or 175 J/cm 2 at a fl uence rate of 75 
mW/cm 2 . The best tumor response was obtained with the 125 
J/cm 2 , which also gave the least phototoxicity to normal foot-
pad. 
 11. Actively-targeted nanoparticles 
 Ideally, PDT holds the promise of dual selectivity, a preferen-
tial tumor uptake of the PS and the restricted illuminated area 
for an improved selectivity. However, for applications of PDT 
in complex anatomical sites, confi ned irradiation is not pos-
sible, leading to phototoxicity to normal tissues. Moreover, 
several cases of prolonged skin photosensitivity after sunlight 
exposition have been reported  [260] . Targeted drug-delivery 
systems are one of the strategies proposed to solve these prob-
lems underlying nonspecifi c PS accumulation. Active target-
ing encompasses the strategy of coupling a specifi c entity 
to the surface of the nanoparticle, enhancing their selective 
interaction with target cells recognized by specifi c markers. 
Although MoAbs has received the most attention, biochemi-
cal, metabolic, and physiological alterations of tumor cells 
offer numerous other potent targets to exploit during the deliv-
ery of PS. Targeting nanoparticles with these specifi c moieties 
offers several advantages. The specifi c localization increases 
the effi ciency and selectivity of PDT, resulting in a lower 
effective dose. Unlike other strategies such as ligand-PS con-
jugates, targeted nanoparticles can deliver thousands of mole-
cules of PS using fewer molecules of ligands per nanoparticle, 
reducing considerably the cost and time-consuming synthesis 
of some of these targeting moieties. In addition, the presen-
tation of multiple targeting molecules on the surface of the 
nanoparticle can restore multivalent binding of monovalent 
antibody fragments and hence increase their binding avidity 
for the target antigens. In this section, we will further describe 
some of these macromolecular moieties used to selectively 
address PS-containing nanoparticles to tumor tissues. Figure 
 16 schematically illustrates some of the targeting ligands that 
have been used to target PS-loaded nanoparticles. 
 Targeted drug delivery is a promising strategy to improve 
the effi cacy and safety of PS. However, a potential drawback 
of active targeting is related to the so-called binding site bar-
rier phenomenon. This hypothesis considers the idea that 
macromolecular ligands could be prevented from penetrating 
tumors through their successful binding to the target receptor. 
Some works have reported direct experimental evidence of 
the binding site barrier phenomenon in various systems  [261, 
262] . 
 11.1. Monoclonal antibodies 
 Antibody-based drug delivery is a widely studied approach 
to improve the selectivity of PDT. MoAbs have the advan-
tage over most of other tumoritropics to possess a high degree 
of specifi city. However, they have some drawbacks such the 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
132  Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ? 
Abs
PEG
Peptides
Hyaluronic acid
Folate ligands
Aptamers
 Figure 16  Schematic illustration of active targeting of nanoparti-
cles. Tumor targeting ligands such as antibodies, peptides, aptamers, 
folate, and hyaluronic can be attached to the PS-containing nanopar-
ticle, frequently by means of linkers such as PEG. 
cost, the time-consuming production and the possible immune 
reactions that limit their extensive use and commercializa-
tion. The use of antibody fragments, such as F 
ab V and scF v 
molecules, is an alternative that preserves the high degree of 
specifi city, but the immune reactions are signifi cantly reduced 
 [28] . Numerous published works prove the validity of the use 
of MoAb in a wide range of nanoparticles for selectively tar-
geted PDT. The high epidermal growth factor (EGF) recep-
tor expression that frequently accompanies several tumor 
types makes this receptor an attractive candidate for target-
ing strategy. Stuchinskaya et al.  [263] recently published an 
antibody-phthalocyanine-AuNP conjugate to selectively tar-
get breast cancer cells that overexpress the HER2 EGF recep-
tor (EGFR). Kameyama et al.  [264] used the conjugation of 
an anti-EGFR MoAb with a verteporfi n-loaded nanoparticles. 
They found a threefold higher incorporation of the complex 
into A431 cells  in vitro , and the tumor size  in vivo experiments 
showed a signifi cant decrease compared with tumors treated 
with verteporfi n-nanoparticle complex without the antibody. 
Nevertheless, the use of MoAb for targeting therapies offers 
a wide range of alternatives. Rancan et al.  [265] developed a 
fullerene hexa-adduct conjugated with the MoAb rituximab. 
The antibody conjugate conserved the affi nity and selectivity 
toward CD20-positive B-lymphocytes, whereas the antibody-
free complex did not show any intracellular uptake. T-43 
MoAb was used to demonstrate a MoAb-dependent enhance-
ment of the uptake by a bladder tumor cell line of a pheo-
phorbide-a liposomes  [266] . In a similar approach, aluminum 
sulfonated phthalocyanine (liposomes linked to a targeting 
MoAb 791T/36 showed an  in vitro antibody-dependent cyto-
toxicity on different cell lines expressing the target antigen 
 [267] . MoAbs have also been attached to MNPs with a pre-
liminary success  [268] . 
 11.2. Aptamers 
 Aptamers are small, simple, and synthetic DNA or RNA oli-
gonucleotides and represent a nonimmunogenic alternative to 
binding to their target proteins specifi cally  [269] . Their intrin-
sic advantages, such as reproducible synthesis, adaptability 
for molecular engineering, easy manipulation, and excellent 
stability make the design of controllable PDT feasible  [270] . 
Zhu et al.  [233] have designed a novel PDT agent using a 
human  α -thrombin aptamer covalently linked with ce6 and 
then wrapping onto the surface of an SWCNT. As SWCNTs 
are effi cient quenchers of  1 O 2 , the photodamage was only 
achieved when the binding of target thrombin disturbed the 
DNA interaction with the SWCNT and caused the aptamer 
to undergo spatial unquenching, restoring  1 O 2 generation. 
Stephanopoulos et al.  [271] used a targeted, multivalent PDT 
vehicle for treatment of Jurkat leukemia T cells. Bacteriophage 
MS2 virus capsid was internally modifi ed with up to 180 por-
phyrins and the exterior with 20 copies of a Jurkat-specifi c 
aptamer. These capsids were able to target and selectively 
kill more that 76 % of cells after illumination. Despite their 
advantages, fewer functional aptamers have been identifi ed 
compared with antibodies. As an attractive alternative, special 
attention is given to vitamins as targeting ligands for selective 
PDT. 
 11.3. Folate ligands 
 Folic acid, also known as vitamin B9, is essential for the 
proliferation and maintenance of cells. The overexpression 
of folate receptor (FR) on a variety of epithelial cancer cells 
including cancers of ovary, lung, kidney, breast, brain, and 
colon  [272] and the high affi nity of folate for its receptor has 
attracted wide attention as a targeting agent for tumor selec-
tivity. Folate-decorated liposomes  [273] , QD-folic acid conju-
gates  [172] , pullulan/folate-PS nanogels  [274] , or FR-targeted 
solid lipid nanoparticles  [275] used the specifi c interaction 
with FR to assess superior cancer cell selectivity. FR cell 
selectivity greatly increases phototoxicity and cellular uptake 
compared with nonfunctionalized drug-delivery systems. 
Huang et al.  [241] also developed the folic acid-conjugated 
GO as a novel targeting drug-delivery system for PDT. It was 
found that ce6-loaded nanocarriers can signifi cantly increase 
the accumulation in tumor cells and lead to a remarkable pho-
todynamic effi cacy on MGC803 cells upon irradiation. These 
fi ndings suggest that folic acid has great potential as an effec-
tive drug-delivery system in targeting PDT. 
 11.4. Peptides 
 Small peptides that selectively recognize tumor cells repre-
sent an excellent approach for targeting therapies. Peptides are 
synthetic molecules consisting of several amino acids linked 
together and, in contrast to proteins, generally do not pos-
sess a well-defi ned three-dimensional structure. Their effec-
tive tissue penetration and selective binding to cancer cells 
make peptides ideal candidates for the delivery of therapeutic 
agents. Anti-angiogenesis-based research has become one of 
the most promising and actively explored fi elds. Recent stud-
ies from Qin [56] and Hah [276] have shown that the attach-
ment of F3 peptide groups to the MB-conjugated polymeric 
nanoparticles results in effective and selective tumor cell 
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killing. F3 has been shown to selectively target to tumor cells 
and angiogenic vasculature and to also have cell-penetrating 
properties. Reddy et al.  [73] also used the surface-localized 
tumor vasculature targeting F3 peptide for a selective treat-
ment and imaging of brain tumors. Treatment of glioma-bear-
ing rats with targeted multifunctional polymeric nanoparticles 
showed a signifi cant improvement in survival rate compared 
with nontargeted nanoparticles. Rozenzhak et al.  [277] dem-
onstrated that the use of a noncovalent peptide (Pep-1) facili-
tated the internalization of QD. Pep-1 seems to be extremely 
effi cient in the targeting of proteins into cells independent of 
endocytosis. Oku and Ishii  [278] used the APRPG peptide, 
specifi c for angiogenic endothelium, to modify BDP-MA-
containing liposomes. This neovessel-targeted strategy results 
in strong tumor destruction with a low dose of the PS. 
 11.5. Hyaluronic acid 
 Hyaluronic acid is a targeting ligand that recognizes CD44, 
known as the hyaluronic acid receptor, which is involved in 
cell adhesion and is also overexpressed on many cancer cells 
 [279] . CD44 targeting has been used to deliver many types 
of anticancer agents, for instance, doxorubicin or mitomycin 
c encapsulated within the aqueous core of the high-molec-
ular-weight hyaluronic-modifi ed liposomes  [280] . Li et al. 
 [281] prepared acetylated low-molecular-weight hyaluronic 
acid/pheophorbide a conjugate for the preparation of nano-
gels (Ac-HA-Pba). The nanogels observed were smaller 
than 200 nm in size, with a monodispersed size distribu-
tion. The nanogels displayed autophotoquenching qualities 
in water. The critical self-quenching concentration of the 
conjugates was found to have decreased as the content of 
Pba increased. Although Pba was conjugated with HA, the 
nanogel photoactivity, in terms of fl uorescent properties, 
 
1
 O 2 generation, and photocytotoxicity, was approximately 
maintained. Confocal imaging and fl ow cytometry analysis 
showed that Ac-HA-Pba nanogels were rapidly internalized 
into HeLa cells  via an HA-induced endocytosis mechanism, 
a process that could be blocked with the application of an 
excess of HA polymer. 
 12.  In vivo studies 
 Most PS molecules are hydrophobic and can aggregate eas-
ily in aqueous media, which can affect their photophysical 
properties (decrease of  1 O 2 formation), chemical properties 
(decrease of solubility), and biological properties (biodistri-
bution and pharmacokinetics). Moreover, some PS that were 
initially considered promising in  in vitro studies have never 
been evaluated for clinical applications, mainly because their 
 in vivo selectivity or effectiveness was not high enough due 
to aggregation. Nanoparticles represent emerging PS carriers 
that show great promise for PDT  in vivo compared with con-
ventional PS. 
 Aliphatic PLA, PGA, and their copolymer PLGA are 
among the most studied synthetic polymers for drug delivery 
 in vivo . 
 Due to its well-vascularized structure, the chorioallantoic 
membrane (CAM) of the developing chick embryo can act as 
an  in vivo model to study photodynamic activity of PS-loaded 
nanoparticles. Vargas et al.  [282] compared the effi cacy 
the vascular effects of  p -THPP either as a free solution or 
encapsulated in polymeric nanoparticles in the CAM model. 
They showed that PDT-induced vascular occlusion of the PS 
 p -THPP is enhanced when encapsulated into nanoparticle 
delivery systems. The superiority of nanoparticles over solu-
bilized  p -THPP might be related to the reduced diffusion of 
 p -THPP nanoparticles out of the vessels. Where free p-THPP 
appeared to leak out before generating an effi cient vascular 
occlusion, nanoparticles appeared to confer a longer resi-
dence time inside the vasculature, thus inducing an increased 
PDT effect  [282] . Recently, they investigated the main 
physicochemical and photochemical properties of  m -THPP 
encapsulated in PLGA nanoparticles of different sizes  via an 
emulsifi cation-diffusion technique. They reported that small-
est size of nanoparticles (117 nm) exhibited the highest rate of 
ROS production and the fastest  m -THPP release in the CAM 
model  [36] . Pegaz et al.  [283] compared the photodynamic 
activities of PS with different hydrophobicity entrapped in 
biodegradable nanoparticles composed of poly( d,l -lactic 
acid). Analysis of nanoparticles showed that the dye was more 
effectively entrapped in the polymeric matrix when its degree 
of lipophilicity increased.  Meso -tetra-(4-carboxyphenyl)-
porphyrin (TCPP) and ce6 were less hydrophobic than 
 m -THPP and pheophorbidea. The nanoparticles loaded with 
the most lipophilic molecule ( m -THPP) induced vascular 
damage in the CAM model. 
 Dendrimers are a new class of polymeric materials with 
repeatedly branched molecules, recognized as the most 
versatile and compositionally and structurally controlled 
nanoscale building blocks. Their properties are dominated 
by the functional groups. Casas et al.  [284] demonstrated 
a good correlation between  in vitro and  in vivo properties 
of an ALA-dendrimer conjugate that is able to induce sus-
tained and effi cient porphyrin production. The ability of the 
dendrimer to enhance porphyrin synthesis was investigated 
in a BALB/c mouse model of subcutaneous LM3 tumors 
after systemic intraperitoneal administration. The ALA-
dendrimer induced sustained porphyrin production for over 
24 h, and background values were not reached until 48 h 
after administration, whereas the porphyrin kinetics from 
ALA exhibited an early peak between 3 and 4 h in most tis-
sues. Integrated porphyrin accumulation from the dendrimer 
and ALA, at equivalent molar ratios, was comparable show-
ing that the majority of ALA residues were liberated from 
the dendrimer. The porphyrin kinetics appeared to be gov-
erned by the rate of enzymatic cleavage of ALA from the 
dendrimer. 
 Reddy et al.  [73] have developed a multifunctional poly-
meric nanoparticle consisting of a surface-localized tumor 
vasculature and tumor-targeting F3 peptide that encapsulated 
Photofrin. The rats from the Photofrin group had a median 
survival time of 13 days, whereas animals treated with the 
F3-targeted Photofrin nanoparticles had a median survival of 
33 days, with three animals surviving past 60 days. Moreover, 
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 Table 1  Examples of nanotoxicology studies from the recent literature. 
Cell function damage or alteration Samples Reference
Cellular damage Membrane Cationic NP, CNT  [290, 291] 
protein Metal oxide NP, polystyrene, dentrimer, carbon nanomaterial  [292, 293] ,
DNA AgNPs  [294] 
Mitochondria Cationic NP, CdSe QD  [290, 295, 296] 
Liposomal Cationic NP, CNT  [290, 295, 297, 298] 
Endoplasmic reticulum QD  [296] 
Oxidative stress UFP, CNT, metal oxide NP, cationic NP  [290, 295, 297 – 299] 
Tissue and organ Infl ammation Metal oxide NP, CNT  [298, 299] 
Fibrogenesis CNT  [298, 300] ,
Blood SiO 2 , AuNP, TiO 2  [301 – 303] 
Lung UFP, AgNP, SiO 2 , TiO 2 , QD, AuNP  [304 – 307] 
Brain UFP, TiO 2  [308, 309] 
Bone marrow QD, metallo-fullerene, polylactic acid NP  [310] 
Liver, kidney UFP, AgNP, AuNP  [304, 311, 312] 
Immune system ZnO  [313] 
 Largely based on a table in the review by Meng et al.  [314] . 
 CNT, carbon nanotube; NP, nanoparticle; QD, quantum dot; UFP, ultrafi ne particle. 
two of these three animals were found to be disease-free 6 
months after treatment. 
 Barth et al.  [285] investigated the possibility of using 
nanotechnology enabled PDT to treat leukemia, a form of 
blood cancer not generally treated with PDT. Indocyanine 
green (ICG), which is a highly fl uorescent NIR dye that 
can also act as a PS, was loaded into nontoxic and nonag-
gregating calcium phosphosilicate nanoparticles (CPSNP). 
Citrate-functionalized CPSNP were activated by 1-ethyl-3
-(3-dimethylaminopropyl)-carbodiimide and then reacted 
with sulfo-NHS to form a high-yield, semistable interme-
diate. The sulfo-NHS ester-containing CPSNP were then 
reacted with heterobifunctional PEG containing both amine 
and carboxyl functional groups. This synthetic process was 
repeated with the carboxyl-PEG functional terminals of the 
pegylated CPSNP to generate sulfo-NHS ester-containing 
pegylated CPSNP, which readily reacted with antibodies 
that recognize CD117 or CD96, surface features enhanced 
on leukemia stem cells. Cell-specifi c PDT killing was 
observed in  in vitro studies with 32D-p210-GFP murine leu-
kemia stem cells and with CD34 + CD38-CD96 + cells from 
an acute myeloid leukemia patient. An  in vivo study used 
intravenous injection of 32D-p210-GFP into C3H/HeJ mice 
to establish myeloid leukemia. The targeted ICG-CPSNP 
was intravenously injected (0.1 ml of 200 n m ICG equiva-
lent concentration) followed within 30 min by 12.5 J/cm 2 
of 810-nm laser directed to the surgically exposed spleen. 
When the treatment was repeated every 3 days, a 29 % dis-
ease-free survival was obtained. 
 13. Nanotoxicology 
 The recent emergence of widespread biomedical and 
industrial applications of nanotechnology has given rise 
to a whole new area of nanotoxicology  [286, 287] . This 
discipline is based on the widely held assumption that 
materials, which are largely harmless on the normal mac-
roscopic scale, can exhibit completely different biological 
properties on the nanoscopic scale and that undiscovered 
harmful effects both on people and on the environment may 
pose threats to health. There is even a new journal titled 
 Nanotoxicology . Nanoparticles have much larger surface 
area to unit mass ratios, which in some cases may lead 
to greater proinfl ammatory effects (for example, in lung 
tissue)  [288] . In addition, some nanoparticles seem to be 
able to translocate from their site of deposition to distant 
sites such as the blood and the brain  [289] . Nanoparticle 
toxicologists study the brain, blood, liver, skin, and gut 
in addition to the traditional concentration on lung toxic-
ity. Table  1 shows a selection of recent reports concern-
ing nanotoxicology both  in vitro and  in vivo based on a 
table in a review by Meng et al.  [314] . Nanotoxicity can 
be caused through inhalation, ingestion, skin uptake, and 
injection of engineered NPs. Importantly, NPS toxicity 
depends on multiple factors derived from both individual 
NPs physicochemical properties and environmental condi-
tions: NPs size, charge, concentration, outer coating bioac-
tivity (capping material, functional groups), and oxidative, 
photolytic, and mechanical stability have each been shown 
to be determining factors in NPs toxicity  [315] . The greater 
surface area per mass compared with larger-sized particles 
of the same chemistry renders NP more active biologically. 
In addition, the internalization of NP was highly dependent 
on size, with the most effi cient uptake occurring within the 
25- to 50-nm size range  [316] . Ultrafi ne particles (UFP) 
are defi ned as a size  < 100 nm NPs, which has most active 
bioactivity. This activity includes a potential for infl amma-
tory and pro-oxidant effects but can also exhibit antioxi-
dant activity. 
 It has long been known that asbestosis fi bers cause asbes-
tosis and mesothelioma when inhaled, and several authors 
have asked whether SWCNT (which have similar char-
acteristics to asbestosis fi bers) can have similar adverse 
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effects  [317 – 319] . Reports that fullerenes exhibited toxic-
ity toward various fi sh  [320, 321] have been discounted by 
other authors  [322] and attributed to the presence of a tetra-
hydrofuran bioproduct introduced during fullerene prepara-
tion  [323] . 
 The other important area of nanotoxicology has been 
that of QD. The possible use of materials such as CdSe 
 [324] and cadmium telluride (CdTe)  [325] in QD construc-
tion has led to concerns about heavy metal toxicity, which 
would preclude any clinical use. These studies concluded 
that QD could cause indirect  in vivo genetic damage, which 
may be attributed to free radical-induced oxidative stress 
in mice. 
 14. Conclusion 
 At the end of this review, it is necessary for the authors to 
address the question that we originally posed,  “ can nano-
technology potentiate PDT ? ” The answer in some areas is an 
unequivocal  “ yes, ” but in other areas, the jury is still out. One 
of the areas where nanotechnology has made huge improve-
ments is in the use of different drug-delivery vehicles for PS, 
particularly in the use of liposomes  [326] . The enormous 
clinical success of Visudyne (total sales of several billion $) 
have made it an important member of the list of approved 
liposomal drugs  [327] . Liposomal Visudyne has also widened 
the acceptance of preformulated drug-delivery vehicles in the 
PDT fi eld. 
 In many of the articles covered in the previous sections of 
the present review, the authors have compared their particu-
lar nanoparticle formulated PS with the identical PS deliv-
ered in its free form. In some cases, major improvements 
in cell uptake, tumor localization, and PDT response were 
observed for the nanoparticle formulation. Some of these 
reports, however, use PSs that are not particularly effec-
tive in their free form so that nanoformulated preparations 
automatically appear better. Such criticisms could be made 
in the case of, for example, ce6 and PPIX. These PS are 
known to be only moderately effective in their free unfor-
mulated form. Other PSs, for example, Foscan ( m -THPC) 
are so effective in their free state that encapsulating them 
into nanoparticles is likely to only reduce their effective-
ness. Of course, it could then be argued that improved phar-
macokinetics, better tumor targeting, or lower normal tissue 
phototoxicity would be a desirable consequence of reducing 
their overall excessive PDT activity, which could otherwise 
damage normal tissue. 
 Lessons learned from past drug-delivery problems in 
PDT will only underscore the necessity of using appro-
priate well-defi ned and well-characterized nanoparticle 
vehicles in the future. It is hoped that these nanocarriers 
will improve the phamacokinetics, serum stability, biodis-
tribution, tumor targeting, and photophysics of many PS. 
The pronounced tendency of most PS to undergo self-ag-
gregation is due to the inherent electron-delocalized planar 
structures needed to have a high visible absorption  [328] . 
When this structural attribute is combined with an over-
all hydrophobic substitution pattern, it is not surprising 
that insolubility and aggregation in water is a big prob-
lem. The ability of these PS to satisfactorily dissolve in 
the hydrophobic domains of lipid bilayers of liposomes  [3] 
or the interior of detergent micelles is responsible for the 
dramatically improved performance of PDT mediated by 
these delivery vehicles. 
 There has recently been an explosion of interest in the 
area of  “ theranostics ”  [329] . This area can be defi ned as the 
combination of diagnostic, imaging, and therapeutic agents 
on the same platform  [330] . These combination agent plat-
forms frequently take the form of multifunctional nanopar-
ticles  [331, 332] . For the detection/imaging functionality, it 
is possible to use one or more from the following list  [333] : 
fl uorescence imaging (based on attached fl uorophores), pho-
toacoustic imaging (based on intrinsic or attached absorb-
ers), SERS (based on intrinsic gold or silver), MRI (based on 
attached paramagnetic relaxation agents), positron emission 
tomography (PET, based on attached PET isotopes), single-
photon emission computed tomography (based on attached 
 γ -emitting isotopes). Although the therapeutic functional-
ity can take the form of attached cytotoxic drugs that are 
released from the nanoparticle  [330] or therapeutic radioiso-
topes  [334] , many groups have constructed a light-activated 
modality into their multifunctional nanoparticle that is either 
photothermal or photodynamic (or even both at the same 
time). This property of multifunctionality is one of the areas 
where the concepts of nanotechnology will be critical in fur-
ther progress. 
 The use of active targeting moieties to direct PS-loaded 
nanoparticles to tumors or other biological targets is another 
rapidly growing area where nanotechnology may provide a 
distinct advantage over traditional conjugation methodology. 
If the targeting ligand (antibody, peptide, folate, aptamer, etc.) 
is attached directly to the PS, the number of PS that can be 
delivered to each tumor cell is limited. Note that a typical 
number of receptors per tumor cell is about 100,000, and the 
number of PS needed to kill a cancer cell could be as high as 
10 7 . Therefore, each receptor might need to deliver as many 
as 100 PS molecules, and the best method of ensuring this 
ratio is to attach the targeting ligand to a nanoparticle loaded 
with PS. 
 The rapid growth in nanotechnology we have seen in the 
last decade is only going to further continue in the coming 
years, and we expect that the applications of nanotechnology 
to potentiate PDT will also continue to grow and become ever 
more convincing. 
 Acknowledgements 
 Research conducted in the Hamblin Laboratory is supported by 
NIH (RO1 AI050875 to MRH) and US Air Force MFEL Program 
(FA9550-04-1-0079). T.D. was partially supported by a Bullock-
Wellman Fellowship Award and an Airlift Research Foundation 
Extremity Trauma Research Grant (grant 109421). L.Y.C. was sup-
ported by NIH grant 1R01CA137108. 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
136  Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ? 
 References 
 [1]  Keene JP, Kessel D, Land EJ, Redmond RW, Truscott TG. Direct 
detection of singlet oxygen sensitized by haematoporphyrin and 
related compounds.  Photochem. Photobiol . 1986, 43, 117 – 120. 
 [2]  Damoiseau X, Schuitmaker HJ, Lagerberg JW, Hoebeke M. 
Increase of the photosensitizing effi ciency of the bacteriochlo-
rin a by liposome-incorporation.  J. Photochem. Photobiol .  B 
2001, 60, 50 – 60. 
 [3]  Derycke AS, de Witte PA. Liposomes for photodynamic ther-
apy.  Adv. Drug Deliv. Rev . 2004, 56, 17 – 30. 
 [4]  Bangham AD. A correlation between surface charge and coagu-
lant action of phospholipids.  Nature 1961, 192, 1197 – 1198. 
 [5]  Paszko E, Ehrhardt C, Senge MO, Kelleher DP, Reynolds 
JV. Nanodrug applications in photodynamic therapy. 
 Photodiagnosis. Photodyn. Ther . 2011, 8, 14 – 29. 
 [6]  Kozlowska D, Foran P, MacMahon P, Shelly MJ, Eustace S, 
O ’ Kennedy R. Molecular and magnetic resonance imaging: the 
value of immunoliposomes.  Adv. Drug Deliv. Rev . 2009, 61, 
1402 – 1411. 
 [7]  Vemuri S, Rhodes CT. Preparation and characterization of lipo-
somes as therapeutic delivery systems: a review.  Pharm. Acta 
Helv . 1995, 70, 95 – 111. 
 [8]  Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: 
an update review.  Curr. Drug Deliv . 2007, 4, 297 – 305. 
 [9]  Jiang F, Lilge L, Grenier J, Li Y, Wilson MD, Chopp M. 
Photodynamic therapy of U87 human glioma in nude rat using 
liposome-delivered Photofrin.  Lasers Surg. Med . 1998, 22, 
74 – 80. 
 [10]  Jiang F, Lilge L, Logie B, Li Y, Chopp M. Photodynamic 
therapy of 9L gliosarcoma with liposome-delivered Photofrin. 
 Photochem. Photobiol . 1997, 65, 701 – 706. 
 [11]  Wang ZJ, He YY, Huang CG, Huang JS, Huang YC, An JY, 
Gu Y, Jiang LJ. Pharmacokinetics, tissue distribution and pho-
todynamic therapy effi cacy of liposomal-delivered hypocrellin 
A, a potential photosensitizer for tumor therapy.  Photochem. 
Photobiol . 1999, 70, 773 – 780. 
 [12]  Liu R. Methods of making liposomes containing hydro-monoben-
zoporphyrin photosensitizer. U. S. Patent 5707608. 1998. 
 [13]  Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic 
therapy with verteporfi n in age-related macular degeneration: 
a systematic review of effi cacy, safety, treatment modifi cations 
and pharmacoeconomic properties.  Acta Ophthalmol . 2009, 87, 
118 – 132. 
 [14]  Isele U, van Hoogevest P, Leuenberger H, Capraro HG, 
Schieweck K. Pharmaceutical development of CGP 55847: a 
liposomal Zn-phthalocyanine formulation using a controlled 
organic solvent dilution method.  Proc. SPIE . 1994, 2078, 397. 
 [15]  Ochsner M. Light scattering of human skin: a comparison 
between zinc (II)-phthalocyanine and Photofrin II.  J. Photochem. 
Photobiol .  B 1996, 32, 3 – 9. 
 [16]  Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos 
D. Sterically stabilized liposomes: a hypothesis on the molecu-
lar origin of the extended circulation times.  Biochim. Biophys. 
Acta 1991, 1070, 187 – 192. 
 [17]  Moreira JN, Gaspar R, Allen TM. Targeting Stealth liposomes 
in a murine model of human small cell lung cancer.  Biochim. 
Biophys. Acta 2001, 1515, 167 – 176. 
 [18]  Needham D, McIntosh TJ, Lasic DD. Repulsive interactions 
and mechanical stability of polymer-grafted lipid membranes. 
 Biochim. Biophys. Acta 1992, 1108, 40 – 48. 
 [19]  Torchilin VP. Recent advances with liposomes as pharmaceuti-
cal carriers.  Nat. Rev. Drug Discov . 2005, 4, 145 – 160. 
 [20]  Gijsens A, Derycke A, Missiaen L, De Vos D, Huwyler J, 
Eberle A, de Witte P. Targeting of the photocytotoxic compound 
AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. 
 Int. J. Cancer 2002, 101, 78 – 85. 
 [21]  Zuluaga MF, Mailhos C, Robinson G, Shima DT, Gurny R, 
Lange N. Synergies of VEGF inhibition and photodynamic 
therapy in the treatment of age-related macular degeneration. 
 Invest. Ophthalmol. Vis. Sci . 2007, 48, 1767 – 1772. 
 [22]  Bikram M, West JL. Thermo-responsive systems for controlled 
drug delivery.  Expert Opin. Drug Deliv . 2008, 5, 1077 – 1091. 
 [23]  Powell ME, Hill SA, Saunders MI, Hoskin PJ, Chaplin DJ. 
Human tumor blood fl ow is enhanced by nicotinamide and car-
bogen breathing.  Cancer Res . 1997, 57, 5261 – 5264. 
 [24]  Oku N, Saito N, Namba Y, Tsukada H, Dolphin D, Okada S. 
Application of long-circulating liposomes to cancer photody-
namic therapy.  Biol. Pharm. Bull . 1997, 20, 670 – 673. 
 [25]  Bakowsky H, Richter T, Kneuer C, Hoekstra D, Rothe U, 
Bendas G, Ehrhardt C, Bakowsky U. Adhesion characteris-
tics and stability assessment of lectin-modifi ed liposomes for 
site-specifi c drug delivery.  Biochim. Biophys. Acta 2008, 1778, 
242 – 249. 
 [26]  Mastrobattista E, Koning GA, Storm G. Immunoliposomes for 
the targeted delivery of antitumor drugs.  Adv. Drug Deliv. Rev . 
1999, 40, 103 – 127. 
 [27]  Sapra P, Allen TM. Internalizing antibodies are necessary for 
improved therapeutic effi cacy of antibody-targeted liposomal 
drugs.  Cancer Res . 2002, 62, 7190 – 7194. 
 [28]  Allen TM, Lopes de Menezes D, Hansen CB, Moase EH. 
Stealth® liposomes for the targeting of drugs in cancer therapy. In 
“Targeting of drugs 6: strategies for stealth therapeutic systems”, 
Gregoriadis G, Ed. Plenum Press: New York, 300, 61–75. 
 [29]  Tammela T, Saaristo A, Holopainen T, Yla-Herttuala S, Andersson 
LC, Virolainen S, Immonen I, Alitalo K. Photodynamic ablation 
of lymphatic vessels and intralymphatic cancer cells prevents 
metastasis.  Sci. Transl. Med . 2011, 3, 69ra11. 
 [30]  Nisnevitch M, Nakonechny F, Nitzan Y. Photodynamic antimi-
crobial chemotherapy by liposome-encapsulated water-soluble 
photosensitizers.  Bioorg. Khim . 2010, 36, 396 – 402. 
 [31]  Tsai T, Yang YT, Wang TH, Chien HF, Chen CT. Improved pho-
todynamic inactivation of gram-positive bacteria using hemato-
porphyrin encapsulated in liposomes and micelles.  Lasers Surg. 
Med . 2009, 41, 316 – 322. 
 [32]  Bombelli C, Bordi F, Ferro S, Giansanti L, Jori G, Mancini G, 
Mazzuca C, Monti D, Ricchelli F, Sennato S, Venanzi M. New 
cationic liposomes as vehicles of m-tetrahydroxyphenylchlorin 
in photodynamic therapy of infectious diseases.  Mol. Pharm . 
2008, 5, 672 – 679. 
 [33]  Ferro S, Ricchelli F, Monti D, Mancini G, Jori G. Effi cient pho-
toinactivation of methicillin-resistant Staphylococcus aureus by 
a novel porphyrin incorporated into a poly-cationic liposome. 
 Int. J. Biochem. Cell Biol . 2007, 39, 1026 – 1034. 
 [34]  Sharma SK, Dai T, Kharkwal GB, Huang YY, Huang L, De Arce 
VJ, Tegos GP, Hamblin MR. Drug discovery of antimicrobial 
photosensitizers using animal models.  Curr. Pharm. Des . 2011. 
 [35]  Longo JP, Leal SC, Simioni AR, de Fatima Menezes Almeida-
Santos M, Tedesco AC, Azevedo RB. Photodynamic therapy 
disinfection of carious tissue mediated by aluminum-chloride-
phthalocyanine entrapped in cationic liposomes: an in vitro and 
clinical study.  Lasers Med. Sci . 2011. DOI: 10.1007/s10103-
011-0962-6 . 
 [36]  Zhou S, Kawakami S, Yamashita F, Hashida M. Intranasal 
administration of CpG DNA lipoplex prevents pulmonary 
metastasis in mice.  Cancer Lett . 2010, 287, 75 – 81. 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ?  137
 [37]  Detty MR, Gibson SL, Wagner SJ. Current clinical and preclinical 
photosensitizers for use in photodynamic therapy.  J. Med. Chem . 
2004, 47, 3897 – 3915. DOI: 10.1007/s10103-011-0962-6. 
 [38]  Shim G, Lee S, Kim YB, Kim CW, Oh YK. Enhanced tumor 
localization and retention of chlorin e6 in cationic nanolipo-
plexes potentiate the tumor ablation effects of photodynamic 
therapy.  Nanotechnology 2011, 22, 365101. 
 [39]  Santos-Magalhaes NS, Pontes A, Pereira VM, Caetano MN. 
Colloidal carriers for benzathine penicillin G: nanoemulsions 
and nanocapsules.  Int. J. Pharm . 2000, 208, 71 – 80. 
 [40]  Tadros T, Izquierdo P, Esquena J, Solans C. Formation and 
stability of nano-emulsions.  Adv. Colloid Interface Sci . 2004, 
108 – 109, 303 – 318. 
 [41]  Junping W, Takayama K, Nagai T, Maitani Y. Pharmacokinetics 
and antitumor effects of vincristine carried by microemulsions 
composed of PEG-lipid, oleic acid, vitamin E and cholesterol. 
 Int. J. Pharm . 2003, 251, 13 – 21. 
 [42]  Primo FL, Bentley MV, Tedesco AC. Photophysical studies 
and in vitro skin permeation/retention of Foscan/nanoemulsion 
(NE) applicable to photodynamic therapy skin cancer treatment. 
 J. Nanosci. Nanotechnol . 2008, 8, 340 – 347. 
 [43]  Primo FL, Rodrigues MM, Simioni AR, Lacava ZG, Morais PC, 
Tedesco AC. Photosensitizer-loaded magnetic nanoemulsion 
for use in synergic photodynamic and magnetohyperthermia 
therapies of neoplastic cells.  J. Nanosci. Nanotechnol . 2008, 8, 
5873 – 5877. 
 [44]  Krammer B, Plaetzer K. ALA and its clinical impact, from bench 
to bedside.  Photochem. Photobiol .  Sci . 2008, 7, 283 – 289. 
 [45]  Donnelly RF, McCarron PA, Morrow DI, Sibani SA, Woolfson 
AD. Photosensitiser delivery for photodynamic therapy. Part 
1: topical carrier platforms.  Expert Opin. Drug Deliv . 2008, 5, 
757 – 766. 
 [46]  Maisch T, Santarelli F, Schreml S, Babilas P, Szeimies RM. 
Fluorescence induction of protoporphyrin IX by a new 5-amin-
olevulinic acid nanoemulsion used for photodynamic therapy in 
a full-thickness ex vivo skin model.  Exp. Dermatol . 2010, 19, 
e302 – e305. 
 [47]  Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka 
T, Krahn-Senftleben G, Reich K, Pabst G, Voss D, Foguet M, 
Gahlmann R, Lubbert H, Reinhold U. Photodynamic therapy 
with BF-200 ALA for the treatment of actinic keratosis: results 
of a prospective, randomized, double-blind, placebo-controlled 
phase III study.  Br. J. Dermatol . 2010, 163, 386 – 394. 
 [48]  Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe 
T, Sasisekharan R. Temporal targeting of tumour cells and neo-
vasculature with a nanoscale delivery system.  Nature 2005, 
436, 568 – 572. 
 [49]  Kerbel RS, Kamen BA. The anti-angiogenic basis of metro-
nomic chemotherapy.  Nat. Rev. Cancer 2004, 4, 423 – 436. 
 [50]  Semenza GL. Surviving ischemia: adaptive responses medi-
ated by hypoxia-inducible factor 1.  J. Clin. Invest . 2000, 106, 
809 – 812. 
 [51]  Lovell JF, Jin CS, Huynh E, Jin H, Kim C, Rubinstein JL, Chan 
WC, Cao W, Wang LV, Zheng G. Porphysome nanovesicles 
generated by porphyrin bilayers for use as multimodal biopho-
tonic contrast agents.  Nat. Mater . 2011, 10, 324 – 332. 
 [52]  de Souza N. One particle to rule them all ?  Nat. Methods . 2011, 
8, 370 – 371. 
 [53]  Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug 
delivery: the need for precision in reporting particle size param-
eters.  Eur. J. Pharm. Biopharm . 2008, 69, 1 – 9. 
 [54]  Maeda H. The enhanced permeability and retention (EPR) 
effect in tumor vasculature: the key role of tumor-selective 
macromolecular drug targeting.  Adv. Enzyme Regul . 2001, 41, 
189 – 207. 
 [55]  Fadel M, Kassab K, Fadeel DA. Zinc phthalocyanine-loaded 
PLGA biodegradable nanoparticles for photodynamic therapy 
in tumor-bearing mice.  Lasers Med. Sci . 2010, 25, 283 – 292. 
 [56]  Qin M, Hah HJ, Kim G, Nie G, Lee YE, Kopelman R. Methylene 
blue covalently loaded polyacrylamide nanoparticles for 
enhanced tumor-targeted photodynamic therapy.  Photochem. 
Photobiol .  Sci . 2011, 10, 832 – 841. 
 [57]  Kopecek J, Kopeckova P, Minko T, Lu Z. HPMA copolymer-
anticancer drug conjugates: design, activity and mechanism of 
action.  Eur. J. Pharm. Biopharm . 2000, 50, 61 – 81. 
 [58]  Battah S, Balaratnam S, Casas A, O ’ Neill S, Edwards C, Batlle 
A, Dobbin P, MacRobert AJ. Macromolecular delivery of 
5-aminolaevulinic acid for photodynamic therapy using den-
drimer conjugates.  Mol. Cancer Ther . 2007, 6, 876 – 885. 
 [59]  Hamblin MR, Miller JL, Rizvi I, Ortel B, Maytin EV, Hasan T. 
Pegylation of a chlorin(e6) polymer conjugate increases tumor 
targeting of photosensitizer.  Cancer Res . 2001, 61, 7155 – 7162. 
 [60]  Lee SJ, Park K, Oh YK, Kwon SH, Her S, Kim IS, Choi K, Kim 
H, Lee SG, Kim K, Kwon IC. Tumor specifi city and therapeutic 
effi cacy of photosensitizer-encapsulated glycol chitosan-based 
nanoparticles in tumor-bearing mice.  Biomaterials 2009, 30, 
2929 – 2939. 
 [61]  Panyam J, Labhasetwar V. Biodegradable nanoparticles for 
drug and gene delivery to cells and tissue.  Adv. Drug Deliv. Rev . 
2003, 55, 329 – 347. 
 [62]  Zeisser-Labouebe M, Lange N, Gurny R, Delie F. Hypericin-
loaded nanoparticles for the photodynamic treatment of ovarian 
cancer.  Int. J. Pharm . 2006, 326, 174 – 181. 
 [63]  Konan YN, Berton M, Gurny R, Allemann E. Enhanced pho-
todynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin 
by incorporation into sub-200 nm nanoparticles.  Eur. J. Pharm. 
Sci . 2003, 18, 241 – 249. 
 [64]  Konan-Kouakou YN, Boch R, Gurny R, Allemann E. In vitro 
and in vivo activities of verteporfi n-loaded nanoparticles.  J. 
Control. Release 2005, 103, 83 – 91. 
 [65]  Vargas A, Eid M, Fanchaouy M, Gurny R, Delie F. In vivo 
photodynamic activity of photosensitizer-loaded nanoparticles: 
formulation properties, administration parameters and biologi-
cal issues involved in PDT outcome.  Eur. J. Pharm. Biopharm . 
2008, 69, 43 – 53. 
 [66]  Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photody-
namic therapy: an emerging paradigm.  Adv. Drug Deliv. Rev . 
2008, 60, 1627 – 1637. 
 [67]  Shive MS, Anderson JM. Biodegradation and biocompatibility 
of PLA and PLGA microspheres.  Adv. Drug Deliv. Rev . 1997, 
28, 5 – 24. 
 [68]  Lee YE, Kopelman R. Polymeric nanoparticles for photody-
namic therapy.  Methods Mol. Biol . 2011, 726, 151 – 178. 
 [69]  Cosmetic Ingredient Review Expert Panel. Amended fi nal report 
on the safety assessment of polyacrylamide and acrylamide resi-
dues in cosmetics.  Int. J. Toxicol . 2005, 24(Suppl 2), 21 – 50. 
 [70]  Koo YE, Reddy GR, Bhojani M, Schneider R, Philbert MA, 
Rehemtulla A, Ross BD, Kopelman R. Brain cancer diagnosis 
and therapy with nanoplatforms.  Adv. Drug Deliv. Rev . 2006, 
58, 1556 – 1577. 
 [71]  Tang W, Xu H, Park EJ, Philbert MA, Kopelman R. 
Encapsulation of methylene blue in polyacrylamide nanoparti-
cle platforms protects its photodynamic effectiveness.  Biochem. 
Biophys. Res. Commun . 2008, 369, 579 – 583. 
 [72]  Tang W, Xu H, Kopelman R, Philbert MA. Photodynamic char-
acterization and in vitro application of methylene blue-containing 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
138  Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ? 
nanoparticle platforms.  Photochem. Photobiol . 2005, 81, 
242 – 249. 
 [73]  Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, 
Hall DE, Kim G, Koo YE, Woolliscroft MJ, Sugai JV, Johnson 
TD, Philbert MA, Kopelman R, Rehemtulla A, Ross BD. 
Vascular targeted nanoparticles for imaging and treatment of 
brain tumors.  Clin. Cancer Res . 2006, 12, 6677 – 6686. 
 [74]  Gao D, Xu H, Philbert MA, Kopelman R. Ultrafi ne hydrogel 
nanoparticles: synthetic approach and therapeutic application in 
living cells.  Angew. Chem. Int. Ed. Engl . 2007, 46, 2224 – 2227. 
 [75]  Wu J, Xu H, Tang W, Kopelman R, Philbert MA, Xi C. 
Eradication of bacteria in suspension and biofi lms using meth-
ylene blue-loaded dynamic nanoplatforms.  Antimicrob. Agents 
Chemother . 2009, 53, 3042 – 3048. 
 [76]  Krinick NL, Sun Y, Joyner D, Spikes JD, Straight RC, Kopecek 
J. A polymeric drug delivery system for the simultaneous deliv-
ery of drugs activatable by enzymes and/or light.  J. Biomater. 
Sci. Polym. Ed . 1994, 5, 303 – 324. 
 [77]  Peterson CM, Lu JM, Sun Y, Peterson CA, Shiah JG, Straight 
RC, Kopecek J. Combination chemotherapy and photody-
namic therapy with N-(2-hydroxypropyl) methacrylamide 
copolymer-bound anticancer drugs inhibit human ovarian car-
cinoma heterotransplanted in nude mice.  Cancer Res . 1996, 56, 
3980 – 3985. 
 [78]  Li WS, Aida T. Dendrimer porphyrins and phthalocyanines. 
 Chem. Rev . 2009, 109, 6047 – 6076. 
 [79]  Nishiyama N, Morimoto Y, Jang WD, Kataoka K. Design and 
development of dendrimer photosensitizer-incorporated poly-
meric micelles for enhanced photodynamic therapy.  Adv. Drug 
Deliv. Rev . 2009, 61, 327 – 338. 
 [80]  Li Y, Jang WD, Nishiyama N, Kishimura A, Kawauchi S, 
Morimoto Y, Miake S, Yamashita T, Kikuchi M, Aida T, Kataoka 
K. Dendrimer generation effects on photodynamic effi cacy of 
dendrimer porphyrins and dendrimer-loaded supramolecular 
nanocarriers.  Chem. Mater . 2007, 19, 5557 – 5562. 
 [81]  Nishiyama N, Nakagishi Y, Morimoto Y, Lai PS, Miyazaki K, 
Urano K, Horie S, Kumagai M, Fukushima S, Cheng Y, Jang 
WD, Kikuchi M, Kataoka K. Enhanced photodynamic cancer 
treatment by supramolecular nanocarriers charged with den-
drimer phthalocyanine.  J. Control. Release 2009, 133, 245 – 251. 
 [82]  Li P, Zhou G, Zhu X, Li G, Yan P, Shen L, Xu Q, Hamblin MR. 
Photodynamic therapy with hyperbranched poly(ether-ester) 
chlorin(e6) nanoparticles on human tongue carcinoma Cal-27 
cells.  Photodiagnosis. Photodyn. Ther . 2011. http://dx.doi.
org/10.1016/j.pdpdt.2011.08.001. 
 [83]  Chen K, Preuss A, Hackbarth S, Wacker M, Langer K, Roder B. 
Novel photosensitizer-protein nanoparticles for photodynamic 
therapy: photophysical characterization and in vitro investiga-
tions.  J. Photochem. Photobiol .  B 2009, 96, 66 – 74. 
 [84]  Deda DK, Uchoa AF, Carita E, Baptista MS, Toma HE, Araki K. 
A new micro/nanoencapsulated porphyrin formulation for PDT 
treatment.  Int. J. Pharm . 2009, 376, 76 – 83. 
 [85]  Labrude P, Becq C. [Pharmacist and chemist Henri Braconnot]. 
 Rev. Hist. Pharm. (Paris) . 2003, 51, 61 – 78. 
 [86]  Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a 
promising system in novel drug delivery.  Chem. Pharm. Bull. 
(Tokyo) . 2010, 58, 1423 – 1430. 
 [87]  Reza Saboktakin M, Tabatabaie RM, Maharramov A, Ali 
Ramazanov M. Synthesis and in vitro studies of biodegradable 
modifi ed chitosan nanoparticles for photodynamic treatment of 
cancer.  Int. J. Biol. Macromol . 2011, 49, 1059 – 1065. 
 [88]  Lee SJ, Koo H, Jeong H, Huh MS, Choi Y, Jeong SY, Byun Y, 
Choi K, Kim K, Kwon IC. Comparative study of photosensitizer 
  loaded and conjugated glycol chitosan nanoparticles for cancer 
therapy.  J. Control. Release 2011, 152, 21 – 29. 
 [89]  Lee SJ, Koo H, Lee DE, Min S, Lee S, Chen X, Choi Y, Leary 
JF, Park K, Jeong SY, Kwon IC, Kim K, Choi K. Tumor-homing 
photosensitizer-conjugated glycol chitosan nanoparticles for 
synchronous photodynamic imaging and therapy based on cel-
lular on/off system.  Biomaterials 2011, 32, 4021 – 4029. 
 [90]  Henderson BW, Bellnier DA. Tissue localization of photosen-
sitizers and the mechanism of photodynamic tissue destruction. 
 Ciba Found. Symp . 1989, 146, 112 – 125; discussion 125 – 130. 
 [91]  Allemann E, Rousseau J, Brasseur N, Kudrevich SV, Lewis K, 
van Lier JE. Photodynamic therapy of tumours with hexadeca-
fl uoro zinc phthalocynine formulated in PEG-coated poly(lactic 
acid) nanoparticles.  Int. J. Cancer 1996, 66, 821 – 824. 
 [92]  Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR Jr, Banaszak 
Holl MM. The binding avidity of a nanoparticle-based multivalent 
targeted drug delivery platform.  Chem. Biol . 2007, 14, 107 – 115. 
 [93]  Torchilin VP. Targeted polymeric micelles for delivery of poorly 
soluble drugs.  Cell. Mol. Life Sci . 2004, 61, 2549 – 2559. 
 [94]  van Nostrum CF. Polymeric micelles to deliver photosensitiz-
ers for photodynamic therapy.  Adv. Drug Deliv. Rev . 2004, 56, 
9 – 16. 
 [95]  Li B, Moriyama EH, Li F, Jarvi MT, Allen C, Wilson BC. 
Diblock copolymer micelles deliver hydrophobic protopor-
phyrin IX for photodynamic therapy.  Photochem. Photobiol . 
2007, 83, 1505 – 1512. 
 [96]  Master AM, Rodriguez ME, Kenney ME, Oleinick NL, Gupta 
AS. Delivery of the photosensitizer Pc 4 in PEG-PCL micelles 
for in vitro PDT studies.  J. Pharm. Sci . 2010, 99, 2386 – 2398. 
 [97]  Peng CL, Shieh MJ, Tsai MH, Chang CC, Lai PS. Self-
assembled star-shaped chlorin-core poly(epsilon-caprolactone)-
poly(ethylene glycol) diblock copolymer micelles for dual 
chemo-photodynamic therapies.  Biomaterials 2008, 29, 
3599 – 3608. 
 [98]  Hofman JW, Carstens MG, van Zeeland F, Helwig C, Flesch FM, 
Hennink WE, van Nostrum CF. Photocytotoxicity of mTHPC 
(temoporfi n) loaded polymeric micelles mediated by lipase 
catalyzed degradation.  Pharm. Res . 2008, 25, 2065 – 2073. 
 [99]  Knop K, Mingotaud AF, El-Akra N, Violleau F, Souchard JP. 
Monomeric pheophorbide(a)-containing poly(ethyleneglycol-
b-epsilon-caprolactone) micelles for photodynamic therapy. 
 Photochem. Photobiol .  Sci . 2009, 8, 396 – 404. 
 [100]  Sugisaki K, Usui T, Nishiyama N, Jang WD, Yanagi Y, 
Yamagami S, Amano S, Kataoka K. Photodynamic therapy for 
corneal neovascularization using polymeric micelles encap-
sulating dendrimer porphyrins.  Invest. Ophthalmol. Vis. Sci . 
2008, 49, 894 – 899. 
 [101]  Jang WD, Nakagishi Y, Nishiyama N, Kawauchi S, Morimoto 
Y, Kikuchi M, Kataoka K. Polyion complex micelles for pho-
todynamic therapy: incorporation of dendritic photosensitizer 
excitable at long wavelength relevant to improved tissue-pen-
etrating property.  J. Control. Release 2006, 113, 73 – 79. 
 [102]  Ding H, Sumer BD, Kessinger CW, Dong Y, Huang G, 
Boothman DA, Gao J. Nanoscopic micelle delivery improves 
the photophysical properties and effi cacy of photodynamic 
therapy of protoporphyrin IX.  J. Control. Release 2011, 151, 
271 – 277. 
 [103]  Ding H, Mora R, Gao J, Sumer BD. Characterization and opti-
mization of mTHPP nanoparticles for photodynamic therapy 
of head and neck cancer.  Otolaryngol. Head Neck Surg . 2011, 
145, 612 – 617. 
 [104]  Cohen EM, Ding H, Kessinger CW, Khemtong C, Gao J, 
Sumer BD. Polymeric micelle nanoparticles for photodynamic 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ?  139
treatment of head and neck cancer cells.  Otolaryngol. Head 
Neck Surg . 2010, 143, 109 – 115. 
 [105]  Gallavardin T, Maurin M, Marotte S, Simon T, Gabudean AM, 
Bretonniere Y, Lindgren M, Lerouge F, Baldeck PL, Stephan 
O, Leverrier Y, Marvel J, Parola S, Maury O, Andraud C. 
Photodynamic therapy and two-photon bio-imaging appli-
cations of hydrophobic chromophores through amphiphilic 
polymer delivery.  Photochem. Photobiol .  Sci . 2011, 10, 
1216 – 1225. 
 [106]  Chowdhary RK, Sharif I, Chansarkar N, Dolphin D, Ratkay L, 
Delaney S, Meadows H. Correlation of photosensitizer deliv-
ery to lipoproteins and effi cacy in tumor and arthritis mouse 
models; comparison of lipid-based and Pluronic P123 formu-
lations.  J. Pharm. Pharm. Sci . 2003, 6, 198 – 204. 
 [107]  Chung JE, Yokoyama M, Yamato M, Aoyagi T, Sakurai Y, 
Okano T. Thermo-responsive drug delivery from polymeric 
micelles constructed using block copolymers of poly(N-iso-
propylacrylamide) and poly(butylmethacrylate).  J. Control. 
Release 1999, 62, 115 – 127. 
 [108]  Le Garrec D, Taillefer J, Van Lier JE, Lenaerts V, Leroux JC. 
Optimizing pH-responsive polymeric micelles for drug deliv-
ery in a cancer photodynamic therapy model.  J. Drug Target . 
2002, 10, 429 – 437. 
 [109]  Koo H, Lee H, Lee S, Min KH, Kim MS, Lee DS, Choi Y, 
Kwon IC, Kim K, Jeong SY. In vivo tumor diagnosis and 
photodynamic therapy via tumoral pH-responsive polymeric 
micelles.  Chem. Commun. (Camb.) . 2010, 46, 5668 – 5670. 
 [110]  Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of 
water-soluble polymers as delivery systems for poorly soluble 
drugs.  Adv. Drug Deliv. Rev . 2004, 56, 1273 – 1289. 
 [111]  Roby A, Erdogan S, Torchilin VP. Enhanced in vivo antitumor 
effi cacy of poorly soluble PDT agent, meso-tetraphenylpor-
phine, in PEG-PE-based tumor-targeted immunomicelles. 
 Cancer Biol. Ther . 2007, 6, 1136 – 1142. 
 [112]  Skidan I, Dholakia P, Torchilin V. Photodynamic therapy of 
experimental B-16 melanoma in mice with tumor-targeted 
5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles.  J. 
Drug Target . 2008, 16, 486 – 493. 
 [113]  Roby A, Erdogan S, Torchilin VP. Solubilization of poorly sol-
uble PDT agent, meso-tetraphenylporphin, in plain or immu-
notargeted PEG-PE micelles results in dramatically improved 
cancer cell killing in vitro.  Eur. J. Pharm. Biopharm . 2006, 62, 
235 – 240. 
 [114]  Zhang JX, Hansen CB, Allen TM, Boey A, Boch R. Lipid-
derivatized poly(ethylene glycol) micellar formulations of 
benzoporphyrin derivatives.  J. Control. Release 2003, 86, 
323 – 338. 
 [115]  Xu H, Jiang XJ, Chan EY, Fong WP, Ng DK. Synthesis, pho-
tophysical properties and in vitro photodynamic activity of 
axially substituted subphthalocyanines.  Org. Biomol. Chem . 
2007, 5, 3987 – 3992. 
 [116]  Feofanov A, Grichine A, Karmakova T, Pljutinskaya A, 
Lebedeva V, Filyasova A, Yakubovskaya R, Mironov A, 
Egret-Charlier M, Vigny P. Near-infrared photosensitizer 
based on a cycloimide derivative of chlorin p6: 13,15-N-(3 ′ -
hydroxypropyl)cycloimide chlorin p6.  Photochem. Photobiol . 
2002, 75, 633 – 643. 
 [117]  Wohrle D, Muller S, Shopova M, Mantareva V, Spassova 
G, Vietri F, Ricchelli F, Jori G. Effect of delivery system 
on the pharmacokinetic and phototherapeutic properties 
of bis(methyloxyethyleneoxy) silicon-phthalocyanine in 
tumor-bearing mice.  J. Photochem. Photobiol .  B 1999, 50, 
124 – 128. 
 [118]  Mroz P, Xia Y, Asanuma D, Konopko A, Zhiyentayev T, Huang 
YY, Sharma SK, Dai T, Khan UJ, Wharton T, Hamblin MR. 
Intraperitoneal photodynamic therapy mediated by a fullerene 
in a mouse model of abdominal dissemination of colon adeno-
carcinoma.  Nanomedicine . 2011, 7, 965 – 974. 
 [119]  Woodburn K, Chang CK, Lee S, Henderson B, Kessel D. 
Biodistribution and PDT effi cacy of a ketochlorin photo-
sensitizer as a function of the delivery vehicle.  Photochem. 
Photobiol . 1994, 60, 154 – 159. 
 [120]  Couleaud P, Morosini V, Frochot C, Richeter S, Raehm L, 
Durand JO. Silica-based nanoparticles for photodynamic ther-
apy applications.  Nanoscale . 2010, 2, 1083 – 1095. 
 [121]  Walter WG, Stober A. Probe method for the microbial sam-
pling of hospital carpets.  Health Lab. Sci . 1968, 5, 162 – 170. 
 [122]  Brevet D, Gary-Bobo M, Raehm L, Richeter S, Hocine O, 
Amro K, Loock B, Couleaud P, Frochot C, Morere A, Maillard 
P, Garcia M, Durand JO. Mannose-targeted mesoporous silica 
nanoparticles for photodynamic therapy.  Chem. Commun. 
(Camb.) . 2009, 1475 – 1477. 
 [123]  Cheng YC, Samia A, Meyers JD, Panagopoulos I, Fei B, Burda 
C. Highly effi cient drug delivery with gold nanoparticle vec-
tors for in vivo photodynamic therapy of cancer.  J. Am. Chem. 
Soc . 2008, 130, 10643 – 10647. 
 [124]  Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, 
Morgan J, Dougherty TJ, Prasad PN. Ceramic-based nanopar-
ticles entrapping water-insoluble photosensitizing anticancer 
drugs: a novel drug-carrier system for photodynamic therapy. 
 J. Am. Chem. Soc . 2003, 125, 7860 – 7865. 
 [125]  Ohulchanskyy TY, Roy I, Goswami LN, Chen Y, Bergey EJ, 
Pandey RK, Oseroff AR, Prasad PN. Organically modifi ed 
silica nanoparticles with covalently incorporated photosensi-
tizer for photodynamic therapy of cancer.  Nano Lett . 2007, 7, 
2835 – 2842. 
 [126]  Hocine O, Gary-Bobo M, Brevet D, Maynadier M, Fontanel 
S, Raehm L, Richeter S, Loock B, Couleaud P, Frochot C, 
Charnay C, Derrien G, Smaihi M, Sahmoune A, Morere A, 
Maillard P, Garcia M, Durand JO. Silicalites and mesoporous 
silica nanoparticles for photodynamic therapy.  Int. J. Pharm . 
2010, 402, 221 – 230. 
 [127]  Yan F, Kopelman R. The embedding of meta-
tetra(hydroxyphenyl)-chlorin into silica nanoparticle platforms 
for photodynamic therapy and their singlet oxygen production 
and pH-dependent optical properties.  Photochem. Photobiol . 
2003, 78, 587 – 591. 
 [128]  Qian HS, Guo HC, Ho PC, Mahendran R, Zhang Y. 
Mesoporous-silica-coated up-conversion fl uorescent nanopar-
ticles for photodynamic therapy.  Small . 2009, 5, 2285 – 2290. 
 [129]  Zhou L, Ning YW, Wei SH, Feng YY, Zhou JH, Yu BY, Shen 
J. A nanoencapsulated hypocrellin A prepared by an improved 
microemulsion method for photodynamic treatment.  J. Mater. 
Sci. Mater. Med . 2010, 21, 2095 – 2101. 
 [130]  Qian J, Gharibi A, He S. Colloidal mesoporous silica nanopar-
ticles with protoporphyrin IX encapsulated for photodynamic 
therapy.  J. Biomed. Opt . 2009, 14, 014012. 
 [131]  Simon V, Devaux C, Darmon A, Donnet T, Thienot E, 
Germain M, Honnorat J, Duval A, Pottier A, Borghi E, Levy 
L, Marill J. Pp IX silica nanoparticles demonstrate differential 
interactions with in vitro tumor cell lines and in vivo mouse 
models of human cancers.  Photochem. Photobiol . 2010, 86, 
213 – 222. 
 [132]  Tu HL, Lin YS, Lin HY, Hung Y, Lo LW, Chen YF, Mou CY. In 
vitro studies of functionalized mesoporous silica nanoparticles 
for photodynamic therapy.  Adv. Mater . 2009, 21, 172 – 177. 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
140  Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ? 
 [133]  Cheng SH, Lee CH, Yang CS, Tseng FG, Mou CY, Lo LW. 
Mesoporous silica nanoparticles functionalized with an oxy-
gen-sensing probe for cell photodynamic therapy: potential 
cancer theranostics.  J. Mater. Chem . 2009, 19, 1252 – 1257. 
 [134]  Rossi LM, Silva PR, Vono LL, Fernandes AU, Tada DB, 
Baptista MS. Protoporphyrin IX nanoparticle carrier: prepa-
ration, optical properties and singlet oxygen generation. 
 Langmuir 2008, 24, 12534 – 12538. 
 [135]  Liu F, Zhou X, Chen Z, Huang P, Wang X, Zhou Y. Preparation 
of purpurin-18 loaded magnetic nanocarriers in cottonseed oil 
for photodynamic therapy.  Mater. Lett . 2008, 62, 2844 – 2847. 
 [136]  Chen ZL, Sun Y, Huang P, Yang XX, Zhou XP. Studies on 
Preparation of photosensitizer loaded magnetic silica nanopar-
ticles and their anti-tumor effects for targeting photodynamic 
therapy.  Nanoscale Res Lett . 2009, 4, 400 – 408. 
 [137]  Wieder ME, Hone DC, Cook MJ, Handsley MM, Gavrilovic 
J, Russell DA. Intracellular photodynamic therapy with pho-
tosensitizer-nanoparticle conjugates: cancer therapy using a 
 ‘ Trojan horse ’ .  Photochem. Photobiol .  Sci . 2006, 5, 727 – 734. 
 [138]  Gu H, Xu K, Yang Z, Chang CK, Xu B. Synthesis and cel-
lular uptake of porphyrin decorated iron oxide nanoparticles 
 – a potential candidate for bimodal anticancer therapy.  Chem. 
Commun. (Camb.) . 2005, 4270 – 4272. 
 [139]  Chen W, Zhang J. Using nanoparticles to enable simultaneous 
radiation and photodynamic therapies for cancer treatment.  J. 
Nanosci. Nanotechnol . 2006, 6, 1159 – 1166. 
 [140]  Elbakry A, Zaky A, Liebl R, Rachel R, Goepferich A, Breunig 
M. Layer-by-layer assembled gold nanoparticles for siRNA 
delivery.  Nano Lett . 2009, 9, 2059 – 2064. 
 [141]  Jain PK, Huang X, El-Sayed IH, El-Sayed MA. Noble met-
als on the nanoscale: optical and photothermal properties and 
some applications in imaging, sensing, biology and medicine. 
 Acc. Chem. Res . 2008, 41, 1578 – 1586. 
 [142]  Gao J, Gu H, Xu B. Multifunctional magnetic nanoparticles: 
design, synthesis and biomedical applications.  Acc. Chem. 
Res . 2009, 42, 1097 – 1107. 
 [143]  Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, 
McLaughlin RE, Tamarkin L. Colloidal gold: a novel nanopar-
ticle vector for tumor directed drug delivery.  Drug Deliv . 2004, 
11, 169 – 183. 
 [144]  Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: 
preparations, imaging, diagnostics, therapies and toxicity. 
 Chem. Soc. Rev . 2009, 38, 1759 – 1782. 
 [145]  Gamaleia NF, Shishko ED, Dolinsky GA, Shcherbakov AB, 
Usatenko AV, Kholin VV. Photodynamic activity of hemato-
porphyrin conjugates with gold nanoparticles: experiments in 
vitro.  Exp. Oncol . 2010, 32, 44 – 47. 
 [146]  Zaruba K, Kralova J, Rezanka P, Pouckova P, Veverkova L, 
Kral V. Modifi ed porphyrin-brucine conjugated to gold nano-
particles and their application in photodynamic therapy.  Org. 
Biomol. Chem . 2010, 8, 3202 – 3206. 
 [147]  Demberelnyamba D, Ariunaa M, Shim YK. Newly synthesized 
water soluble cholinium-purpurin photosensitizers and their 
stabilized gold nanoparticles as promising anticancer agents. 
 Int. J. Mol. Sci . 2008, 9, 864 – 871. 
 [148]  Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted 
nanoshells for integrated cancer imaging and therapy.  Nano 
Lett . 2005, 5, 709 – 711. 
 [149]  Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. 
Gold nanoparticles are taken up by human cells but do not 
cause acute cytotoxicity.  Small . 2005, 1, 325 – 327. 
 [150]  Cheng Y, Meyers JD, Broome AM, Kenney ME, Basilion 
JP, Burda C. Deep penetration of a PDT drug into tumors by 
noncovalent drug-gold nanoparticle conjugates.  J. Am. Chem. 
Soc . 2011, 133, 2583 – 2591. 
 [151]  Liu Y, Shipton MK, Ryan J, Kaufman ED, Franzen S, Feldheim 
DL. Synthesis, stability and cellular internalization of gold 
nanoparticles containing mixed peptide-poly(ethylene glycol) 
monolayers.  Anal. Chem . 2007, 79, 2221 – 2229. 
 [152]  Greenwald RB, Choe YH, McGuire J, Conover CD. Effective 
drug delivery by PEGylated drug conjugates.  Adv. Drug Deliv. 
Rev . 2003, 55, 217 – 250. 
 [153]  Cheng Y, Samia AC, Li J, Kenney ME, Resnick A, Burda C. 
Delivery and effi cacy of a cancer drug as a function of the 
bond to the gold nanoparticle surface.  Langmuir 2010, 26, 
2248 – 2255. 
 [154]  Csaki A, Schneider T, Wirth J, Jahr N, Steinbruck A, Stranik O, 
Garwe F, Muller R, Fritzsche W. Molecular plasmonics: light 
meets molecules at the nanoscale.  Philos. Transact. A Math. 
Phys. Eng. Sci . 2011, 369, 3483 – 3496. 
 [155]  Fales AM, Yuan H, Vo-Dinh T. Silica-coated gold nanostars for 
combined surface-enhanced Raman scattering (SERS) detec-
tion and singlet-oxygen generation: a potential nanoplatform 
for theranostics.  Langmuir 2011, 27, 12186 – 12190. 
 [156]  Khlebtsov B, Panfi lova E, Khanadeev V, Bibikova O, 
Terentyuk G, Ivanov A, Rumyantseva V, Shilov I, Ryabova 
A, Loshchenov V, Khlebtsov NG. Nanocomposites con-
taining silica-coated gold-silver nanocages and Yb-2,4-
dimethoxyhematoporphyrin: multifunctional capability of 
IR-luminescence detection, photosensitization and photother-
molysis.  ACS Nano . 2011, 5, 7077 – 7089. 
 [157]  Lipovsky A, Gedanken A, Nitzan Y, Lubart R. Enhanced inacti-
vation of bacteria by metal-oxide nanoparticles combined with 
visible light irradiation.  Lasers Surg. Med . 2011, 43, 236 – 240. 
 [158]  Konaka R, Kasahara E, Dunlap WC, Yamamoto Y, Chien KC, 
Inoue M. Irradiation of titanium dioxide generates both singlet 
oxygen and superoxide anion.  Free Radic. Biol. Med . 1999, 27, 
294 – 300. 
 [159]  Konaka R, Kasahara E, Dunlap WC, Yamamoto Y, Chien KC, 
Inoue M. Ultraviolet irradiation of titanium dioxide in aque-
ous dispersion generates singlet oxygen.  Redox Rep . 2001, 6, 
319 – 325. 
 [160]  Rehman S, Ullah R, Butt AM, Gohar ND. Strategies of making 
TiO 2 and ZnO visible light active.  J. Hazard. Mater . 2009, 170, 
560 – 569. 
 [161]  Zhang H, Chen B, Jiang H, Wang C, Wang H, Wang X. A strat-
egy for ZnO nanorod mediated multi-mode cancer treatment. 
 Biomaterials 2011, 32, 1906 – 1914. 
 [162]  Foster HA, Ditta IB, Varghese S, Steele A. Photocatalytic dis-
infection using titanium dioxide: spectrum and mechanism of 
antimicrobial activity.  Appl. Microbiol. Biotechnol . 2011, 90, 
1847 – 1868. 
 [163]  Yamaguchi S, Kobayashi H, Narita T, Kanehira K, Sonezaki S, 
Kubota Y, Terasaka S, Iwasaki Y. Novel photodynamic therapy 
using water-dispersed TiO 2 -polyethylene glycol compound: 
evaluation of antitumor effect on glioma cells and spheroids in 
vitro.  Photochem. Photobiol . 2010, 86, 964 – 971. 
 [164]  Zhang AP, Sun YP. Photocatalytic killing effect of TiO 2 nano-
particles on Ls-174-t human colon carcinoma cells.  World J. 
Gastroenterol . 2004, 10, 3191 – 3193. 
 [165]  Wang C, Cao S, Tie X, Qiu B, Wu A, Zheng Z. Induction of 
cytotoxicity by photoexcitation of TiO 2 can prolong survival in 
glioma-bearing mice.  Mol. Biol. Rep . 2011, 38, 523 – 530. 
 [166]  Bakalova R, Ohba H, Zhelev Z, Ishikawa M, Baba Y. 
Quantum dots as photosensitizers ?  Nat. Biotechnol . 2004, 22, 
1360 – 1361. 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ?  141
 [167]  Samia AC, Chen X, Burda C. Semiconductor quantum dots 
for photodynamic therapy.  J. Am. Chem. Soc . 2003, 125, 
15736 – 15737. 
 [168]  Baron ED, Malbasa CL, Santo-Domingo D, Fu P, Miller JD, 
Hanneman KK, Hsia AH, Oleinick NL, Colussi VC, Cooper 
KD. Silicon phthalocyanine (Pc 4) photodynamic therapy is 
a safe modality for cutaneous neoplasms: results of a phase 1 
clinical trial.  Lasers Surg. Med . 2010, 42, 728 – 735. 
 [169]  He J, Larkin HE, Li YS, Rihter D, Zaidi SI, Rodgers MA, 
Mukhtar H, Kenney ME, Oleinick NL. The synthesis, photo-
physical and photobiological properties and in vitro structure-
activity relationships of a set of silicon phthalocyanine PDT 
photosensitizers.  Photochem. Photobiol . 1997, 65, 581 – 586. 
 [170]  Jose R, Zhelev Z, Nagase T, Bakalova R, Baba Y, Ishikawa M. 
Self-surface passivation of CdX (X = Se, Te) quantum dots.  J. 
Nanosci. Nanotechnol . 2006, 6, 618 – 623. 
 [171]  Generalov R, Kavaliauskiene S, Westrom S, Chen W, 
Kristensen S, Juzenas P. Entrapment in phospholipid vesicles 
quenches photoactivity of quantum dots.  Int. J. Nanomed . 
2011, 6, 1875 – 1888. 
 [172]  Morosini V, Bastogne T, Frochot C, Schneider R, Francois A, 
Guillemin F, Barberi-Heyob M. Quantum dot-folic acid conju-
gates as potential photosensitizers in photodynamic therapy of 
cancer.  Photochem. Photobiol .  Sci . 2011, 10, 842 – 851. 
 [173]  Mroz P, Pawlak A, Satti M, Lee H, Wharton T, Gali H, Sarna 
T, Hamblin MR. Functionalized fullerenes mediate photody-
namic killing of cancer cells: type I versus type II photochemi-
cal mechanism.  Free Radic. Biol. Med . 2007, 43, 711 – 719. 
 [174]  Chiang LY, Padmawar PA, Rogers-Haley JE, So G, Canteenwala 
T, Thota S, Tan LS, Pritzker K, Huang YY, Sharma SK, Kurup 
DB, Hamblin MR, Wilson B, Urbas A. Synthesis and charac-
terization of highly photoresponsive fullerenyl dyads with a 
close chromophore antenna-C(60) contact and effective photo-
dynamic potential.  J. Mater. Chem . 2010, 20, 5280 – 5293. 
 [175]  Tegos GP, Demidova TN, Arcila-Lopez D, Lee H, Wharton 
T, Gali H, Hamblin MR. Cationic fullerenes are effective and 
selective antimicrobial photosensitizers.  Chem. Biol. 2005, 12, 
1127 – 1135. 
 [176]  Lu Z, Dai T, Huang L, Kurup DB, Tegos GP, Jahnke A, 
Wharton T, Hamblin MR. Photodynamic therapy with a cat-
ionic functionalized fullerene rescues mice from fatal wound 
infections.  Nanomedicine (Lond) . 2010, 5, 1525 – 1533. 
 [177]  Chi Y, Canteenwala T, Chen HC, Chen BJ, Canteenwala M, 
Chiang LY. Hexa(sulfobutyl)fullerene-induced photodynamic 
effect on tumors in vivo and toxicity study in rats.  Proc. 
Electrochem. Soc . 1999, 99, 234 – 249. 
 [178]  Hotze EM, Labille J, Alvarez P, Wiesner MR. Mechanisms 
of photochemistry and reactive oxygen production by fuller-
ene suspensions in water.  Environ. Sci. Technol . 2008, 42, 
4175 – 4180. 
 [179]  Duncan LK, Jinschek JR, Vikesland PJ. C60 colloid forma-
tion in aqueous systems: effects of preparation method on size, 
structure and surface charge.  Environ. Sci. Technol . 2008, 42, 
173 – 178. 
 [180]  Culotta L, Koshland DE Jr. Buckyballs: wide open playing 
fi eld for chemists.  Science 1991, 254, 1706 – 1709. 
 [181]  Kato S, Aoshima H, Saitoh Y, Miwa N. Biological safety of 
liposome-fullerene consisting of hydrogenated lecithin, gly-
cine soja sterols and fullerene-C60 upon photocytotoxicity and 
bacterial reverse mutagenicity.  Toxicol. Ind. Health 2009, 25, 
197 – 203. 
 [182]  Kato S, Aoshima H, Saitoh Y, Miwa N. Fullerene-C60/lipo-
some complex: defensive effects against uva-induced damages 
in skin structure, nucleus and collagen type I/IV fi brils and the 
permeability into human skin tissue.  J. Photochem. Photobiol . 
 B 2009, 98, 99 – 105. 
 [183]  Doi Y, Ikeda A, Akiyama M, Nagano M, Shigematsu T, Ogawa 
T, Takeya T, Nagasaki T. Intracellular uptake and photody-
namic activity of water-soluble [60]- and [70]fullerenes incor-
porated in liposomes.  Chemistry 2008, 14, 8892 – 8897. 
 [184]  Yan A, Von Dem Bussche A, Kane AB, Hurt RH. Tocopheryl 
polyethylene glycol succinate as a safe, antioxidant surfactant 
for processing carbon nanotubes and fullerenes.  Carbon NY . 
2007, 45, 2463 – 2470. 
 [185]  Akiyama M, Ikeda A, Shintani T, Doi Y, Kikuchi J, Ogawa T, 
Yogo K, Takeya T, Yamamoto N. Solubilisation of [60]fuller-
enes using block copolymers and evaluation of their photody-
namic activities.  Org. Biomol. Chem . 2008, 6, 1015 – 1019. 
 [186]  Kojima C, Toi Y, Harada A, Kono K. Aqueous solubilization of 
fullerenes using poly(amidoamine) dendrimers bearing cyclo-
dextrin and poly(ethylene glycol).  Bioconjug. Chem . 2008, 19, 
2280 – 2284. 
 [187]  Pan B, Cui D, Xu P, Ozkan C, Feng G, Ozkan M, Huang T, Chu 
B, Li Q, He R, Hu G. Synthesis and characterization of poly-
amidoamine dendrimer-coated multi-walled carbon nanotubes 
and their application in gene delivery systems.  Nanotechnology 
2009, 20, 125101. 
 [188]  Hooper JB, Bedrov D, Smith GD. Supramolecular self-or-
ganization in PEO-modifi ed C60 fullerene/water solutions: 
infl uence of polymer molecular weight and nanoparticle con-
centration.  Langmuir 2008, 24, 4550 – 4557. 
 [189]  Nitta N, Seko A, Sonoda A, Ohta S, Tanaka T, Takahashi M, 
Murata K, Takemura S, Sakamoto T, Tabata Y. Is the use of 
fullerene in photodynamic therapy effective for atherosclero-
sis ?  Cardiovasc. Intervent. Radiol . 2008, 31, 359 – 366. 
 [190]  Liu J, Ohta S, Sonoda A, Yamada M, Yamamoto M, Nitta N, 
Murata K, Tabata Y. Preparation of PEG-conjugated fullerene 
containing Gd3 + ions for photodynamic therapy.  J. Control. 
Release 2007, 117, 104 – 110. 
 [191]  Tabata Y, Murakami Y, Ikada Y. Photodynamic effect of poly-
ethylene glycol-modifi ed fullerene on tumor.  Jpn. J. Cancer 
Res . 1997, 88, 1108 – 1116. 
 [192]  Filippone S, Heimann F, Rassat A. A highly water-soluble 
2:1 beta-cyclodextrin-fullerene conjugate.  Chem. Commun. 
(Camb.) . 2002, 1508 – 1509. 
 [193]  Zhao B, He YY, Bilski PJ, Chignell CF. Pristine (C60) and 
hydroxylated [C60(OH)24] fullerene phototoxicity towards 
HaCaT keratinocytes: type I vs type II mechanisms.  Chem. 
Res. Toxicol . 2008, 21, 1056 – 1063. 
 [194]  Bansal T, Mustafa G, Khan ZI, Ahmad FJ, Khar RK, 
Talegaonkar S. Solid self-nanoemulsifying delivery systems as 
a platform technology for formulation of poorly soluble drugs. 
 Crit. Rev. Ther. Drug Carrier Syst . 2008, 25, 63 – 116. 
 [195]  Bali V, Ali M, Ali J. Novel nanoemulsion for minimizing vari-
ations in bioavailability of ezetimibe.  J. Drug Target . 2010, 18, 
506 – 519. 
 [196]  Amani A, York P, Chrystyn H, Clark BJ. Factors affecting the 
stability of nanoemulsions  – use of artifi cial neural networks. 
 Pharm. Res . 2010, 27, 37 – 45. 
 [197]  Shakeel F, Faisal MS. Nanoemulsion: a promising tool for 
solubility and dissolution enhancement of celecoxib.  Pharm. 
Dev. Technol . 2009, 15, 53–56. 
 [198]  Boyd PD, Reed CA. Fullerene-porphyrin constructs.  Acc. 
Chem. Res . 2005, 38, 235 – 242. 
 [199]  El-Khouly ME, Araki Y, Ito O, Gadde S, McCarty AL, Karr 
PA, Zandler ME, D ’ Souza F. Spectral, electrochemical and 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
142  Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ? 
photophysical studies of a magnesium porphyrin-fullerene 
dyad.  Phys. Chem. Chem. Phys . 2005, 7, 3163 – 3171. 
 [200]  Imahori H. Porphyrin-fullerene linked systems as artifi -
cial photosynthetic mimics.  Org. Biomol. Chem . 2004, 2, 
1425 – 1433. 
 [201]  Schuster DI, Cheng P, Jarowski PD, Guldi DM, Luo C, 
Echegoyen L, Pyo S, Holzwarth AR, Braslavsky SE, Williams 
RM, Klihm G. Design, synthesis and photophysical studies of 
a porphyrin-fullerene dyad with parachute topology; charge 
recombination in the marcus inverted region.  J. Am. Chem. 
Soc . 2004, 126, 7257 – 7270. 
 [202]  Vail SA, Schuster DI, Guldi DM, Isosomppi M, Tkachenko 
N, Lemmetyinen H, Palkar A, Echegoyen L, Chen X, Zhang 
JZ. Energy and electron transfer in beta-alkynyl-linked por-
phyrin-[60]fullerene dyads.  J. Phys. Chem. B 2006, 110, 
14155 – 14166. 
 [203]  Gebhart SC, Lin WC, Mahadevan-Jansen A. In vitro deter-
mination of normal and neoplastic human brain tissue optical 
properties using inverse adding-doubling.  Phys. Med. Biol . 
2006, 51, 2011 – 2027. 
 [204]  Tuchin VV, Wang RK, Yeh AT. Optical clearing of tissues and 
cells.  J. Biomed. Opt . 2008, 13, 021101. 
 [205]  Hirshburg J, Choi B, Nelson JS, Yeh AT. Correlation between 
collagen solubility and skin optical clearing using sugars. 
 Lasers Surg. Med . 2007, 39, 140 – 144. 
 [206]  Jiang J, Boese M, Turner P, Wang RK. Penetration kinetics of 
dimethyl sulphoxide and glycerol in dynamic optical clearing 
of porcine skin tissue in vitro studied by Fourier transform 
infrared spectroscopic imaging.  J. Biomed. Opt . 2008, 13, 
021105. 
 [207]  Kogan A, Garti N. Microemulsions as transdermal drug 
delivery vehicles.  Adv. Colloid Interface Sci . 2006, 123 – 126, 
369 – 385. 
 [208]  Goeppert-Mayer M.  Ü ber Elementarakte mit zwei Quantens-
pr ü ngen.  Ann. Phys . 1931, 9, 273 – 295. 
 [209]  Bhawalkar JD, Kumar ND, Zhao CF, Prasad PN. Two-photon 
photodynamic therapy.  J. Clin. Laser Med. Surg . 1997, 15, 
201 – 204. 
 [210]  Karotki A, Khurana M, Lepock JR, Wilson BC. Simultaneous 
two-photon excitation of Photofrin in relation to photodynamic 
therapy.  Photochem. Photobiol . 2006, 82, 443 – 452. 
 [211]  Samkoe KS, Clancy AA, Karotki A, Wilson BC, Cramb DT. 
Complete blood vessel occlusion in the chick chorioallantoic 
membrane using two-photon excitation photodynamic therapy: 
implications for treatment of wet age-related macular degen-
eration.  J. Biomed. Opt . 2007, 12, 034025. 
 [212]  Samkoe KS, Cramb DT. Application of an ex ovo chicken 
chorioallantoic membrane model for two-photon excitation 
photodynamic therapy of age-related macular degeneration.  J. 
Biomed. Opt . 2003, 8, 410 – 417. 
 [213]  Lens M, Medenica L, Citernesi U. Antioxidative capacity of 
C(60) (buckminsterfullerene) and newly synthesized fullero-
pyrrolidine derivatives encapsulated in liposomes.  Biotechnol. 
Appl. Biochem . 2008, 51, 135 – 140. 
 [214]  Spohn P, Hirsch C, Hasler F, Bruinink A, Krug HF, Wick P. 
C60 fullerene: a powerful antioxidant, or a damaging agent ? 
The importance of an in-depth material characterization prior 
to toxicity assays.  Environ. Pollut . 2009, 157, 1134 – 1139. 
 [215]  Cai X, Jia H, Liu Z, Hou B, Luo C, Feng Z, Li W, Liu J. 
Polyhydroxylated fullerene derivative C(60)(OH)(24) pre-
vents mitochondrial dysfunction and oxidative damage in an 
MPP( + )-induced cellular model of Parkinson ’ s disease.  J. 
Neurosci. Res . 2008, 86, 3622 – 3634. 
 [216]  Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, 
Moussa F. [60]fullerene is a powerful antioxidant in vivo with 
no acute or subacute toxicity.  Nano Lett . 2005, 5, 2578 – 2585. 
 [217]  Dugan LL, Gabrielsen JK, Yu SP, Lin TS, Choi DW. 
Buckminsterfullerenol free radical scavengers reduce exci-
totoxic and apoptotic death of cultured cortical neurons. 
 Neurobiol. Dis . 1996, 3, 129 – 135. 
 [218]  Andrievsky GV, Bruskov VI, Tykhomyrov AA, Gudkov SV. 
Peculiarities of the antioxidant and radioprotective effects of 
hydrated C60 fullerene nanostuctures in vitro and in vivo.  Free 
Radic. Biol. Med . 2009, 47, 786 – 793. 
 [219]  Weiss DR, Raschke TM, Levitt M. How hydrophobic buck-
minsterfullerene affects surrounding water structure.  J. Phys. 
Chem. B 2008, 112, 2981 – 2990. 
 [220]  Mroz P, Tegos GP, Gali H, Wharton T, Sarna T, Hamblin MR. 
Photodynamic therapy with fullerenes.  Photochem. Photobiol . 
 Sci . 2007, 6, 1139 – 1149. 
 [221]  Sharma SK, Chiang LY, Hamblin MR. Photodynamic therapy 
with fullerenes in vivo: reality or a dream ?  Nanomedicine 
(UK) . 2011, 6, 1813 – 1825. 
 [222]  Tokuyama H, Yamago S, Nakamura E. Photoinduced bio-
chemical activity of fullerene carboxylic acid.  J. Am. Chem. 
Soc . 1993, 115, 7918 – 7919. 
 [223]  Rancan F, Rosan S, Boehm F, Cantrell A, Brellreich M, 
Schoenberger H, Hirsch A, Moussa F. Cytotoxicity and photo-
cytotoxicity of a dendritic C(60) mono-adduct and a malonic 
acid C(60) tris-adduct on Jurkat cells.  J. Photochem. Photobiol . 
 B 2002, 67, 157 – 162. 
 [224]  Burlaka AP, Sidorik YP, Prylutska SV, Matyshevska OP, Golub 
OA, Prylutskyy YI, Scharff P. Catalytic system of the reactive 
oxygen species on the C60 fullerene basis.  Exp. Oncol. 2004, 
26, 326 – 327. 
 [225]  Yang XL, Fan CH, Zhu HS. Photo-induced cytotoxicity of 
malonic acid [C(60)]fullerene derivatives and its mechanism. 
 Toxicol. In Vitro 2002, 16, 41 – 46. 
 [226]  Spesia MB, Milanesio ME, Durantini EN. Synthesis, prop-
erties and photodynamic inactivation of Escherichia coli by 
novel cationic fullerene C60 derivatives.  Eur. J. Med. Chem . 
2008, 43, 853 – 861. 
 [227]  Lee I, Mackeyev Y, Cho M, Li D, Kim JH, Wilson LJ, Alvarez 
PJ. Photochemical and antimicrobial properties of novel C60 
derivatives in aqueous systems.  Environ. Sci. Technol . 2009, 
43, 6604 – 6610. 
 [228]  Huang L, Terakawa M, Zhiyentayev T, Huang YY, Sawayama 
Y, Jahnke A, Tegos GP, Wharton T, Hamblin MR. Innovative 
cationic fullerenes as broad-spectrum light-activated antimi-
crobials.  Nanomedicine . 2009, 6, 442–452. 
 [229]  Ikeda A, Doi Y, Nishiguchi K, Kitamura K, Hashizume M, 
Kikuchi J, Yogo K, Ogawa T, Takeya T. Induction of cell death 
by photodynamic therapy with water-soluble lipid-membrane-
incorporated [60]fullerene.  Org. Biomol. Chem . 2007, 5, 
1158 – 1160. 
 [230]  Ikeda A, Matsumoto M, Akiyama M, Kikuchi J, Ogawa T, 
Takeya T. Direct and short-time uptake of [70]fullerene into the 
cell membrane using an exchange reaction from a [70]fuller-
ene-gamma-cyclodextrin complex and the resulting photody-
namic activity.  Chem. Commun. (Camb.) . 2009, 1547 – 1549. 
 [231]  Ikeda A, Nagano M, Akiyama M, Matsumoto M, Ito S, Mukai 
M, Hashizume M, Kikuchi J, Katagiri K, Ogawa T, Takeya 
T. Photodynamic activity of C70 caged within surface-cross-
linked liposomes.  Chem. Asian J . 2009, 4, 199 – 205. 
 [232]  Wang X, Li Q, Xie J, Jin Z, Wang J, Li Y, Jiang K, Fan S. 
Fabrication of ultralong and electrically uniform single-walled 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ?  143
carbon nanotubes on clean substrates.  Nano Lett . 2009, 9, 
3137 – 3141. 
 [233]  Zhu Z, Tang Z, Phillips JA, Yang R, Wang H, Tan W. Regulation 
of singlet oxygen generation using single-walled carbon nano-
tubes.  J. Am. Chem. Soc . 2008, 130, 10856 – 10857. 
 [234]  Erbas S, Gorgulu A, Kocakusakogullari M, Akkaya EU. Non-
covalent functionalized SWNTs as delivery agents for novel 
Bodipy-based potential PDT sensitizers.  Chem. Commun. 
(Camb.) . 2009, 4956 – 4958. 
 [235]  Shiraki T, Dawn A, Le TN, Tsuchiya Y, Tamaru S, Shinkai S. 
Heat and light dual switching of a single-walled carbon nano-
tube/thermo-responsive helical polysaccharide complex: a 
new responsive system applicable to photodynamic therapy. 
 Chem. Commun. (Camb.) . 2011, 47, 7065 – 7067. 
 [236]  Wang Y, Li Z, Wang J, Li J, Lin Y. Graphene and graphene 
oxide: biofunctionalization and applications in biotechnology. 
 Trends Biotechnol . 2011, 29, 205 – 212. 
 [237]  Sun X, Liu Z, Welsher K, Robinson JT, Goodwin A, Zaric S, 
Dai H. Nano-graphene oxide for cellular imaging and drug 
delivery.  Nano Res . 2008, 1, 203 – 212. 
 [238]  Zhang L, Xia J, Zhao Q, Liu L, Zhang Z. Functional graphene 
oxide as a nanocarrier for controlled loading and targeted 
delivery of mixed anticancer drugs.  Small . 2010, 6, 537 – 544. 
 [239]  Zhou L, Wang W, Tang J, Zhou JH, Jiang HJ, Shen J. Graphene 
oxide noncovalent photosensitizer and its anticancer activity in 
vitro.  Chemistry 2011, 17, 12084 – 12091. 
 [240]  Zhenjun D, Lown JW. Hypocrellins and their use in photosen-
sitization.  Photochem. Photobiol . 1990, 52, 609 – 616. 
 [241]  Huang P, Xu C, Lin J, Wang C, Wang X, Zhang C, Zhou X, 
Guo S, Cui D. Folic acid-conjugated graphene oxide loaded 
with photosensitizers for targeting photodynamic therapy. 
 Theranostics 2011, 1, 240 – 250. 
 [242]  Tian B, Wang C, Zhang S, Feng L, Liu Z. Photothermally 
enhanced photodynamic therapy delivered by nano-graphene 
oxide.  ACS Nano . 2011, 5, 7000 – 7009. 
 [243]  Haase M, Schafer H. Upconverting nanoparticles.  Angew. 
Chem. Int. Ed. Engl . 2011, 50, 5808 – 5829. 
 [244]  Menyuk N, Dwight K, Pierce J. NaYF4: Yb, Er  – an effi cient 
upconversion phosphor.  Appl. Phys. Lett . 1972, 21, 159 – 161. 
 [245]  Chatterjee DK, Yong Z. Upconverting nanoparticles as 
nanotransducers for photodynamic therapy in cancer cells. 
 Nanomedicine (Lond) . 2008, 3, 73 – 82. 
 [246]  Ungun B, Prud ’ homme RK, Budijon SJ, Shan J, Lim SF, Ju Y, 
Austin R. Nanofabricated upconversion nanoparticles for pho-
todynamic therapy.  Opt. Express . 2009, 17, 80 – 86. 
 [247]  Johnson BK, Prud ’ homme RK. Flash nanoprecipitation of 
organic actives and block copolymers using a confi ned imping-
ing jets mixer.  Aust. J. Chem . 2003, 56, 1021 – 1024. 
 [248]  Wang C, Tao H, Cheng L, Liu Z. Near-infrared light induced in 
vivo photodynamic therapy of cancer based on upconversion 
nanoparticles.  Biomaterials 2011, 32, 6145 – 6154. 
 [249]  Gary-Bobo M, Mir Y, Rouxel C, Brevet D, Basile I, Maynadier 
M, Vaillant O, Mongin O, Blanchard-Desce M, Morere A, 
Garcia M, Durand JO, Raehm L. Mannose-functionalized 
mesoporous silica nanoparticles for effi cient two-photon pho-
todynamic therapy of solid tumors.  Angew. Chem. Int. Ed. 
Engl . 2011, 50, 11425–11429. 
 [250]  Grimland JL, Wu C, Ramoutar RR, Brumaghim JL, McNeill 
J. Photosensitizer-doped conjugated polymer nanoparticles 
with high cross-sections for one- and two-photon excitation. 
 Nanoscale 2011, 3, 1451 – 1455. 
 [251]  Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide 
nanoparticles: a versatile platform for targeted molecular 
imaging, molecular diagnostics and therapy.  Acc. Chem. Res . 
2011, 44, 842 – 852. 
 [252]  McCarthy JR, Kelly KA, Sun EY, Weissleder R. Targeted deliv-
ery of multifunctional magnetic nanoparticles.  Nanomedicine 
(Lond) . 2007, 2, 153 – 167. 
 [253]  Huang P, Li Z, Lin J, Yang D, Gao G, Xu C, Bao L, Zhang C, 
Wang K, Song H, Hu H, Cui D. Photosensitizer-conjugated 
magnetic nanoparticles for in vivo simultaneous magnetofl uo-
rescent imaging and targeting therapy.  Biomaterials 2011, 32, 
3447 – 3458. 
 [254]  Tada DB, Vono LL, Duarte EL, Itri R, Kiyohara PK, Baptista 
MS, Rossi LM. Methylene blue-containing silica-coated mag-
netic particles: a potential magnetic carrier for photodynamic 
therapy.  Langmuir 2007, 23, 8194 – 8199. 
 [255]  Ding J, Zhao J, Cheng K, Liu G, Xiu D. In vivo photodynamic 
therapy and magnetic resonance imaging of cancer by TSPP-
coated Fe3O4 nanoconjugates.  J. Biomed. Nanotechnol . 2010, 
6, 683 – 686. 
 [256]  Sun Y, Chen ZL, Yang XX, Huang P, Zhou XP, Du XX. 
Magnetic chitosan nanoparticles as a drug delivery system for 
targeting photodynamic therapy.  Nanotechnology 2009, 20, 
135102. 
 [257]  Ng KK, Lovell JF, Zheng G. Lipoprotein-inspired nano-
particles for cancer theranostics.  Acc. Chem. Res . 2011, 44, 
1105 – 1113. 
 [258]  Li H, Marotta DE, Kim S, Busch TM, Wileyto EP, Zheng G. 
High payload delivery of optical imaging and photodynamic 
therapy agents to tumors using phthalocyanine-reconstituted 
low-density lipoprotein nanoparticles.  J. Biomed. Opt . 2005, 
10, 41203. 
 [259]  Marotta DE, Cao W, Wileyto EP, Li H, Corbin I, Rickter E, 
Glickson JD, Chance B, Zheng G, Busch TM. Evaluation of 
bacteriochlorophyll-reconstituted low-density lipoprotein 
nanoparticles for photodynamic therapy effi cacy in vivo. 
 Nanomedicine . 2011, 6, 475 – 487. 
 [260]  Brown SB, Brown EA, Walker I. The present and future role 
of photodynamic therapy in cancer treatment.  Lancet Oncol . 
2004, 5, 497 – 508. 
 [261]  Weinstein JN, van Osdol W. Early intervention in cancer using 
monoclonal antibodies and other biological ligands: micro-
pharmacology and the  “ binding site barrier ” .  Cancer Res . 
1992, 52, 2747s – 2751s. 
 [262]  Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, 
Alpaugh RK, Marks JD, Weiner LM. High affi nity restricts the 
localization and tumor penetration of single-chain fv antibody 
molecules.  Cancer Res . 2001, 61, 4750 – 4755. 
 [263]  Stuchinskaya T, Moreno M, Cook MJ, Edwards DR, Russell 
DA. Targeted photodynamic therapy of breast cancer cells 
using antibody-phthalocyanine-gold nanoparticle conjugates. 
 Photochem. Photobiol .  Sci . 2011, 10, 822 – 831. 
 [264]  Kameyama N, Matsuda S, Itano O, Ito A, Konno T, Arai T, 
Ishihara K, Ueda M, Kitagawa Y. Photodynamic therapy 
using an anti-EGF receptor antibody complexed with verte-
porfi n nanoparticles: a proof of concept study.  Cancer Biother. 
Radiopharm . 2011, 26, 697 – 704. 
 [265]  Rancan F, Helmreich M, Molich A, Ermilov EA, Jux N, 
Roder B, Hirsch A, Bohm F. Synthesis and in vitro testing of 
a pyropheophorbide-a-fullerene hexakis adduct immunoconju-
gate for photodynamic therapy.  Bioconjug. Chem . 2007, 18, 
1078 – 1086. 
 [266]  Bergstrom LC, Vucenik I, Hagen IK, Chernomorsky SA, 
Poretz RD. In-vitro photocytotoxicity of lysosomotropic 
immunoliposomes containing pheophorbide a with human 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
144  Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ? 
bladder carcinoma cells.  J. Photochem. Photobiol .  B 1994, 24, 
17 – 23. 
 [267]  Morgan J, Gray AG, Huehns ER. Specifi c targeting and toxic-
ity of sulphonated aluminium phthalocyanine photosensitised 
liposomes directed to cells by monoclonal antibody in vitro. 
 Br. J. Cancer 1989, 59, 366 – 370. 
 [268]  Xu J, Sun Y, Huang J, Chen C, Liu G, Jiang Y, Zhao Y, Jiang Z. 
Photokilling cancer cells using highly cell-specifi c antibody-
TiO(2) bioconjugates and electroporation.  Bioelectrochemistry . 
2007, 71, 217 – 222. 
 [269]  Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerg-
ing class of therapeutics.  Annu. Rev. Med . 2005, 56, 555 – 583. 
 [270]  Lee JH, Yigit MV, Mazumdar D, Lu Y. Molecular diagnostic 
and drug delivery agents based on aptamer-nanomaterial con-
jugates.  Adv. Drug Deliv. Rev . 2010, 62, 592 – 605. 
 [271]  Stephanopoulos N, Tong GJ, Hsiao SC, Francis MB. Dual-
surface modifi ed virus capsids for targeted delivery of 
photodynamic agents to cancer cells.  ACS Nano . 2010, 4, 
6014 – 6020. 
 [272]  Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon 
CP. Folate receptor expression in carcinomas and normal tis-
sues determined by a quantitative radioligand binding assay. 
 Anal. Biochem . 2005, 338, 284 – 293. 
 [273]  Garcia-Diaz M, Nonell S, Villanueva A, Stockert JC, Canete M, 
Casado A, Mora M, Sagrista ML. Do folate-receptor targeted 
liposomal photosensitizers enhance photodynamic therapy 
selectivity ?  Biochim. Biophys. Acta 2011, 1808, 1063 – 1071. 
 [274]  Bae BC, Na K. Self-quenching polysaccharide-based nanogels 
of pullulan/folate-photosensitizer conjugates for photody-
namic therapy.  Biomaterials 2010, 31, 6325 – 6335. 
 [275]  Stevens PJ, Sekido M, Lee RJ. Synthesis and evaluation of a 
hematoporphyrin derivative in a folate receptor-targeted sol-
id-lipid nanoparticle formulation.  Anticancer Res . 2004, 24, 
161 – 165. 
 [276]  Hah HJ, Kim G, Lee YE, Orringer DA, Sagher O, Philbert MA, 
Kopelman R. Methylene blue-conjugated hydrogel nanoparti-
cles and tumor-cell targeted photodynamic therapy.  Macromol. 
Biosci . 2011, 11, 90 – 99. 
 [277]  Rozenzhak SM, Kadakia MP, Caserta TM, Westbrook TR, 
Stone MO, Naik RR. Cellular internalization and targeting of 
semiconductor quantum dots.  Chem. Commun. (Camb.) . 2005, 
2217 – 2219. 
 [278]  Oku N, Ishii T. Antiangiogenic photodynamic therapy with tar-
geted liposomes.  Methods Enzymol . 2009, 465, 313 – 330. 
 [279]  Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. 
 Mol. Pathol . 1997, 50, 57 – 71. 
 [280]  Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting 
macromolecules and nanocarriers to hyaluronan or CD44, a 
hyaluronan receptor.  Mol. Pharm . 2008, 5, 474 – 486. 
 [281]  Li F, Bae BC, Na K. Acetylated hyaluronic acid/photosensitizer 
conjugate for the preparation of nanogels with controllable 
phototoxicity: synthesis, characterization, autophotoquench-
ing properties and in vitro phototoxicity against HeLa cells. 
 Bioconjug. Chem . 2010, 21, 1312 – 1320. 
 [282]  Vargas A, Pegaz B, Debefve E, Konan-Kouakou Y, Lange N, 
Ballini JP, van den Bergh H, Gurny R, Delie F. Improved pho-
todynamic activity of porphyrin loaded into nanoparticles: an 
in vivo evaluation using chick embryos.  Int. J. Pharm . 2004, 
286, 131 – 145. 
 [283]  Pegaz B, Debefve E, Borle F, Ballini JP, van den Bergh H, 
Kouakou-Konan YN. Encapsulation of porphyrins and chlo-
rins in biodegradable nanoparticles: the effect of dye lipo-
philicity on the extravasation and the photothrombic activity. 
A comparative study.  J. Photochem. Photobiol .  B 2005, 80, 
19 – 27. 
 [284]  Casas A, Battah S, Di Venosa G, Dobbin P, Rodriguez L, 
Fukuda H, Batlle A, MacRobert AJ. Sustained and effi cient 
porphyrin generation in vivo using dendrimer conjugates of 
5-ALA for photodynamic therapy.  J. Control. Release 2009, 
135, 136 – 143. 
 [285]  Barth BM, Altinog˘lu EI, Shanmugavelandy SS, Kaiser JM, 
Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, 
Keasey NR, Adair JH, Loughran TP Jr, Claxton DF, Kester M. 
Targeted indocyanine-green-loaded calcium phosphosilicate 
nanoparticles for in vivo photodynamic therapy of leukemia. 
 ACS Nano . 2011, 5, 5325 – 5337. 
 [286]  Oberdorster G, Maynard A, Donaldson K, Castranova V, 
Fitzpatrick J, Ausman K, Carter J, Karn B, Kreyling W, Lai D, 
Olin S, Monteiro-Riviere N, Warheit D, Yang H. Principles for 
characterizing the potential human health effects from expo-
sure to nanomaterials: elements of a screening strategy.  Part 
Fibre Toxicol . 2005, 2, 8. 
 [287]  Oberdorster G. Safety assessment for nanotechnology and 
nanomedicine: concepts of nanotoxicology.  J. Intern. Med . 
2010, 267, 89 – 105. 
 [288]  Fubini B, Fenoglio I, Tomatis M, Turci F. Effect of chemical 
composition and state of the surface on the toxic response to 
high aspect ratio nanomaterials.  Nanomedicine (Lond) . 2011, 
6, 899 – 920. 
 [289]  Oberdorster G, Elder A, Rinderknecht A. Nanoparticles and 
the brain: cause for concern ?  J. Nanosci. Nanotechnol . 2009, 
9, 4996 – 5007. 
 [290]  Xia T, Kovochich M, Liong M, Zink JI, Nel AE. Cationic 
polystyrene nanosphere toxicity depends on cell-specifi c endo-
cytic and mitochondrial injury pathways.  ACS Nano . 2008, 2, 
85 – 96. 
 [291]  Liu J, Hopfi nger AJ. Identifi cation of possible sources of 
nanotoxicity from carbon nanotubes inserted into membrane 
bilayers using membrane interaction quantitative structure  – 
activity relationship analysis.  Chem. Res. Toxicol . 2008, 21, 
459 – 466. 
 [292]  Linse S, Cabaleiro-Lago C, Xue WF, Lynch I, Lindman S, 
Thulin E, Radford SE, Dawson KA. Nucleation of protein 
fi brillation by nanoparticles.  Proc. Natl. Acad. Sci. USA 2007, 
104, 8691 – 8696. 
 [293]  Pan BF, Gao F, Gu HC. Dendrimer modifi ed magnetite nano-
particles for protein immobilization.  J. Colloid Interface Sci . 
2005, 284, 1 – 6. 
 [294]  AshaRani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. 
Cytotoxicity and genotoxicity of silver nanoparticles in human 
cells.  ACS Nano . 2009, 3, 279 – 290. 
 [295]  Li N, Xia T, Nel AE. The role of oxidative stress in ambient 
particulate matter-induced lung diseases and its implications 
in the toxicity of engineered nanoparticles.  Free Radic. Biol. 
Med . 2008, 44, 1689 – 1699. 
 [296]  Tang M, Wang M, Xing T, Zeng J, Wang H, Ruan DY. 
Mechanisms of unmodifi ed CdSe quantum dot-induced eleva-
tion of cytoplasmic calcium levels in primary cultures of rat 
hippocampal neurons.  Biomaterials 2008, 29, 4383 – 4391. 
 [297]  Li N, Hao M, Phalen RF, Hinds WC, Nel AE. Particulate air 
pollutants and asthma. A paradigm for the role of oxidative 
stress in PM-induced adverse health effects.  Clin. Immunol . 
2003, 109, 250 – 265. 
 [298]  Poland CA, Duffi n R, Kinloch I, Maynard A, Wallace WA, 
Seaton A, Stone V, Brown S, Macnee W, Donaldson K. Carbon 
nanotubes introduced into the abdominal cavity of mice show 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ?  145
asbestos-like pathogenicity in a pilot study.  Nat. Nanotechnol . 
2008, 3, 423 – 428. 
 [299]  Xia T, Kovochich M, Liong M, Madler L, Gilbert B, Shi H, 
Yeh JI, Zink JI, Nel AE. Comparison of the mechanism of tox-
icity of zinc oxide and cerium oxide nanoparticles based on 
dissolution and oxidative stress properties.  ACS Nano . 2008, 
2, 2121 – 2134. 
 [300]  Shvedova AA, Kisin ER, Mercer R, Murray AR, Johnson VJ, 
Potapovich AI, Tyurina YY, Gorelik O, Arepalli S, Schwegler-
Berry D, Hubbs AF, Antonini J, Evans DE, Ku BK, Ramsey 
D, Maynard A, Kagan VE, Castranova V, Baron P. Unusual 
infl ammatory and fi brogenic pulmonary responses to single-
walled carbon nanotubes in mice.  Am. J. Physiol. Lung Cell. 
Mol. Physiol . 2005, 289, L698 – L708. 
 [301]  Chen Z, Meng H, Xing G, Yuan H, Zhao F, Liu R, Chang X, 
Gao X, Wang T, Jia G, Ye C, Chai Z, Zhao Y. Age-related dif-
ferences in pulmonary and cardiovascular responses to SiO2 
nanoparticle inhalation: nanotoxicity has susceptible popula-
tion.  Environ. Sci. Technol . 2008, 42, 8985 – 8992. 
 [302]  Berry JP, Arnoux B, Stanislas G, Galle P, Chretien J. A micro-
analytic study of particles transport across the alveoli: role of 
blood platelets.  Biomedicine . 1977, 27, 354 – 357. 
 [303]  Li SQ, Zhu RR, Zhu H, Xue M, Sun XY, Yao SD, Wang SL. 
Nanotoxicity of TiO(2) nanoparticles to erythrocyte in vitro. 
 Food Chem. Toxicol . 2008, 46, 3626 – 3631. 
 [304]  Park EJ, Bae E, Yi J, Kim Y, Choi K, Lee SH, Yoon J, Lee BC, 
Park K. Repeated-dose toxicity and infl ammatory responses in 
mice by oral administration of silver nanoparticles.  Environ. 
Toxicol. Pharmacol . 2010, 30, 162 – 168. 
 [305]  Yu T, Malugin A, Ghandehari H. Impact of silica nanoparticle 
design on cellular toxicity and hemolytic activity.  ACS Nano . 
2011, 5, 5717 – 5728. 
 [306]  Grassian VH, O ’ Shaughnessy PT, Adamcakova-Dodd A, 
Pettibone JM, Thorne PS. Inhalation exposure study of tita-
nium dioxide nanoparticles with a primary particle size of 2 to 
5 nm.  Environ. Health Perspect . 2007, 115, 397 – 402. 
 [307]  Geys J, Nemmar A, Verbeken E, Smolders E, Ratoi M, 
Hoylaerts MF, Nemery B, Hoet PH. Acute toxicity and pro-
thrombotic effects of quantum dots: impact of surface charge. 
 Environ. Health Perspect . 2008, 116, 1607 – 1613. 
 [308]  Oberdorster G, Sharp Z, Atudorei V, Elder A, Gelein R, 
Kreyling W, Cox C. Translocation of inhaled ultrafi ne particles 
to the brain.  Inhal. Toxicol . 2004, 16, 437 – 445. 
 [309]  Long TC, Tajuba J, Sama P, Saleh N, Swartz C, Parker J, 
Hester S, Lowry GV, Veronesi B. Nanosize titanium dioxide 
stimulates reactive oxygen species in brain microglia and dam-
ages neurons in vitro.  Environ. Health Perspect . 2007, 115, 
1631 – 1637. 
 [310]  Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner 
AS. Noninvasive imaging of quantum dots in mice.  Bioconjug. 
Chem . 2004, 15, 79 – 86. 
 [311]  Oberdorster G, Sharp Z, Atudorei V, Elder A, Gelein R, 
Lunts A, Kreyling W, Cox C. Extrapulmonary translocation 
of ultrafi ne carbon particles following whole-body inhala-
tion exposure of rats.  J. Toxicol. Environ. Health A 2002, 65, 
1531 – 1543. 
 [312]  Chen YS, Hung YC, Liau I, Huang GS. Assessment of the in 
vivo toxicity of gold nanoparticles.  Nanoscale Res. Lett . 2009, 
4, 858 – 864. 
 [313]  Hanley C, Thurber A, Hanna C, Punnoose A, Zhang J, Wingett 
DG. The infl uences of cell type and ZnO nanoparticle size on 
immune cell cytotoxicity and cytokine induction.  Nanoscale 
Res. Lett . 2009, 4, 1409 – 1420. 
 [314]  Meng H, Xia T, George S, Nel AE. A predictive toxicologi-
cal paradigm for the safety assessment of nanomaterials.  ACS 
Nano . 2009, 3, 1620 – 1627. 
 [315]  Krug HF, Wick P. Nanotoxicology: an interdisciplin-
ary challenge.  Angew. Chem. Int. Ed. Engl . 2011, 50, 
1260 – 1278. 
 [316]  Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated 
cellular response is size-dependent.  Nat. Nanotechnol . 2008, 3, 
145 – 150. 
 [317]  Palomaki J, Valimaki E, Sund J, Vippola M, Clausen PA, 
Jensen KA, Savolainen K, Matikainen S, Alenius H. Long, 
needle-like carbon nanotubes and asbestos activate the NLRP3 
infl ammasome through a similar mechanism.  ACS Nano . 2011, 
5, 6861 – 6870. 
 [318]  Stella GM. Carbon nanotubes and pleural damage: per-
spectives of nanosafety in the light of asbestos experience. 
 Biointerphases . 2011, 6, P1 – 17. 
 [319]  Murphy FA, Poland CA, Duffi n R, Al-Jamal KT, Ali-
Boucetta H, Nunes A, Byrne F, Prina-Mello A, Volkov Y, 
Li S, Mather SJ, Bianco A, Prato M, Macnee W, Wallace 
WA, Kostarelos K, Donaldson K. Length-dependent reten-
tion of carbon nanotubes in the pleural space of mice 
initiates sustained infl ammation and progressive fi bro-
sis on the parietal pleura.  Am. J. Pathol . 2011, 178, 
2587 – 2600. 
 [320]  Fraser TW, Reinardy HC, Shaw BJ, Henry TB, Handy RD. 
Dietary toxicity of single-walled carbon nanotubes and 
fullerenes (C60) in rainbow trout (Oncorhynchus mykiss). 
 Nanotoxicology . 2011, 5, 98 – 108. 
 [321]  Jovanovic B, Anastasova L, Rowe EW, Palic D. Hydroxylated 
fullerenes inhibit neutrophil function in fathead minnow 
(Pimephales promelas Rafi nesque, 1820).  Aquat. Toxicol . 
2011, 101, 474 – 482. 
 [322]  Henry TB, Petersen EJ, Compton RN. Aqueous fullerene 
aggregates (nC60) generate minimal reactive oxygen species 
and are of low toxicity in fi sh: a revision of previous reports. 
 Curr. Opin. Biotechnol . 2011, 22, 533 – 537. 
 [323]  Kovochich M, Espinasse B, Auffan M, Hotze EM, Wessel 
L, Xia T, Nel AE, Wiesner MR. Comparative toxicity of 
C60 aggregates toward mammalian cells: role of tetrahydro-
furan (THF) decomposition.  Environ. Sci. Technol . 2009, 43, 
6378 – 6384. 
 [324]  Khalil WK, Girgis E, Emam AN, Mohamed MB, Rao KV. 
Genotoxicity evaluation of nanomaterials: DNA damage, 
micronuclei and 8-hydroxy-2-deoxyguanosine induced by 
magnetic doped CdSe quantum dots in male mice.  Chem. Res. 
Toxicol . 2011, 24, 640 – 650. 
 [325]  Tino A, Ambrosone A, Mattera L, Marchesano V, Susha A, 
Rogach A, Tortiglione C. A new in vivo model system to assess 
the toxicity of semiconductor nanocrystals.  Int. J. Biomater . 
2011. Doi:  10.1155/2011/792854. 
 [326]  Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, 
Barberi-Heyob M. Nanoparticles as vehicles for delivery of 
photodynamic therapy agents.  Trends Biotechnol . 2008, 26, 
612 – 621. 
 [327]  Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad 
OC. Nanoparticles in medicine: therapeutic applica-
tions and developments.  Clin. Pharmacol. Ther . 2008, 83, 
761 – 769. 
 [328]  Uchoa AF, de Oliveira KT, Baptista MS, Bortoluzzi AJ, 
Iamamoto Y, Serra OA. Chlorin photosensitizers sterically 
designed to prevent self-aggregation.  J. Org. Chem . 2011, 76, 
8824 – 8832. 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
146  Y.-Y. Huang et al.: Can nanotechnology potentiate photodynamic therapy ? 
 [329]  Lee DY, Li KC. Molecular theranostics: a primer for the imag-
ing professional.  AJR Am. J. Roentgenol . 2011, 197, 318 – 324. 
 [330]  Janib SM, Moses AS, MacKay JA. Imaging and drug delivery 
using theranostic nanoparticles.  Adv. Drug Deliv. Rev . 2010, 
62, 1052 – 1063. 
 [331]  Fernandez-Fernandez A, Manchanda R, McGoron AJ. 
Theranostic applications of nanomaterials in cancer: drug 
delivery, image-guided therapy and multifunctional platforms. 
 Appl. Biochem. Biotechnol . 2011, 165, 1628 – 1651. 
 [332]  Hahn MA, Singh AK, Sharma P, Brown SC, Moudgil BM. 
Nanoparticles as contrast agents for in-vivo bioimaging: 
current status and future perspectives.  Anal. Bioanal. Chem . 
2011, 399, 3 – 27. 
 [333]  Cheon J, Lee JH. Synergistically integrated nanoparticles as 
multimodal probes for nanobiotechnology.  Acc. Chem. Res . 
2008, 41, 1630 – 1640. 
 [334]  Grimm J, Scheinberg DA. Will nanotechnology infl uence 
targeted cancer therapy ?  Semin. Radiat. Oncol . 2011, 21, 
80 – 87. 
Received October 28, 2011; accepted January 12, 2012
 Ying-Ying Huang, MD, has 
been a postdoctoral fellow in 
Dr. Hamblin’s laboratory for 
4 years.   Her research inter-
ests lie in Quantitative struc-
ture–activity relationship of 
photosensitizers in photody-
namic therapy and cellular 
response and mechanism of 
low level light therapy. She 
has published over 20 peer 
review articles. 
 Long Y. Chiang, PhD, is Pro-
fessor of Chemistry at the 
University of Massachusetts 
Lowell and has collaborated 
with Dr. Hamblin for 4 years. 
 Michael R. Hamblin, PhD, 
is a principal investigator 
at the Wellman Center for 
Photomedicine at Massa-
chusetts General Hospital 
and an associate Professor 
of Dermatology at Harvard 
Medical School and Harvard-
MIT Division of Health Sci-
ence and Technology. His 
research interests lie in the 
areas of photodynamic thera-
py and low-level light therapy. He has published more than 
160 peer-reviewed articles. 
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/9/16 8:05 PM
